Heart failure outcomes by Berge, J.C. (Jan) van den
Jan C. van den Berge














Jan C. van den Berge
Colofon
Financial support for the publication of this thesis was generously provided by:
 
ISBN:   978-94-6416-700-9
Cover image:   Christopher Brown
Lay-out:   Publiss | www.publiss.nl
Print:    Ridderprint | www.ridderprint.nl
© Copyright 2021: Jan C. van den Berge, Alblasserdam, The Netherlands 
All rights reserved. No part of this publication may be reproduced, stored in a 
retrieval system, or transmitted in any form or by any means, electronic, mechanical, 
by photocopying, recording, or otherwise, without the prior written permission of the 
author. 
Heart Failure Outcomes
Klinische implicaties van hartfalen
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnifi cus
Prof. dr. F.A. van der Duijn Schouten 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
donderdag 30 september 2021 om 10.30 uur.
door
Jan Cornelis van den Berge
geboren te Goes. 
Promotiecommissie
Promotor: prof. dr. J.W. Deckers
Overige leden: prof. dr. J.W. Roos - Hesselink
prof. dr. F. Zijlstra
dr. A. Mosterd
Copromotor: dr. K.M. Akkerhuis





Chapter 1 General introduction and outline of thesis 9
Part I Impact of improved heart failure therapy on left ventricular 
remodeling and prognosis
19
Chapter 2 Temporal trends in long-term mortality of patients with acute 
heart failure: Data from 1985-2008.
21
Chapter 3 Trends in long-term mortality in women compared to men with 
acute heart failure between 1985 and 2008
37
Chapter 4 Short- and long-term prognosis of patients with acute heart failure 
with and without diabetes: changes over the last three decades 
55
Chapter 5 Renal function and anemia in relation to short- and long-term 
prognosis of patients with acute heart failure in the period 1985-
2008: A clinical cohort study.
75
Chapter 6 Relative conditional survival analysis provides additional insights 
into the prognosis of heart failure patients 
95
Chapter 7 Left ventricular remodeling and prognosis after discharge in new-
onset acute heart failure with reduced ejection fraction 
109
Chapter 8 Preventive ICD-therapy in Contemporary Clinical Practice; More 
stringent selection criteria long overdue
131
Part II Patient reported outcomes in acute heart failure 147
Chapter 9 Determinants of quality of life in acute heart failure patients with 
and without comorbidities
149
Chapter 10 Symptoms and depression in acute heart failure patients 167
7
Part III Heart failure at a population level 193
Chapter 11 Implications of the ACC/AHA risk score for prediction of heart 
failure: The Rotterdam Study.
195
Chapter 12 Risk factors for longitudinal changes in left ventricular diastolic 
function among women and men.
219
Part IV Epilogue 247
Chapter 13 Summary and general discussion 249
Chapter 14 Nederlandse samenvatting 261
Chapter 15 Dankwoord 271
Chapter 16 List of publications 277
Chapter 17 PhD portfolio 281




General introduction and outline of thesis
10
CHAPTER 1  
Heart failure (HF) is “a clinical syndrome characterized by typical symptoms that may 
be accompanied by signs caused by a structural and/or functional cardiac abnormality, 
resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest 
or during stress”1. HF can be caused by myocardial abnormalities or other causes 
including valve dysfunction, arrhythmias and pericarditis.1 Numerous risk factors for 
the development of HF have been established.2 Ischemic heart disease is the most 
common myocardial abnormality causing HF.2 Toxin-mediated cardiomyopathy, dilated 
cardiomyopathy, hypertrophic cardiomyopathy, inflammatory cardiomyopathy and 
peripartum cardiomyopathy are frequent non-ischemic origins of systolic and/or diastolic 
myocardial dysfunction.1
Classification of HF cannot only be made based on the etiology but also in relation to 
the time course: acute versus chronic HF. Acute HF, in turn, is either new-onset HF or 
worsening of signs and symptoms of pre-existent, chronic HF. Acute HF mostly occurs 
after a cardiac (e.g. myocardial infarction, arrhythmia, acute valve insufficiency) or non-
cardiac (e.g. hypertension, drug/diet non-adherence, pulmonary embolism or infection) 
trigger.1 Once patients have had an episode of HF they will be considered chronic HF 
patients.
Furthermore, left ventricular function in terms of ejection fraction is a common measure 
to classify HF. Traditionally, the parameter divided HF into two categories: HF with reduced 
ejection fraction en HF with preserved ejection fraction. Since 2016, the Task Force for 
the diagnosis and treatment of acute and chronic heart failure of the European Society 
of Cardiology has added a third category, namely HF with mid-range ejection fraction.3 
It has been observed that a significant number of patients with HF with reduced ejection 
fraction may develop an improvement in their left ventricular ejection fraction (LVEF).4, 
5 Several factors were found to be associated with LVEF improvement,6-9 such as female 
sex. The comorbidities hypertension and diabetes have also been correlated with LVEF 
improvement, especially upon treatment of the underlying condition. Furthermore, it 
has been observed that LVEF improvement was more common in patients with HF of 
non-ischaemic cause than in those with ischaemic HF. Also, HF medication was found to 
improve the LVEF.4
Since left ventricular remodeling and LVEEF improvement have been described, a new 
discussion on implantable cardioverter defibrillator (ICD) implantation for primary 
prevention in HF patients with poor left ventricular function is justified, especially since 
the relevant studies included patients about 20 years ago.10-12 In that period, only few 
pharmacological treatment options were available. Nowadays, medical therapy has 
been improved and, as a result, the risk of ventricular tachycardia and fibrillation has 
decreased. Therefore, it is currently less cost-effective to implant an ICD for primary 
prevention than a few decades ago. The recommended cut-off value for preventive ICD 
implantation is currently still an LVEF <35%.3 However, this might be criticized because 
the majority of the included patient in the so-called landmark trials had an LVEF <30% 
and were thus included in an era with less optimal pharmacological HF medication as 
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compared to the treatment patients receive nowadays.10-12 The appropriateness of ICD 
implantation in patient with an LVEF between 30 and 35% may thus be questioned.
Epidemiology
Worldwide, HF is a major public health issue with a prevalence of 1 to 14% depending on 
definition and population characteristics.2, 13 As a result of improved treatment of other 
cardiovascular diseases (especially ischemic heart disease and acute coronary syndrome), 
and giving an aging population and increasing prevalence of diabetes, obesity and atrial 
fibrillation, HF prevalence is expected to increase further in the next decades.2, 14
In the United States and Europe, HF is a leading cause of hospitalisation. HF-
rehospitalization rates up to 27% within 30 days after initial hospitalization are not 
uncommon.2 Since HF-rehospitalizations were found to be associated with increased 
mortality,15, 16 such events are not innocent and negligible facts. Therefore, limiting the HF-
rehospitalization rate should be a therapeutic goal. The 30-day mortality in patients with 
acute HF was found to be in the broad range of 4 and 30%.17 Studies investigating long 
term mortality have reported 1-year mortality rates of 20-30%18-21 and 5-year mortality 
rates of 45-75%2, 22. Indeed, HF patients have a poor prognosis. The prognosis of HF is 
at least as poor as that of several common cancers,23, 24 a fact few people are aware of.
In addition to HF-rehospitalization,15, 16 numerous other risk factors for mortality have 
been identified.1, 25, 26 The demographic variables older age and male sex have been 
found to be associated with a worse prognosis. The presence of cardiovascular (including 
atrial fibrillation, peripheral artery disease and previous stroke) and non-cardiovascular 
(including diabetes, anemia, chronic obstructive pulmonary disease and depression) 
comorbidities are also associated with an impaired prognosis. Furthermore, patients 
with non-ischemic HF have a better prognosis than those with ischemic HF. Importantly, 
improvement in left ventricular function is also associated with improvement in 
prognosis.25, 26 Several risk scores have been made in order to predict the prognosis of 
individual HF patients. However, these models were found to be only moderately useful 
in clinical practice.25, 26
During the last decades, HF treatment has seen major improvements. Other than diuretics 
and lifestyle interventions, no other HF treatment was available before the 1980s. Since 
that time, angiotensin converting enzyme inhibitors and beta-blockers have been 
introduced in the 1980s and 1990s. Later, mineralocorticoid receptor antagonists were 
added to the therapeutic options. More recently, ivabradine and angiotensin receptor 
neprilysin inhibitor have been shown to be effective as HF treatment. In addition to new 
medical therapeutic options, new devices have been developed and introduced. Not only 
ICDs and cardiac resynchronization therapy became available for HF treatment but also 
left ventricular assist devices are gaining ground in HF therapy.27, 28
This improvement in HF therapy has resulted in improved prognosis during the last 
decades.22, 29, 30 However, above mentioned therapeutics were predominantly therapies 
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for chronic HF and have benefitted patients with chronic conditions. In contrast, hardly 
any therapeutic development for acute HF treatment has become available. Indeed, 
although much research has been invested in this topic, significant results have not been 
obtained.31
In addition to improvement in HF prognosis, optimal medical treatment also induces left 
ventricular remodeling.4 This reverse remodeling was mainly found in patients with non-
ischemic etiology of HF. Several other factors were also found to be associated with left 
ventricular remodeling like age, gender, diabetes and hypertension.32
Patient-reported outcomes
Traditionally, prognosis has been used as the main outcome measure in clinical HF 
trials. However, the use of patient-reported outcome has been advocated33, 34 and is 
increasingly becoming a more important study endpoint, in addition to mortality and 
HF rehospitalization. ‘Patient-reported outcomes’ is a comprehensive term including a 
great variety of outcomes reported by patients themselves. For example health-related 
quality of life (HRQoL), symptom occurrence, symptom burden and physical limitation 
are relevant in this perpective.33 Especially for HF patients with preserved LVEF, patient-
reported outcome is an important parameter because there is limited prognostic benefit 
from current pharmacological treatment in this predominantly older population.35 Since 
the majority of HF patients prefer quality of life above longevity per se,36, 37 patient-
reported outcomes are also important from a clinical perspective.
In addition to a poor prognosis, HF patients were also found to have an impaired 
HRQoL.38 This HRQoL was not only worse than that of the general population but also 
worse than in patients with other chronic conditions.39, 40 Factors influencing HRQoL 
become more and more clear and important. Age, sex, clinical status, presence of (non-) 
cardiac comorbidities but also socioeconomic status and symptom occurrence and 
symptom burden are determinants of HRQoL.41-43 Overall, patient-reported outcomes 
are increasingly relevant topics in HF research but many questions remain.
Aims and outline of this thesis
This thesis has several aims: First, to study the impact of improved HF therapy on 
prognosis over time. In addition to short- and long-term mortality, also other end-points 
have been included. Furthermore, we investigated  determinants of patient reported 
outcomes like HRQoL and symptom status. Lastly, we studied prediction models and 
associations in heart failure patients at a population level.
In the first part of this thesis, trends in mortality of patients admitted with acute HF 
are described. To this end, we used a prospective database of patients admitted to the 
(Intensive) Coronary Care Unit of the Erasmus Medical Center in the period of 1985 
until 2008. The trends in mortality were also studied in several subgroups defined by 
13
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sex, diabetes mellitus status and presence or absence of kidney disease or anemia. 
Furthermore, the use of conditional survival versus the ‘conventional’ survival time is 
described in detail. We also studied reverse remodeling in patients with non-ischemic 
and ischemic HF based on data of a retrospective study among patients admitted with de 
novo HF. Lastly, this part includes a review in which the current selection criteria for ICDs 
in patient with HF are questioned.
The second part of this thesis is on patient reported outcomes. We studied whether there 
were differences in HRQoL between HF patients with and without the comorbidities 
chronic obstructive pulmonary disease, cerebrovascular accident, diabetes mellitus and 
chronic kidney disease. Second, we investigated the differences in symptom occurrence 
and symptom burden in HF patients with and without depression using data from the 
TRIUMPH study, a prospective, multicenter study enrolling acute HF patients.44
The last part of this thesis includes investigations based on data of the Rotterdam Study.45 
Therefore, this section is not based on data of patients, but of a selection of population 
based data. This allowed us to perform an analysis on prediction of HF events. To this 
end, we compared the relatively simple ACC/AHA risk score46 with the more complex 
Health ABC model47 and ARIC model48. Furthermore, we studied difference in risk factors 
for longitudinal changes in left ventricular diastolic function between men and women.
14
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Background – Heart failure (HF) has a poor prognosis. Patients with acute heart failure 
in particular have a high risk of dying. However, there is a lack of data regarding their 
long-term mortality and changes there-in with time.  The aim of our study was to describe 
trends in short- and long-term mortality of patients hospitalized with acute HF in the 
period from 1985 through 2008. In addition, we determined the prognostic worth of the 
aetiology of HF. 
Methods and results – We included a consecutive series of 1810 patients with acute HF 
in this prospective registry in the period of 1985 through 2008. The cumulative one-year 
mortality rate of the patients was 35%. The short-term prognosis remained unchanged 
over the decades. However, the cumulative mortality rate ten years after admission 
was lowest in the last decade (73% in 2000-2008 vs. 78% in 1985-1999, p=0.001). After 
multivariable adjustment, the ten-year mortality rate was lower in the last decade as 
compared to the first decade (hazard ratio (HR) 0.83; 95% confidence interval (CI) 0.71-
0.96). Ischemic cardiomyopathy was associated with a higher mortality (HR 1.32; 95% CI 
1.12-1.54) when compared to other causes of HF.
Conclusions – Patients admitted with acute HF were found to have both high short-
term and long-term mortality. Long-term prognostic improvement in the last decade was 
observed among patients with a reduced ejection fraction. While patients with HF due to 
valvular heart disease had the best prognosis, an ischemic aetiology of HF was associated 
with the worst outcome. 
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Introduction
Worldwide, heart failure (HF) is a major public health issue. Its prevalence is 2%, but since 
HF increases with age, the prevalence is much higher in the elderly.[1, 2] There are many 
different causes for HF,[3] but ischemic heart disease is the most common aetiology of 
HF.[1] Other frequent aetiologies include HF secondary to uncontrolled hypertension as 
well as to valvular heart disease.[4] The cause of HF is related to prognosis.[5] 
Since the 2000s, several registries have investigated the short-term outcome in this 
population. In-hospital mortality rates range from 4% to 30%,[4] whereas one-year 
mortality rates are reported to be as high as 20% to 30%.[6-10] One study has even 
reported a one-year mortality rate of almost 50% in patients with acute HF admitted 
to the intensive care or cardiac care unit.[11] With respect to longer-term outcome, 
prognosis is even worse, and five-year mortality figures in the order of 45-75% have been 
published.[1, 12]
In the last decades, several advances in the treatment of HF have taken place. 
Amongst others, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and 
mineralocorticoid receptor antagonists (MRAs) have been introduced in clinical practice.
[13-21] Furthermore, the increasing use of implantable cardioverter defibrillators (ICDs) 
and cardiac resynchronization therapy in the last decades may also have contributed 
also to a better prognosis.[22-26] Nevertheless, despite these improvements in the 
management and treatment of HF, the condition is and remains one with high mortality.
[1, 2, 27] Importantly, there is no data regarding the trends in ten-year mortality in 
patients hospitalized with acute HF. Therefore, the aim of our study was to describe the 
trends in short- and long-term mortality of patients hospitalized with acute HF in the 
period from 1985 through 2008. In addition, we determined the impact of the aetiology 
of HF on long-term mortality. 
Methods
Inclusion
This prospective registry included all consecutive patients from 18 years and older 
admitted with acute HF to the Intensive Coronary Care Unit (ICCU) of the Erasmus Medical 
Centre. The inclusion period started on 1st January 1985 and ended on 31st December 
2008. The Erasmus Medical Centre is a tertiary referral centre in the South-West of The 
Netherlands and the only referral centre for advanced HF with need for mechanical 
circulatory support or heart transplantation for almost half of The Netherlands. Following 
their initial hospitalization and treatment at our centre, most patients are subsequently 
transferred to a referring hospital after stabilization. 
Patients were included when a diagnosis of acute HF or cardiogenic shock was made by 
the physician at admission. Both patients with a rapid, new onset of HF symptoms or 
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patients with worsening of symptoms of chronic HF were included. Patients admitted for 
acute HF caused by an acute coronary syndrome without evidence of sustained systolic 
or diastolic dysfunction were excluded. If patients were admitted for acute HF more than 
once during the study period, only the first admission was included.
Ethics statement
This was a prospective cohort registry. During the enrolment of the patients, approval 
from the local research ethics committee to conduct this study was not required. The 
study was conducted according to the Helsinki Declaration.[28]
Baseline variables
The baseline variables were extracted from the patient records or discharge letters. 
Only the variables until discharge from the ICCU were available as most patients 
are routinely transferred to a referring non-tertiary hospital after stabilization. The 
demographic variables age and gender were collected. The following clinical variables 
were also collected: prior myocardial infarction, coronary revascularization (coronary 
artery bypass graft (CABG) or percutaneous coronary intervention (PCI)), cardiac surgery 
other than CABG, heart transplantation or waiting for heart transplantation, rhythm or 
conduction disturbance, previous HF, hypertension and diabetes), aetiology of the HF, 
Body Mass Index (BMI), left ventricular ejection fraction (LVEF) and heart rate at moment 
of admission. Furthermore, the treatment at the ICCU was registered. 
Diabetes mellitus was considered to be present when patients received antidiabetic 
therapy. The LVEF was classified into the following qualitative categories: good, moderate 
and poor. If quantitative outcome for the LVEF was used, we applied the following 
cut-offs: ≥45%, 30-44% and <30% for good, moderate and poor LVEF, respectively. 
The aetiology of HF was categorized into four groups: ischemic cardiomyopathy, non-
ischemic cardiomyopathy, cardiac dysfunction due to valvular heart disease, and other/
unknown aetiology. The non-ischemic cardiomyopathy group included patients with 
hypertensive cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, 
immune-mediated cardiomyopathy, toxic cardiomyopathy, endocrine/nutritional 
cardiomyopathy, and peripartum cardiomyopathy.
End-point
The primary study endpoint was of all-cause mortality at one and ten years. Heart 
transplantation and implantation of a left ventricular assist device (LVAD) should be 
considered as equivalent to death. 
Survival status was obtained from the Municipal Civil Registries in January 2016. The 
survival status was available for 98% of all included patients. 
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Statistical analysis
The population was divided into the following time periods: 1985-1989, 1990-1999 
and 2000-2008. Categorized variables are presented as frequencies and percentages. 
Continuous variables are presented as mean values and standard deviation. The 
categorized variables were compared with the χ2 test or the Fisher-Freeman-Halton exact 
test. The continuous variables were compared by using one-way ANOVA.
Data for LVEF was not complete in 28% of the patients: 51% missing in the 1980s, 23% 
in the 1990s and 18% in the 2000s. Therefore, multiple imputation was applied using 
baseline characteristics as predictors. Pooled means were given for LVEF.
Cumulative mortality curves are presented by the Kaplan-Meier method. For comparing 
the mortality curves, the log-rank test was used. As a secondary analysis, landmark 
analyses were performed for the 30-day survivors. The Cox proportional hazard model 
was used for comparing ten-year mortality rates, adjusted for period of admission, age, 
gender, history of HF, prior rhythm- or conduction disorder, diabetes in history, aetiology 
of HF and LVEF.
All tests were two-tailed and p-values <0.05 were considered statistically significant. 
Results of the Cox proportional hazard model were reported in hazard ratios (HRs) with 
their corresponding 95% confidence interval (95% CI). All data were analysed using SPSS 
software (SPSS 21.0, IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
In total, 1810 patients were included, all hospitalized for acute HF in the period between 
1985 and 2008. Over these periods, their baseline characteristics slightly changed (Table 
1). Over time, the mean age remained stable although the percentage of patients older 
than 75 years increased. In addition, the proportion of male patients decreased, although 
male sex still represented the majority in each decade. Also, with time, patients less 
often had a history of prior myocardial infarction. Still, they were more likely to have 
undergone coronary revascularization, and to have rhythm- or conduction disorders, 
hypertension and diabetes mellitus. The aetiology of HF changed over time: the number 
of patients with ischemic cardiomyopathy decreased, while the number of patients with a 
non-ischemic cardiomyopathy increased. Valvular heart disease became a less common 
cause of HF. The distribution of LVEF did not change over time.
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Table 1. Baseline characteristics
1985-1989 1990-1999 2000-2008 p-value
No. of patients 389 842 579
Baseline
Age (mean, y) 62±13 64±15 64±15 0.24
Age categories 0.008
18-54 years 100 (26%) 209 (25%) 142 (25%)
55-64 years 102 (26%) 170 (20%) 127 (22%)
65-74 years 129 (33%) 258 (31%) 171 (30%)
75 years and older 58 (15%) 205 (24%) 139 (24%)
Male 273 (70%) 510 (61%) 370 (64%) 0.005
BMI 24±5.2 25±4.4 26±5.4 0.01
Medical history
Myocardial infarction 185 (48%) 332 (39%) 197 (34%) <0.001
Coronary revascularization* 78 (20%) 150 (18%) 162 (28%) <0.001
Heart surgery (not CAGB) 52 (13%) 103 (12%) 82 (14%) 0.56
Heart transplantation 1 (0.3%) 5 (0.6%) 3 (0.5%) 0.83
Waiting for heart transplantation 9 (2%) 14 (2%) 12 (2%) 0.68
Heart failure 188 (48%) 403 (48%) 297 (51%) 0.42
Rhythm- or conduction disorder 90 (23%) 183 (22%) 173 (30%) 0.001
Hypertension 91 (23%) 275 (33%) 224 (39%) <0.001
Diabetes 56 (14%) 174 (21%) 154 (27%) <0.001
Heart failure
Aetiology of heart failure 0.02
Ischemic cardiomyopathy 171 (44%) 332 (39%) 237 (41%)
Non-ischemic cardiomyopathy 61 (16%) 198 (24%) 143 (25%)
Valvular heart disease 91 (23%) 178 (21%) 101 (17%)
Other/unknown 66 (17%) 134 (16%) 98 (17%)
Atrial fibrillation at admission 79 (20%) 181 (22%) 131 (23%) 0.69
Left ventricular ejection fraction NS
Good 112 (29%) 255 (30%) 159 (27%)
Moderate 83 (21%) 208 (25%) 139 (24%)
Poor 195 (50%) 379 (45%) 281 (49%)
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The median length of stay at the ICCU was 2 days (interquartile range: 1 to 4 days) and did 
not differ between the three decades (p=0.28). The heart rate at admission was 106±26 
beats per minute and was similar in all periods (p=0.68). Therapy during ICCU hospitalization 
changed over time (Table 2). For instance, more patients received mechanical ventilation in 
the most recent decade. In the period 1990-1999, inotropic drugs and nitrates were more 
often prescribed than in the other decades, while the use of mechanical circulatory support 
increased. The use of beta-blockers and ACE-inhibitors or angiotensin receptor blockers 
(ARBs) increased over time, while therapy with digitalis decreased.
Table 2. Therapy during ICCU hospitalization
1985-1989 1990-1999 2000-2008 p-value
Intubation 29 (8%) 104 (12%) 114 (20%) <0.001
Resuscitation 18 (5%) 36 (4%) 18 (3%) 0.41
Mechanical circulatory support* 12 (3%) 56 (7%) 37 (6%) 0.04
Inotropics 103 (27%) 306 (36%) 170 (29%) 0.001
Beta-blocker 17 (4%) 94 (11%) 195 (34%) <0.001
Antiarrhythmics 58 (15%) 128 (15%) 131 (23%) <0.001
Calcium antagonist 76 (20%) 128 (15%) 57 (10%) <0.001
Digitalis 213 (55%) 383 (46%) 146 (25%) <0.001
ACE-inhibitor or ARB 136 (35%) 456 (54%) 377 (65%) <0.001
Diuretics 361 (93%) 746 (89%) 527 (91%) 0.05
Nitrates 87 (22%) 375 (45%) 183 (32%) <0.001
Nitroprusside 71 (18%) 81 (10%) 9 (2%) <0.001
Antiplatelet agents 27 (7%) 176 (21%) 266 (46%) <0.001
Oral anticoagulant 227 (58%) 469 (56%) 206 (36%) <0.001
Mortality over time
During the whole follow-up time, 1555 (86%) patients reached the primary endpoint: 
1474 (81%) patients died, 77 (4%) patients underwent heart transplantation and 4 (0.2%) 
LVAD implantation. The cumulative mortality rate at one and ten years was 35% and 76%, 
respectively. The ten-year cumulative mortality curve of the three periods is depicted 
in Figure 1. Early mortality rates at 30 days and 1 year after admission were similar in 
all decades. In contrast, the cumulative mortality rate ten years after admission was 
lowest in the last decade (73% in 2000-2008 vs. 78% in the combined period 1985-1999, 
p=0.001). After multivariable adjustment, ten-year mortality was significantly lower in the 
last decade as compared to the first decade (adjusted HR 0.83; 95% CI 0.71-0.96). No 
difference in the mortality was found between the first and the second decade (adjusted 
HR 1.00; 95% CI 0.87-1.15). (Table 3)
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Figure 1. Kaplan-Meier curve total population




1990-2000 1.02 (0.89-1.16) 1.02 (0.88-1.17)
2000-2008 0.89 (0.76-1.03) 0.83 (0.71-0.97)
Age 1.016 (1.012-1.020) -
Age categorical
18-54 years Reference Reference
55-64 years 1.25 (1.07-1.48) 1.24 (1.05-1.46)
65-74 years 1.38 (1.19-1.61) 1.37 (1.17-1.60)
75 years and older 1.81 (1.54-2.12) 2.00 (1.69-2.36)
Male gender 1.26 (1.13-1.41) 1.23 (1.10-1.38)
Medical history
Myocardial infarction 1.35 (1.21-1.50) -
Coronary revascularisation* 1.05 (0.92-1.19) -
Heart surgery (not CAGB) 0.90 (0.77-1.06) -
Heart transplantation 4.48 (2.32-8.65) -
Waiting for heart transplantation 2.50 (1.75-3.56) -
Heart failure 1.71 (1.54-1.90) 1.66 (1.48-1.86)
Rhythm- or conduction disorder 1.24 (1.10-1.40) 1.05 (0.92-1.19)
Hypertension 0.98 (0.88-1.10) -
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Univariable Multivariable
Diabetes 1.20 (1.06-1.36) 1.16 (1.02-1.32)
Aetiology of heart failure
Ischemic cardiomyopathy Reference Reference
Non-ischemic cardiomyopathy 0.80 (0.69-0.92) 0.98 (0.85-1.14)
Valvular heart disease 0.65 (0.56-0.75) 0.81 (0.69-0.95)
Other/unknown 0.86 (0.74-0.996) 1.02 (0.87-1.19)
Atrial fibrillation at admission 1.00 (0.88-1.13) -
Left ventricular ejection fraction
Good Reference Reference
Moderate 1.06 (0.89-1.28) 0.99 (0.80-1.22)
Poor 1.55 (1.33-1.81) 1.39 (1.16-1.66)
Results given in hazard ratio with corresponding 95% confidence interval. Dark cells indicate significant results
CABG, coronary artery bypass graft; *Percutaneous coronary intervention and/or CABG
When the analysis was restricted to the 30-day survivors, more pronounced differences 
in long-term mortality between the last decade and the other two decades became 
apparent (Figure 2). The cumulative mortality after ten years was lower in the period 2000-
2008 than in the period 1985-1999 (69% vs. 77%, p=0.004). After adjustment for baseline 
characteristics, the adjusted ten-year mortality rate was also significantly lower in the last 
decade than in the first decade (adjusted HR 0.72; 95% CI 0.61-0.87) in the 30-day survivors.
Figure 2. Kaplan-Meier curve 30-day survivors
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Furthermore, we analysed the mortality over time among patients with preserved LVEF 
(LVEF≥45%) and those with a reduced LVEF (LVEF<45%). The ten-year mortality of the 
patients with a preserved LVEF was not different in the last decade as compared to the 
first decade (adjusted HR 0.95; 95% CI 0.70-1.29). However, the ten-year prognosis of 
the patients with a reduced LVEF improved in the last decade (adjusted HR 0.81; 95% CI 
0.68-0.95).
Aetiology and mortality
The survival curves of all patients according to the four groups categorized on the basis 
of the aetiology of HF are shown in Figure 3. Patients with an ischemic cause of HF were 
found to have the worst prognosis. Patients with a non-ischemic cardiomyopathy and 
with HF due to valvular heart disease had the lowest mortality rates.
Figure 3. Kaplan-Meier curve split up in etiology
After univariable adjustment, ischemic cardiomyopathy was found to have the worst 
prognosis, compared to all other aetiologies. After multivariable adjustment, ischemic 
cardiomyopathy was associated with a higher mortality (adjusted HR 1.32; 95% CI 1.12-
1.54) only when compared to HF due to valvular heart disease (Table 3). 
Other clinical parameters independently associated with a poor outcome in multivariable 
analysis were advanced age (per one year increase HR 1.018; 95% CI 1.014-1.023), male 
sex (HR 1.23; 95% CI 1.10-1.38), previous heart failure (HR 1.66; 95% CI 1.48-1.86), diabetes 
(HR 1.16; 95% CI 1.02-1.32) and poor LVEF (HR 1.39; 95% CI 1.16-1.66).
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Discussion
In this study of patients hospitalized with acute HF, we found high mortality rates, both 
for the short-term and the long-term. Within a period of ten years after their initial 
hospitalization, approximately three-quarter of the patients had died. Although the long-
term prognosis of the studied patients was poor in all three decades, an improvement in 
outcome was observed in the most recent decade. Compared to those hospitalized in the 
1980s and 1990s, patients admitted in the last decade had a significantly lower ten-year 
mortality. Importantly, the improved prognosis was found in the patients with a reduced 
LVEF and not in those with a preserved LVEF. No difference in long-term mortality was 
found between the first two decades. When we analysed the prognosis of the 30-day 
survivors, a more pronounced ten-year mortality benefit of the patients admitted in the last 
decade could be established. Importantly, no change was observed in short-term mortality 
between the last three decades, with identical one-year mortality rates in the order of 35%.
An additional aim of this study was to determine the influence of the aetiology of HF on 
long-term mortality. The conclusion from our data is that, relative to other causes of HF, 
acute HF based on ischemic heart disease carried the worst prognosis, both with respect 
to the short and the long term. This remained significant after multivariable adjustment 
and, compared to valvular heart disease, the presence of ischemic cardiomyopathy 
remained associated with the highest mortality. 
Importantly, the characteristics of the patients changed during the course of our study. 
The number of patients of 75 years and older increased, although the mean age did not 
change. Moreover, the percentage of women increased, and fewer patients experienced 
a previous myocardial infarction. Nevertheless, the number of patients who had 
previously undergone coronary revascularization increased. There was some decrease 
in the number of patients with HF based on ischemic heart disease. These findings are 
consistent with a lower incidence of myocardial infarction and a more contemporary 
management of coronary artery disease in the last study period. The number of patients 
with valvular heart disease decreased over time, while non-ischemic cardiomyopathy as 
an aetiology of acute HF was found to have increased in the last decades. 
Since short-term mortality rates were identical, the observed mortality benefit in the 
last decade was most likely due to therapeutic improvements initiated after hospital 
discharge. Treatment with beta-blockers as well as ACE inhibitors has been shown to 
reduce mortality in patients with HF.[13-20] In accordance with the implementation 
and subsequent application of these new drugs in clinical practice, treatment with both 
drugs in our study increased over time. Although we were unable to establish which 
medication our patients were using following their hospitalization, we found increased 
use of ACE-inhibitors and beta-blockers already during the course of their hospitalization. 
It is reasonable to assume that such treatment was continued in patients on these 
drugs or was initiated in those not already taking these drugs. Since it takes time to 
titrate patients to the optimal dose of ACE-inhibitors and beta-blockers[29], the optimal 
treatment period would most likely have been reached during the course of follow-up. 
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Furthermore, ICDs have been found to induce a survival benefit when using for primary 
or secondary prevention in patients with HF.[22, 23] Since the new therapeutic options 
have shown their efficacy in HF with a reduced LVEF, the decline in mortality rate in the 
last decade among patients with a reduced LVEF corresponds well with the development 
of these new treatment modalities. Therefore, the lower long-term mortality that we 
observed in patients hospitalized in the last decade most likely was not related to an 
improved treatment in the acute phase, but rather a combination of better medical and 
device treatment in the follow-up period after hospital discharge.
Our study is the first to report ten-year mortality rates of patients hospitalized with 
acute HF. The longest follow-up time reported in the literature is only five years.[8, 12, 
30, 31] Our results extend various previous findings. The finding that patients with HF 
based on ischemic heart disease have the worst outcome is in agreement with results 
from other studies. [5, 12, 32] The one-year mortality rate of about 35% in our study is 
relatively high compared to other publications that reported one-year mortality rates 
between 20% and 30%.[6-10] The fact that the current analysis was done in a tertiary 
referral ICCU population is a plausible explanation. Selection bias might have occurred 
due to admission of a more selected population of patients with severe and advanced 
acute HF. However, our one-year mortality rate was lower than reported in another study 
performed at an ICCU in France.[11] The high mortality rate in that study was most likely 
related to the high number of patients with cardiogenic shock. In addition, compared 
to our study, more respiratory support and positive inotropic drugs were used. We 
observed no clear temporal trend in improved outcome at one, three or five years of 
follow-up like other studies.[12, 30-34] This was also true when we limited the analysis 
to the 30-day survivors as suggested by others.[12, 31-33] The improvement in mortality 
rate that we observed was not as pronounced as in other studies.[12, 30-33] This might 
be due to the character of our patients and centre: a tertiary referral hospital as ours 
is most likely to recruit the most critical ill patients. The fact that our study population 
comprised patients who were much younger, who had less diabetes and hypertension 
and who were more men than in other studies,[4, 8, 12, 30-33] supports the specific 
nature of our study participants. In line with this, our patients were more often treated 
with inotropics, mechanical circulatory support and mechanical ventilation.[4, 8] The fact 
that our patients were relatively young, and had less co-morbidity tan the elderly patients 
with HF, strengthens the finding that acute HF on its own carries such a poor prognosis.
The finding that the prognosis improved among the patients with a reduced LVEF (and 
not among those with a preserved LVEF) is consistent with findings from Cole et al.[34] 
While this study had unique strengths, some limitations deserve to be mentioned. We 
registered all-cause mortality, heart transplantation and LVAD implantation during follow-
up, and other outcome measures or interventions were not collected. In addition, we 
were unable to consider the therapeutic regimen following the discharge of our patients 
from the ICCU. However, given the nature of our observational study, these parameters 
might be of little additive value. 
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In conclusion, patients admitted with acute HF were found to have both high short-term 
and long-term mortality. A temporal trend in improvement of one-year mortality could 
not be established. However, an improvement in long-term prognosis was observed with 
significant lower ten-year mortality rates in the last decade. This prognostic improvement 
was only found in patients with a reduced LVEF and not in those with a preserved LVEF. 
While patients with HF due to valvular heart disease had the best prognosis, an ischemic 
aetiology of HF was associated with the worst prognosis. Our findings thus underscore 
the very poor long-term prognosis of patients with acute HF who require admission to 
an ICCU, and underscore the need for measures to prevent acute HF to develop, as well 
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Objective: We studied differences in long-term (i.e. 10 year) prognosis among patients 
with acute heart failure (HF) with and without diabetes over the last three decades. In 
addition, we investigated whether the degree of prognostic improvement in that period 
was comparable between patients with and without diabetes.
Research Design and Methods: This prospective registry included all consecutive 
patients aged 18 years and older admitted to de (Intensive) Coronary Care Unit with acute 
HF in the period of 1985-2008. A total of 1810 patients were included, 384 patients (21%) 
had diabetes. The outcome measure was the composite of all-cause mortality, heart 
transplantation and left ventricular assist device implantation after 10 year follow-up.
Results: The 10-year outcome in patients with diabetes was significantly worse than in 
those without diabetes (87% vs. 76%; adjusted hazard ratio [HR] 1.17; 95% confidence 
interval [CI] 1.02-1.33). Patients admitted in the last decade had a significantly lower 10-
year event rate than patients admitted in the first two decades, both among patients 
without diabetes (adjusted HR 0.86; 95% CI 0.75-0.99) and patients with diabetes (adjusted 
HR 0.80; 95% CI 0.63-1.00).
Conclusions: The long-term outcome of patients with diabetes is worse than that of 
patients without diabetes. However, the long-term prognosis improved over time in 
both groups. Importantly, this improvement in long-term prognosis was comparable in 
patients with and without diabetes. Despite these promising results, more awareness 
for diabetes in patients with acute HF is necessary and there is still need for optimal 
treatment of diabetes in acute HF.
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Introduction
The prevalence of both heart failure (HF) and diabetes has increased over the last 
decades and is expected to do so in the upcoming decades.(1; 2) Therefore, the presence 
of diabetes in patients with HF is also likely to increase and this is anticipated to become 
a major health concern. The actual prevalence of diabetes in patients with acute HF in 
different registries has varied, but may be as high as 45%.(3)  Because the structure and 
function of the heart is directly influenced by the presence of diabetes, diabetes is to be 
considered to represent more than just a comorbid condition in HF.(4) 
Diabetes has shown to be an independent risk factor for the development of HF.(5; 6) 
Moreover, this risk has been shown to be age- and sex-dependent. Compared to patients 
without diabetes, the presence of diabetes doubles the risk of HF in men, while the risk of 
developing HF in women may be as much as four times higher.(5) These associations may 
even be stronger in younger patients.(5) Furthermore, the presence of diabetes has been 
associated with longer duration of hospitalization and higher rates of rehospitalization among 
patients with acute HF.(7; 8) Importantly, in patients with HF, it has been established that 
the presence of diabetes is not only associated with an increased cardiovascular morbidity, 
but also with an increased mortality.(9-13) However, the prognostic value of diabetes on in-
hospital and long-term mortality among patients with acute HF is still controversial.(7; 14-19)
Since the 2000s, several new treatment modalities have been added to the therapeutic 
regime of chronic HF, resulting in an improved prognosis of these patients.(20-23) However, 
it has not been established whether the improvement of prognosis in patients with acute 
HF patients was influenced by the presence of diabetes. For these reasons, we studied 
differences in long-term prognosis among patients with acute HF with and without diabetes 
over the last three decades. In addition, we investigated whether the degree of prognostic 
improvement in that period was comparable between patients with and without diabetes.
Research Design and Methods
Inclusion
The study population and the design of the study have been described previously.(23) 
Briefly, all patients aged 18 years and older admitted at the Intensive Coronary Care Unit 
(ICCU) with acute HF were included in this prospective registry. The inclusion period was 
from 1985 until 2008. All patients were recruited from the Erasmus Medical Center. 
Patients were included when the admitting physician established a diagnosis of acute 
HF or cardiogenic shock. We included patients with acute, new onset HF as well as 
patients with decompensated chronic HF. Patients admitted for acute HF caused by an 
acute coronary syndrome without evidence of sustained systolic or diastolic dysfunction 
were excluded. If a patient was admitted more than once with acute HF, only the first 




This was a prospective cohort registry. During the enrolment of the patients, approval 
from the local research ethics committee to conduct this study was not required. The 
study was conducted according to the Declaration of Helsinki.(24)
Baseline variables
Patient records and discharge letters were used for the collection of the baseline 
variables. Age and gender were collected as demographic variables. The following clinical 
variables were collected: previous medical history, etiology of HF, left ventricular ejection 
fraction (LVEF) and BMI. Also, the type of treatment at the ICCU was registered.
Diabetes mellitus was considered to be present when patients received oral antidiabetic 
therapy and/or subcutaneous insulin prior to admission. The LVEF was classified into 
the following qualitative categories: good, moderate and poor. Quantitative measures 
for LVEF were categorized as follows: >45%, 30-44% and <30% for preserved, moderately 
depressed and severely depressed LVEF, respectively.  The etiology of HF was categorized 
into ischemic HF and non-ischemic HF.
Endpoint
The outcome measure of this study was the composite of all-cause mortality, heart 
transplantation and implantation of a left ventricular assist device (LVAD) 10 years after 
the initial hospitalization.
Survival status was assessed by using the Municipal Civil Registries in January 2017 and 
was available for 98% of the included patients.
Statistical analysis
The study population was categorized into three groups: patients admitted in 1985-1989, 
1990-1999 and 2000-2008. We chose these time frames according to the development 
of heart failure therapy (in particular angiotensin converting enzyme [ACE] inhibitors and 
beta-blockers). In the 1980s, there was no evidence-based therapy for heart failure. New 
drug therapy like ACE-inhibitors and beta-blockers were developed and subsequently 
implemented in daily practice in the 1990s and it had become common practice to 
prescribe them in the 2000s. Therefore, we hypothesized that the prognosis of patients 
admitted in the first decade was worse and that the prognosis would improve in the 
second decade and continued to improve in the last decade. Moreover, we have also 
performed additional statistical analyses with the study population divided into three 
equal groups of periods of eight years (1985-1992, 1993-2000, 2001-2008) in order to 
make sure the results were not depending on the chosen time period.
59
Diabetes and prognostic trends in acute HF
Data was summarized as mean with standard deviation for continuous variables and 
as frequencies with percentage for categorized variables. The Student’s t-test or ANOVA 
was used for comparing continuous variables and the χ2 test for comparing categorized 
variables.
Since the LVEF was not reported in 28% of the patients and the etiology was not reported 
in 12% of the patients, we applied multiple imputation. Baseline characteristics were 
used as predictors. Pooled means were given for LVEF and etiology.
The Kaplan-Meier method was used to present the cumulative event curves. The log-rank 
test was applied for comparing the Kaplan-Meier curves. Landmark analyses for the 30-
day event-free survivors (defined as patients who did not reach the composite endpoint) 
were done as secondary analyses. We used logistic regression for 30-day outcome and 
the Cox proportional hazard model for 1- and 10-year outcome in order to evaluate the 
independent association between diabetes and the composite endpoint of all-cause 
mortality, heart transplantation and LVAD implantation. In multivariable analysis for 30-
day and 1-year outcome, adjustments were made for age, gender, BMI, atrial fibrillation 
at admission, etiology of HF, LVEF and a history of HF, rhythm- or conduction disorder 
and hypertension. In the analysis of the 10-year outcome , corrections were made for 
age, gender, BMI, etiology of HF, LVEF, period of admission and a history of myocardial 
infarction, HF and rhythm- or conduction disorder. All variables were categorical, except 
for age which was retained as a continuous variable. Results of logistic regression and 
the Cox proportional hazard model were reported as odds ratios (ORs) and hazard ratios 
(HRs), respectively, with their corresponding 95% confidence interval (95% CI).
All tests were two-tailed and p-values <0.05 were considered statistically significant. All 
data were analyzed using SPSS software (SPSS 21.0, IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
We identified 1810 patients admitted with acute HF to our ICCU in the period of 1985 
until 2008. Of these, 384 patients (21%) had diabetes. The prevalence of diabetes 
increased: in the 1980s, 14% of the patients had diabetes, compared to 21% in the 1990s 
and 27% in the most recent study period (p for trend <0.001). Baseline characteristics of 
patients with and without diabetes were different (Table 1). On average, patients with 
diabetes were 5 years older, were more often female and had a higher BMI as compared 
to patients without diabetes. Furthermore, patients with diabetes more frequently had 
history of hypertension, myocardial infarction and coronary revascularization. Presence 
of diabetes was more commonly associated with ischemic HF, while patients without 
diabetes more often sustained HF of a non-ischemic origin. The distribution of the left 
ventricular function was not influenced by the presence of diabetes.
60
CHAPTER 4









No. of patients 1810 384 1426
Age (mean, y) 63.5 ± 14.8 67.1 ± 11.1 62.3 ± 15.5 <0.001
Male 1153 (64%) 223 (58%) 930 (65%) 0.01
Body Mass Index 25.1 ± 4.9 27.1 ± 6.3 24.6 ± 4.5 <0.001
Medical history
Myocardial infarction 714 (39%) 188 (49%) 526 (37%) <0.001
Coronary revascularization† 390 (22%) 108 (28%) 282 (20%) <0.001
Heart surgery (not CABG) 237 (13%) 38 (10%) 199 (14%) 0.04
Heart transplantation 9 (0.5%) 1 (0.3%) 8 (0.6%) 0.69
Waiting for heart transplantation 35 (2%) 4 (1%) 31 (2%) 0.15
Heart failure 888 (49%) 184 (48%) 704 (49%) 0.61
Rhythm- or conduction disorder 445 (25%) 83 (22%) 362 (25%) 0.13
Hypertension 590 (33%) 184 (48%) 406 (29%) <0.001
Heart failure
Etiology of heart failure <0.001
Ischemic origin 845 (47%) 239 (62%) 606 (42%)
Non-ischemic origin 965 (53%) 145 (38%) 820 (58%)
Atrial fibrillation at admission 391 (22%) 75 (20%) 316 (22%) 0.27
Left ventricular ejection fraction >0.05
Preserved 522 (29%) 122 (32%) 400 (28%)
Moderately depressed 427 (24%) 91 (24%) 336 (24%)
Severely depressed 861 (48%) 171 (44%) 690 (48%)  
CABG, coronary artery bypass graft; *Comparison between patients with and without diabetes †Percutaneous 
coronary intervention and/or CABG
Diabetes and mortality
Compared to patients without diabetes, patients with diabetes less frequently reached 
the composite endpoint of all-cause mortality, heart transplantation and LVAD 
implantation at 30 days (9% vs 16%; unadjusted OR 0.51; 95% CI 0.35-0.75; Figure 1). 
After multivariable adjustment, the difference in the 30-day event rate was somewhat 
attenuated but remained lower in patients with diabetes (adjusted OR 0.61; 95% CI 0.41-
0.92). The cumulative 1-year event rate was comparable between patients with and 
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without diabetes (p=0.13; Figure 1A). When the analysis was restricted to the 30-day 
event-free survivors only, the number of patients who reached the composite endpoint 
was almost identical in patients with diabetes and in those without diabetes (26% and 
25%, respectively; p=0.63; Figure 1B).
Figure 1. Kaplan-Meier curve of the cumulative incidence of reaching the composite endpoint of all-cause 
mortality, heart transplantation and left ventricular assist device (LVAD) implantation in (A) the total population 
and a landmark analysis in (B) the 30-day event-free survivors: patients with diabetes vs. those without diabetes
The number of patients who reached the composite endpoint of all-cause mortality, heart 
transplantation and LVAD implantation after 10 years of follow-up  was higher in patients 
with diabetes than in those without diabetes (87% vs. 76%; unadjusted HR 1.19 [95% CI 1.06-
1.36]; Figure 1A) and this remained the case after multivariable adjustment (adjusted HR 
1.17 [95% CI 1.02-1.33]). A more pronounced difference in the 10-year event rate between 
patients with and without diabetes became apparent when the analysis was restricted to 
the 30-day event-free survivors (adjusted HR 1.33 [95% CI 1.15-1.53]; Figure 1B).
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Patients with diabetes more frequently had prior myocardial infarction and an ischemic 
cause of HF was more common among these patients. However, since we did not find 
a significant interaction in the multivariable Cox proportional hazard model neither 
between diabetes and previous myocardial infarction (p=0.95) nor between diabetes and 
etiology of HF (p=0.95), there was no difference in impact on long-term outcome of these 
factors between patients with and without diabetes. 
Long-term prognosis over time
The baseline characteristics of patients with and without diabetes changed during 
the three decades of observation (Supplemental Table 1). With time, the presence of 
coronary revascularization, rhythm- or conduction disorder and hypertension became 
more frequent among both subgroups. In addition, the patients without diabetes 
more commonly were women and had less prior myocardial infarction over time. The 
distribution of etiology of HF and LVEF remained stable over time in both patients with 
and without diabetes.
The short- and long-term event rate of patients admitted in the second decade was 
comparable with the outcome in the first decade, independent of the presence of 
diabetes whether or not. For the purpose of comparison with the outcome of patients 
studied in the most recent time period, patients admitted from 1985 until 1999 were 
pooled into one group.  This comparison demonstrated that the 1-year outcome did not 
significantly improve over time, neither in patients with diabetes nor in those without 
diabetes (adjusted HR 0.93 [95% CI 0.64-1.36] and adjusted HR 0.92 [95% CI 0.76-1.12], 
respectively). In contrast, the long-term event rate showed improvement, both in acute 
HF patients with and in those without diabetes (Figure 2). Patients without diabetes 
admitted in the last decade less frequently reached the composite endpoint 10 years 
after initial hospitalization than patients admitted in the first two decades (adjusted HR 
0.86; 95% CI 0.75-0.99). A similar improvement in long-term outcome was found among 
the patients with diabetes (adjusted HR 0.80; 95% CI 0.63-1.00). This improvement in long-
term outcome over time was more pronounced in both patients without and those with 
diabetes when the analysis was restricted to the 30-day event-free survivors (adjusted HR 
0.81 [95% CI 0.69-0.95] and adjusted HR 0.74 [95% CI 0.58-0.95], respectively).
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Figure 2. Multivariable adjusted trends in 10-year prognosis among patients with acute heart failure: patients with 
diabetes vs. those without diabetes. Analyses were separately done in (A) the total population and in (B) the 30-day 
event-free survivors. The dataset was divided according to the three decades.
CI, confidence interval; HR, hazard ratio.
When we analyzed the temporal trend in the long-term prognosis of the patients divided 
into three equal groups of periods of eight years, we found that the prognosis of patients 
admitted in the first period (1985-1992) was comparable with the outcome in the patients 
admitted in the period of 1993 until 2000. Therefore, we pooled these patients into one 
group and compared their long-term outcome with the outcome in patients admitted 
in the period 2001-2008 (Figure 3). The outcome of these analyses was comparable to 
the results of the analyses in patients divided according to the decades. Hence, we can 




Figure 3. Multivariable adjusted trends in 10-year prognosis among patients with acute heart failure: patients with 
diabetes vs. those without diabetes. Analyses were separately done in (A) the total population and in (B) the 30-day 
event-free survivors. The dataset was divided according to the three groups of equal length in years.
CI, confidence interval; HR, hazard ratio.
Discussion
In this cohort study of patients with acute HF, studied over a period of 24 years, the 
prevalence of diabetes increased over time, with almost 30% of the patients found to 
have diabetes in the last decade. This study shows that among patients with acute HF, 
the presence of diabetes is associated with a clear prognostic disadvantage at long-term 
(i.e. 10 years) when compared to those without diabetes. More important, we clearly 
demonstrated that the temporal reduction in long-term outcome (i.e. the composite of 
all-cause mortality, heart transplantation and LVAD implantation) in patients admitted 
with acute HF, achieved in the last decade, was at least as high in patients with diabetes 
and in those without diabetes.
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Short- and long-term outcome in patients with and without diabetes
This study added results to the controversial evidence available in literature about 
prognostic impact of diabetes on the 1-year prognosis among patients admitted 
with acute HF. We found that patients with and without diabetes equally reached the 
composite endpoint of all-cause mortality, heart transplantation and LVAD implantation 
after 1 year follow-up. This endorsed the findings by others who reported a comparable 
prognosis in patients with and without diabetes.(19) However, our findings were also in 
contrast with previous studies. DIAMOND-CHF was a large, Danish trial with more than 
5000 patients reporting higher 1-year mortality rates among patients with diabetes.(14) 
Two other European registries also found a prognostic disadvantage of diabetes on the 
1-year prognosis.(15; 18) Last, a large retrospective, Scottish population study found also 
a prognostic disadvantage after 1 year follow-up of patients with diabetes.(16) A potential 
reason for these discrepancies is the difference in study population. Generally, patients 
in our study were younger, more commonly had a myocardial infarction or HF in history 
and were found to have less frequently a history of hypertension.
Importantly, after a longer follow-up duration, acute HF patients with diabetes had a 
prognostic disadvantage compared to those without diabetes. This resulted in a higher 
10-year event rates among patients with diabetes. These results confirmed the results 
reported by others.(14; 25; 26)
The poorer long-term prognosis in patients with diabetes is an important finding and 
has implications for the future. Since the incidence of diabetes in HF patients is likely to 
further increase in the future, this will become a major healthcare problem with high 
morbidity and mortality, as well as high costs for society.(27) Therefore, it is important to 
recognize diabetes in patients with HF and to start an adequate therapy for the diabetes. 
However, there is little evidence for the best therapy of glycemic control in HF patients 
in practice.(28) For that reason, more future clinical research is required for the medical 
treatment of diabetes in patients with HF. We believe that better glycemic control in that 
specific subset of patients may contribute to a further improvement in prognosis.
Temporal trends in long-term prognosis
Several previous studies have reported trends in long-term outcome,(20-23) but temporal 
trends among acute HF patients stratified by the presence of diabetes have not been 
described previously, neither short-term trends nor long-term trends. Novel treatment 
modalities for HF, like ACE-inhibitors, beta-blockers, mineralocorticoid receptor antagonists, 
implantable cardioverter defibrillators and cardiac resynchronization therapy have all been 
implemented in clinical practice in the last decades. This change in the therapeutic regimen 
was associated with a lower long-term mortality in the total population with acute HF,(20-
23) and it caused the improved long-term prognosis of the patients without diabetes. 
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However, our study cannot definitely elucidate the mechanisms that resulted in the 
improved long-term prognosis among the diabetes subgroup. Since the novel treatment 
modalities have been found to have comparable mortality benefit in both in patients 
with and without diabetes,(27) it is possible that this is the (only) reason for the improved 
long-term prognosis among the acute HF patients with diabetes. On the other hand, 
previous studies among patients with diabetes (not in an acute HF population) showed an 
improved survival over the last decades,(29; 30) which attributed to a growing awareness 
of diabetes, more focus on cardiovascular prevention by treating comorbidities and an 
improvement in the treatment of acute myocardial infarction.(29-31) We hypothesized 
that the improved prognosis among acute HF patients with diabetes may a result from 
the combination of both above-mentioned potential mechanisms. Therefore, despite the 
impaired prognosis associated with diabetes in acute HF, both patients admitted with 
acute HF with diabetes and those without diabetes showed a comparable improvement 
over time in long-term prognosis.
Thirty-day outcome of patients with and without diabetes
Contrary to expectations, we found that patients with acute HF with diabetes less 
frequently reached the composite endpoint at 30 days than those without diabetes. This 
is not a unique finding, but data on this topic vary. Some studies reported comparable in-
hospital mortality in patients with and without diabetes,(7) but other analyses described 
worse in-hospital outcome in patients with diabetes.(17; 18) A large Scottish database 
reported that diabetes was associated with lower 30-day mortality.(16) The hypothesis 
put forward by these investigators was that patients with diabetes would most likely have 
a better ejection fraction than subjects without diabetes. Since the authors were unable 
to adjust for LVEF, they could not establish this hypothesis. When we adjusted for LVEF 
in our analyses, we found that – despite this – patients with diabetes continued to have 
better 30-day outcome.
We think there might be two potential reasons for this prognostic disadvantage of the 
patients without diabetes in our study. First, the patients without diabetes who reached 
the composite endpoint within 30 days were most likely predominantly patients with 
end-stage HF or, given the fact that patients without diabetes more often were treated 
with mechanical circulatory support, patients with cardiogenic shock. It is well known that 
cardiogenic shock is associated with elevated in-hospital mortality.(32; 33) The second 
reason why patients without diabetes were found to have poorer 30-day prognosis may 
be due to the fact that the patients in our survey were admitted at an intensive care 
unit. A lower in-hospital mortality among patients with diabetes admitted at a general 
intensive care unit has also been described by Graham et al. and Martin et al.(34; 35) 
These two studies constitute the largest reports that investigated in the in-hospital 
prognosis among patients with diabetes admitted at the general intensive care unit. 
However, the mechanism of the lower in-hospital mortality among these patients with 
diabetes admitted at an intensive care unit was not stipulated.
67
Diabetes and prognostic trends in acute HF
Strengths and limitations
This study has several strengths. First, we studied long-term outcome (i.e. 10 years) in a 
large population of patients with acute HF over a study period of 24 years. Furthermore, 
this is the first study reporting temporal trends in prognosis among acute HF patients 
with diabetes and those without diabetes.
Despite these unique strengths, some limitations should be acknowledged. First, this 
study was performed in a single center. Therefore, this could result in a lower external 
validity. Furthermore, no distinction was made between type 1 and type 2 diabetes. 
Also, any information regarding the development of diabetes during follow-up among 
the patients without diabetes at baseline was not available. Development of diabetes 
during follow-up may also have influenced the prognosis. Finally, information about 
drug therapy of diabetes was not reported in our database. This may be of added value 
because the type of diabetes treatment could influence HF symptoms, hospitalization 
and mortality.(36-38) 
Conclusion
In conclusion, we showed that patients admitted with acute HF had a poor prognosis. 
Moreover, the long-term outcome (i.e. the composite of all-cause mortality, heart 
transplantation and LVAD implantation) of patient with diabetes is worse as compared to 
those without diabetes. However, the long-term mortality prognosis improved over time 
as a result of an improved treatment of HF. Importantly, this improvement in long-term 
prognosis was at least as high in patients without diabetes as in those with diabetes. This 
study does not only emphasize the need to improve the treatment of HF, but this also 
emphasizes the need for optimal treatment of diabetes in acute HF as well as to create 
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Renal function and anemia in relation to 
short- and long-term prognosis of patients 
with acute heart failure in the period  
1985-2008: A clinical cohort study.










Background: Renal dysfunction and anaemia are common in patients with acute heart 
failure (HF). It is not known whether their combined presence has additive prognostic 
value. We investigated their prognostic value separately and in combination, on prognosis 
in acute HF patients. Furthermore, we examined whether the improvement in prognosis 
was comparable between patients with and without renal dysfunction.
Methods and Results: This prospective registry includes 1783 patients admitted to the 
(Intensive) Coronary Care Unit for acute HF in the period of 1985-2008. The outcome 
measure was the composite of all-cause mortality, heart transplantation and left 
ventricular assist device implantation. In patients without renal dysfunction, anemia was 
associated with worse 30-day outcome (HR 2.91; [95% CI 1.69-5.00]), but not with 10-year 
outcome (HR 1.13 [95% CI 0.93-1.37]). On the contrary, anemia was found to influence 
prognosis in patients with renal dysfunction, both at 30 days (HR 1.93 [95% CI 1.33-2.80]) 
and at 10 years (HR 1.27 [95% CI 1.10-1.47]). Over time, the 10-year survival rate improved 
in patients with preserved renal function (HR 0.73 [95% CI 0.55-0.97]), but not in patients 
with renal dysfunction.
Conclusion: The long-term prognosis of acute HF patients with a preserved renal function 
was found to have improved significantly. However, the prognosis of patients with renal 
dysfunction did not change. Anemia was a strong prognosticator for short-term outcome 
in all patients. In patients with renal dysfunction, anemia was also associated with 
impaired long-term prognosis.
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Introduction
Acute heart failure (HF) is commonly accompanied by various non-cardiovascular 
comorbidities. Renal dysfunction is among one of the most common although its exact 
prevalence has varied between studies.[1, 2] Renal dysfunction in acute HF is associated 
with various adverse outcomes: longer hospital stay, higher re-hospitalization rate, and 
higher mortality.[1, 2] Of note, the follow-up period in most of these studies is restricted 
to only 1 year after the initial hospitalization.
In the last decades, an improvement in long-term outcome has been observed among 
patients with acute HF in several cohorts.[3-5] New therapeutic options and an increased 
understanding of the pathophysiology of HF are most likely responsible for this trend. 
Importantly, renal dysfunction is a (relative) contra-indication for some of the new 
therapeutic modalities[6]. As of yet, it has not been established whether the improvement 
in prognosis over time of patients with acute HF is modified by the presence of renal 
dysfunction.
Anemia is another important and common comorbidity in patients with acute HF, with 
a prevalence up to almost 60%.[7-12] There is conflicting data regarding the prognostic 
impact of anemia in patients with acute HF.[10-13] Moreover, the combination of HF, renal 
dysfunction and anemia carries an incremental negative prognostic impact in patients 
with chronic HF.[14] However, the additive prognostic value of anemia in patients with 
acute HF with and without renal dysfunction remains scarce.
Therefore, the aims of the present study were (1) to examine the impact of renal function 
on short- and long-term prognosis of patients with acute HF, (2) to determine whether 
the improvement in prognosis of patients with acute HF and renal impairment was 
comparable to that of patients with normal renal function, and (3) to study the impact 




This prospective registry was carried out among patients who were admitted with acute 
HF at the Intensive Coronary Care Unit (ICCU) in our hospital during the period from 1985 
until 2008. The study design and inclusion have been described previously.[5] Briefly, 
consecutive patients aged 18 years and older were included when they were diagnosed 
with acute HF or cardiogenic shock at admission. Both patients with de novo HF and 
patients with worsening symptoms of chronic HF were included. Patients could only 
contribute once to the database, and if patients were admitted more than once with 
acute HF during the inclusion period, only the first admission was included for analyses.
78
CHAPTER 5
This was a prospective cohort registry. For analyses, we used completely anonymized 
data. During the enrolment of the patients, approval from the research ethics committee 
of the Erasmus MC to conduct this study was not required. At a later stage, the committee 
confirmed that we did not need their approval to conduct this study. Furthermore, there 
was no requirement for patients’ informed consent. The study was conducted according 
to the Declaration of Helsinki.[15]
Endpoints
The outcome measure was the composite of  all-cause mortality, heart transplantation 
and left ventricular assist device (LVAD) implantation at 30 days, 1 year and 10 years after 
the initial hospitalization.
Survival status was assessed by using the Municipal Civil Registries in January 2017 and 
was available for 98% of the included patients. To determine whether patients received 
an LVAD or underwent heart transplantation, we used prospectively collected data from 
our hospital information system.
Variables and definitions
Baseline variables were derived from patient records and discharge letters. We collected 
the following variables: age, gender, Body Mass Index (BMI), cardiac history, etiology of 
HF, left ventricular ejection fraction (LVEF) and treatment at the ICCU. Furthermore, the 
results of the following laboratory tests were collected: sodium (mmol/L), potassium 
(mmol/L), creatinine (µmol/L), urea (mmol/L) and hemoglobin (mmol/L).
Diabetes mellitus was considered to be present when patients received antidiabetic 
therapy. The LVEF was classified into the following qualitative categories: good, moderate 
and poor. If quantitative outcome for the LVEF was used, we applied the following cut-
offs: >45%, 30-44% and <30% for good, moderate and poor LVEF, respectively.[5] The 
etiology of HF was categorized into ischemic cause versus non-ischemic cause of HF. 
For all laboratory tests, the first measured value during hospitalization was taken into 
account. The estimated glomerular filtration rate (eGFR) was estimated by using the 
Modification of Diet in Renal Disease (MDRD) equation for serum creatinine (µmol/L): 
eGFR = 30849 × serum creatinine −1.154 × age −0.203 × 0.742 (if female) [eGFR in mL/
min/1.73 m2].[16] In line with the most recent HF guideline of the European Society of 
Cardiology,[6] renal function was categorized as follows: preserved renal function: eGFR 
≥60 mL/min/1.73 m2; moderately impaired renal function eGFR 30-59 mL/min/1.73 m2; 
severely impaired renal function eGFR <30 mL/min/1.73 m2. We used the definition of the 
World Health Organization to define anemia: hemoglobin <7.5 mmol/L in women and 
<8.2 mmol/L in men. Hyponatremia was defined as a serum sodium level ≤135 mmol/L. 
For the definition of hypo- and hyperkalemia the following cut-off values were applied: 
serum potassium <3.5 mmol/L and >5.0 mmol/L, respectively.
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Statistical analysis
Categorical variables are presented as frequencies and percentages. The χ2 test and the 
Fisher-Freeman-Halton exact test were used to compare categorical variables. Normally 
distributed, continuous data are presented as mean values with standard deviation and 
were compared using the one-way ANOVA. Continuous data that were not normally 
distributed are presented as median and interquartile range (IQR). The Mann-Whitney U 
test or the Kruskal-Wallis H test was used to compare these data.
Since data for LVEF and etiology were incomplete for, respectively, 28% and 12% of 
the patients, multiple imputation was performed by using baseline characteristics as 
predictors. Pooled means are given for LVEF and etiology.
The Kaplan-Meier method was used for presenting the cumulative event curves and they 
were compared using the log-rank test. Secondary analyses were carried out among 
the 30-day event-free survivors. Logistic regression for 30-day outcome and the Cox 
proportional hazard method for long-term outcome were applied in order to examine 
the independent association between renal function and the composite endpoint of 
all-cause mortality, heart transplantation and LVAD implantation, as well as between 
anemia and the composite endpoint. Adjustments were made for age, gender, history 
of HF, diabetes, hypertension, etiology of HF, atrial fibrillation at admission, LVEF, renal 
function and anemia.
All tests were two-tailed and p-values <0.05 were considered statistically significant. 
Results of logistic regression and the Cox proportional hazard model were reported as 
odds ratios (ORs) and hazard ratios (HRs), respectively, with their corresponding 95% 
confidence interval (95% CI). All statistical analyses were carried out using SPSS software 
(SPSS 21.0, IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
In total, 1810 patients were admitted with acute HF in the period 1985-2008. Of these, 
1783 (99%) patients had at least one creatinine measurement and they constitute the 
present study population. Over half of the patients were found to have renal dysfunction, 
which was severely impaired in 18%. The proportion of patients with severe renal 
impairment remained stable over time, whereas the number of patients with preserved 




Figure 1. Distribution of the study population according to the renal function and the admission period. 
eGFR, estimated glomerular filtration rate in mL/min/1.73 m2
Compared to patients with renal dysfunction, patients with preserved renal function were 
on average 6 years younger (Table 1). In addition, they less often had prior myocardial 
infarction and coronary revascularization. With decreasing renal function, the prevalence 
of prior HF, diabetes and hypertension increased. Hyponatremia was also more common 
in patients with renal dysfunction, as was anemia.
Table 1. Baseline characteristics and therapy according to renal function
eGFR ≥60 eGFR 30-59 eGFR <30 p-value*
No. of patients 688 (39%) 778 (44%) 317 (18%)
Baseline
Age (mean, y) 59.7 ± 16.3 66.1 ± 13.2 65.9 ± 12.9 <0.001
Male 458 (67%) 475 (61%) 201 (63%) 0.09
BMI 25.4 ± 5.2 24.9 ± 4.8 25.0 ± 4.7 0.57
Medical history
Myocardial infarction 237 (34%) 347 (45%) 120 (38%) <0.001
Coronary revascularization† 124 (18%) 187 (24%) 75 (24%) 0.01
Heart surgery (not CABG) 111 (16%) 87 (11%) 36 (11%) 0.01
Heart transplantation 2 (0.3%) 1 (0.1%) 6 (2%) 0.002
Waiting for heart transplantation 16 (2.3%) 11 (1.4%) 8 (2.5%) 0.33
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eGFR ≥60 eGFR 30-59 eGFR <30 p-value*
Heart failure 300 (44%) 390 (50%) 188 (59%) <0.001
Rhythm- or conduction disorder 157 (23%) 210 (27%) 73 (23%) 0.14
Diabetes 132 (19%) 168 (22%) 81 (26%) 0.07
Hypertension 194 (28%) 257 (33%) 133 (42%) <0.001
Heart failure
Etiology of heart failure <0.05
Ischemic origin 302 (44%) 392 (50%) 140 (44%)
Non-ischemic origin 386 (56%) 386 (50%) 177 (56%)
Atrial fibrillation at admission 159 (23%) 178 (23%) 49 (16%) 0.01
Left ventricular ejection fraction <0.05
Good 199 (29%) 225 (29%) 91 (29%)
Moderate 187 (27%) 156 (20%) 76 (24%)
Poor 302 (44%) 396 (51%) 149 (47%)
Laboratory values
Sodium 137 ± 5 137 ± 6 135 ± 6 <0.001
Potassium 4.0 ± 0.6 4.2 ± 0.7 4.6 ± 0.9 <0.001
Urea (median, IQR) 7.2 (5.7-9.3) 10.6 (8.2-14.4) 23.5 (17.5-30.8) <0.001
eGFR (median, IQR) 75 (66-89) 47 (39-53) 20 (14-25) <0.001
Creatinine (median, IQR) 80 (71-96) 123 (109-142) 258 (215-346) <0.001
Hemoglobin 8.3 ± 1.3 8.1 ± 1.4 6.9 ± 1.5 <0.001
Hyponatremia 221 (32%) 224 (29%) 151 (48%) <0.001
Hypokalemia 106 (15%) 98 (13%) 23 (7%) <0.001
Hyperkalemia 38 (6%) 81 (10%) 85 (27%) <0.001
Anemia 262 (38%) 334 (43%) 244 (77%) <0.001
Therapy during ICCU hospitalization
Intubation 69 (10%) 117 (15%) 57 (18%) 0.001
Resuscitation 19 (3%) 36 (5%) 15 (5%) 0.13
Mechanical circulatory support‡ 34 (5%) 41 (5%) 29 (9%) 0.02
Inotropics 196 (29%) 253 (33%) 123 (39%) 0.01
Beta-blocker 146 (21%) 111 (14%) 47 (15%) 0.001
Antiarrhythmics 115 (17%) 154 (20%) 45 (14%) 0.06
Calcium antagonist 77 (11%) 102 (13%) 72 (23%) <0.001
Digitalis 300 (44%) 347 (45%) 87 (27%) <0.001
ACE-inhibitor or ARB 422 (61%) 430 (55%) 113 (36%) <0.001
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eGFR ≥60 eGFR 30-59 eGFR <30 p-value*
Diuretics 640 (93%) 718 (92%) 257 (81%) <0.001
Nitrates 234 (34%) 289 (37%) 121 (38%) 0.24
Nitroprusside 46 (7%) 74 (10%) 39 (12%) 0.01
Antiplatelet agents 200 (29%) 189 (24%) 71 (22%) 0.04
Oral anticoagulant 351 (51%) 406 (52%) 136 (43%) 0.02
ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; BMI, Body Mass Index; CABG, coronary 
artery bypass graft; eGFR, estimated glomerular filtration rate; ICCU, intensive cardiac care unit; IQR, interquartile 
range; *p for any difference; †Percutaneous coronary intervention and/or CABG; ‡Intra-aortic balloon pump and/
or left ventricular assist device and/or extracorporeal membrane oxygenation
Regarding therapy, patients with renal impairment were more frequently treated with 
intubation and mechanical ventilation, mechanical circulatory support and inotropic 
agents (Table 1). Moreover, the degree of renal impairment was associated with lower 
in-hospital usage of beta-blockers, ACE-inhibitors and diuretics.
Renal function and outcome
The median survival of patients with a severely impaired, moderately impaired and 
preserved renal function was 1.0, 2.1 and 4.4 years, respectively. The impact of renal 
function on outcome is shown in Figure 2 and Table 2. Patients with a severely impaired 
renal function had the worst prognosis both at short- and long-term. 
Figure 2. Kaplan-Meier curve of patients with acute heart failure according to the renal function. 
eGFR, estimated glomerular filtration rate in mL/min/1.73 m2; LVAD, left ventricular assist device
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Table 2. Prognosis at different follow-up moments according to renal function
  All-cause mortality, 
heart transplantation or 
LVAD implantation
Univariable analysis* Multivariable 
analysis*
30 days    
eGFR ≥60 10% Reference Reference
eGFR 30-59 14% 1.51 (1.10-2.08) 1.50 (1.06-2.11)
eGFR <30 24% 2.85 (1.99-4.08) 2.32 (1.55-3.47)
1 year    
eGFR ≥60 28% Reference Reference
eGFR 30-59 36% 1.41 (1.17-1.69) 1.34 (1.11-1.62)
eGFR <30 50% 2.21 (1.79-2.73) 1.81 (1.44-2.28)
10 years    
eGFR ≥60 69% Reference Reference
eGFR 30-59 81% 1.42 (1.33-1.51) 1.24 (1.09-1.40)
eGFR <30 92% 2.14 (1.99-2.31) 1.68 (1.43-1.96)
eGFR, estimated glomerular filtration rate in mL/min/1.73 m2; LVAD, left ventricular assist device; *Odds ratio with 
95% confidence interval (CI) for 30-day outcome, hazard ratio with 95% CI for 1-year and 10-year outcome
These findings remained unchanged after multivariable adjustment for other prognostic 
factors. Although the influence of renal function on prognosis became less prominent 
with longer duration of follow-up, renal function still remained a strong predictor of the 
composite endpoint of all-cause mortality, heart transplantation and LVAD implantation. 
Over time, the 10-year outcome of patients with a preserved renal function improved 
significantly, both unadjusted (HR 0.70 [95% CI 0.61-0.81] for most recent period versus 
first period) and after adjustment for confounding variables (adjusted HR 0.73 [95% 
CI 0.55-0.97]; Figure 3A). This improvement was more pronounced among the 30-day 
survivors (adjusted HR 0.65 [95% CI 0.48-0.88]; Figure 3B). In contrast, this pattern was 
not present in patients with renal dysfunction. Consequently, the prognosis of these 
patients did not improve over time.
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Figure 3. Prognosis over time among (A) the total population and (B) the 30-day survivors of patients with acute 
heart failure. 
Results were divided into three groups according to the renal function. CI, confidence interval; eGFR, estimated 
glomerular filtration rate in mL/min/1.73 m2; HR, hazard ratio
Anemia and outcome
Almost 50% of the patients were found to have anemia. The characteristics of these 
patients differed in some aspects from those without anemia (Table 3). Anemic patients 
more frequently had previous HF and atrial fibrillation at admission. Importantly, they 
more often had impaired renal function.
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Table 3. Baseline characteristics and therapy of patients with and without anemia
  Anemia + Anemia - p-value
No. of patients 850 (48%) 919 (52%)
Baseline
Age (mean, y) 63.1 ± 14.5 64.1 ± 15.0 0.15
Male 565 (67%) 560 (61%) 0.02
BMI 24.8 ± 4.8 25.4 ± 5.2 0.20
Medical history
Myocardial infarction 336 (40%) 362 (39%) 0.95
Coronary revascularization* 199 (23%) 183 (20%) 0.07
Heart surgery (not CABG) 131 (15%) 102 (11%) 0.01
Heart transplantation 8 (0.9%) 1 (0.1%) 0.02
Waiting for heart transplantation 22 (2.6%) 12 (1.3%) 0.05
Heart failure 440 (52%) 425 (46%) 0.02
Rhythm- or conduction disorder 215 (25%) 218 (24%) 0.44
Diabetes 199 (23%) 181 (20%) 0.06
Hypertension 271 (32%) 308 (34%) 0.47
Heart failure
Etiology of heart failure >0.05
Ischemic origin 387 (45%) 438 (48%)
Non-ischemic origin 463 (55%) 481 (52%)
Atrial fibrillation at admission 141 (17%) 243 (26%) <0.001
Left ventricular ejection fraction >0.05
Good 260 (31%) 250 (27%)
Moderate 192 (23%) 227 (25%)
Poor 399 (47%) 442 (48%)
Laboratory values
Sodium 136 ± 6 138 ± 5 <0.001
Potassium 4.3 ± 0.8 4.1 ± 0.7 0.001
Urea (median, IQR) 12.6 (8.3-20.4) 8.4 (6.6-11.6) <0.001
eGFR (median, IQR) 47 (26-64) 57 (43-73) <0.001
Creatinine (median, IQR) 123 (94-200) 102 (82-130) <0.001
Hemoglobin 6.7 ± 0.9 9.0 ± 0.8 <0.001
Hyponatremia 359 (42%) 233 (25%) <0.001
Hypokalemia 100 (12%) 125 (14%) 0.28
Hyperkalemia 122 (14%) 85 (9%) 0.001
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  Anemia + Anemia - p-value
Therapy during ICCU hospitalization
Intubation 151 (18%) 92 (10%) <0.001
Resuscitation 36 (4%) 34 (4%) 0.56
Mechanical circulatory support† 80 (9%) 23 (3%) <0.001
Inotropics 329 (39%) 238 (26%) <0.001
Beta-blocker 128 (15%) 174 (19%) 0.03
Antiarrhythmics 143 (17%) 165 (18%) 0.53
Calcium antagonist 130 (15%) 123 (13%) 0.25
Digitalis 305 (36%) 419 (46%) <0.001
ACE-inhibitor or ARB 417 (49%) 540 (59%) <0.001
Diuretics 747 (88%) 854 (93%) <0.001
Nitrates 295 (35%) 342 (37%) 0.27
Nitroprusside 73 (9%) 86 (9%) 0.57
Antiplatelet agents 238 (28%) 224 (24%) 0.08
Oral anticoagulant 383 (45%) 497 (54%) <0.001
ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; BMI, Body Mass Index; CABG, coronary 
artery bypass graft; eGFR, estimated glomerular filtration rate; ICCU, intensive cardiac care unit; IQR, interquartile 
range; *Percutaneous coronary intervention and/or CABG; †Intra-aortic balloon pump and/or left ventricular assist 
device and/or extracorporeal membrane oxygenation
The prognosis of patients with anemia was worse than of patients without anemia 
(Figure 4). After adjustment for confounders, anemia remained significantly associated 
with increased for reaching the composite endpoint of all-cause mortality, heart 
transplantation and LVAD implantation at 30 days, 1 year and 10 years (HR 2.23 [95% CI 
1.64-3.03], HR 1.58 [95% CI 1.33-1.87] and HR 1.24 [1.11-1.39], respectively; Table 4). 
Figure 4. Kaplan-Meier curve of acute heart failure patients with and without anemia. 
LVAD, left ventricular assist device
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Table 4. Prognosis at different follow-up moments according to the presence of anemia
  All-cause mortality, 
heart transplantation or 
LVAD implantation
Univariable analysis* Multivariable 
analysis*
30 days    
No anemia 9% Reference Reference
Anemia 20% 2.55 (1.92-3.38) 2.23 (1.64-3.03)
1 year    
No anemia 28% Reference Reference
Anemia 43% 1.75 (1.49-2.05) 1.58 (1.33-1.87)
10 years    
No anemia 75% Reference Reference
Anemia 83% 1.35 (1.28-1.43) 1.24 (1.11-1.39)
LVAD, left ventricular assist device; * Odds ratio with 95% confidence interval (CI) for 30-day outcome, hazard ratio 
with 95% CI for 1-year and 10-year outcome
Since anemia was a predictor of poor outcome in the total population of acute HF 
patients, we separately analyzed whether anemia had incremental prognostic value 
independent from renal dysfunction (Figure 5). Among patients with a preserved renal 
function, anemia proved to be a strong predictor for 30-day outcome, but its prognostic 
value decreased with longer duration of follow-up. In contrast, anemia was associated 
with worse outcome both during short- and long-term follow-up among patients with 
renal dysfunction. This relationship persisted after the exclusion of patients who died 
within 30 days after admission.
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Figure 5. Prognostic impact of anemia at different follow-up moments in the total population and 30-day survivors. 
Analyses were separately done for renal impairment whether or not. CI, confidence interval; eGFR, estimated 
glomerular filtration rate in mL/min/1.73 m2; HR, hazard ratio; *outcome at 30 days was reported as odds ratio 
with 95% CI.
Discussion
In this prospective registry of patients with acute HF, we found that renal dysfunction 
was a strong predictor for poor outcome (i.e. the composite of all-cause mortality, heart 
transplantation and LVAD implantation) up to 10 years following initial hospitalization. 
Importantly, this study is the first to show that patients with acute HF and an impaired 
renal function had no improvement in prognosis that occurred in the last three decades. 
This contrasts findings in patients with a preserved renal function. Furthermore, we found 
that the prognostic impact of anemia was dependent on the presence of renal function. 
Anemia had no impact on the long-term prognosis of patients with a preserved renal 
function. On the other hand, anemia was associated with impaired prognosis among 
patients with renal dysfunction.
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Renal function and prognosis
Renal dysfunction proved to be a strong predictor of a poor outcome: the poorer the 
renal function, the poorer the prognosis. Among studies that demonstrated the adverse 
association between renal dysfunction and poor survival,[1, 2] most only used a short 
follow-up period, usually up to 1 year after hospitalization. Our results support and 
extend these findings by demonstrating that renal dysfunction continued to be a strong 
predictor for long-term outcome (i.e. 10 years). 
It is generally assumed that the new therapeutic options for the treatment of HF developed 
during the last decades are responsible for the prognostic improvement in the total 
population of patients acute HF. Our finding that only patients with a normal renal function 
experienced an improved long-term prognosis in the most recently study period is novel. 
This contrasts with the findings currently obtained among patients with renal dysfunction. 
Their prognosis remained stable over time. So far, the temporal trends in prognosis have 
not been studied separately for patients with and without renal dysfunction. Two potential 
mechanisms may explain this finding. First, some of the new therapeutics, like ACE inhibitors, 
ARBs and MRAs, that are considered to be responsible for the prognostic improvement of 
patients with HF over the last decades, interact with the renal function.[6] Moreover, patients 
with lower eGFR were also less frequently treated with diuretics during ICCU admission. 
Therefore, it is plausible that patients with renal dysfunction were less frequently treated 
with these drugs and that, in case they were treated, the optimal dose was not achieved. 
Indeed, we found that ACE inhibitors were less frequently prescribed during admission in 
patients with renal dysfunction. Although data on medical therapy during follow-up were 
not included in this registry, it can be assumed that this pattern of prescription continued 
after discharge. Another possible explanation for the disparity in temporal trends between 
patients with and without renal dysfunction may be the grade of their illness. Patients with 
renal dysfunction had more comorbidities and were more frequently treated with intubation, 
mechanical circulatory support and inotropics than patients with preserved renal function. 
This suggests that patients with renal dysfunction were more critically ill as compared to 
those with a preserved renal function, and they might thus experience a more progressive 
course of their disease and, therefore, a poorer prognosis.
Anemia and prognosis
The second result of our study was the finding that anemia was associated with both 
an impaired short- and long-term prognosis among patients with acute HF. The relation 
between anemia and adverse outcome in patients with acute HF has been published 
previously, although the data are not consistent.[10-13] Two studies that did not report 
anemia to be a prognosticator of poor outcome had study populations with quite 
different characteristics than ours.[10, 13] 
When we studied the prognostic value of anemia in more detail, we found that anemia 
was an independent predictor of short-term outcome in all patients, irrespective of renal 
function. However, while anemia also was independently associated with an impaired 
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outcome during long-term follow-up in patients with renal dysfunction, its presence had 
no incremental long-term prognostic impact in patients with a preserved renal function. 
The reasons for this difference are not totally clear. A possible explanation may be the 
actual cause of the anemia. However, as we were not able to assess the exact etiology of 
the anemia, the following hypothesis should be studied further in the future. 
Anemia in patients with HF is well known, and has been attributed to multiple factors 
including iron deficiency, renal dysfunction, HF as a chronic disease and hemodilution.
[14] The iron status was not assessed in our patients so we cannot make any conclusions 
as whether there was a difference in iron status between patients with and without renal 
dysfunction. The fact that anemia was associated with impaired long-term outcome in 
patients with renal dysfunction but not in patients with a preserved renal function might 
be due to the fact that patients with renal dysfunction more frequently had ‘true anemia’. 
Hemodilution is one of the potential causes of anemia in patients with HF.[17] The 
causal factor in that case is a low hemoglobin level caused by an increased extracellular 
volume. When the extracellular volume decreases, for example by diuretic therapy, 
the hemoglobin level will increase and the patient will no longer be classified as having 
anemia. Therefore, in case of hemodilution anemia should be seen as a marker of fluid 
retention, just as sodium level. We hypothesize that hemodilution as the only cause of 
anemia was more frequent in patients without renal dysfunction than in those with renal 
dysfunction. Probably, patients with an impaired renal function had also anemia based 
on hemodilution but in addition, could also have suffered from ‘true anemia’. There 
are several reasons for such a phenomenon. First, it is well known that renal failure is 
associated with anemia.[14] Second, in our study, chronic HF was more common among 
patients with renal dysfunction than among those without renal dysfunction. Since 
chronic HF has been associated with elevated plasma levels of cytokines,[18] chronic HF 
can cause anemia of chronic diseases. These cytokines suppress the erythropoietic stem 
cells in the bone marrow and reduce the release of iron form the reticulo-endothelial 
system, resulting in anemia.[19]
The so-called cardiorenal anemia syndrome has not been investigated extensively in 
patients with acute HF. Investigators form the ATTEND registry also found anemia to be 
a strong predictor of in-hospital mortality both among patients with and without renal 
dysfunction.[20] Furthermore, their results with respect to the 1-year outcome were 
consistent with our data. In addition, these authors also showed that anemia had additive 
prognostic value for increased 1-year mortality only in the patients with renal dysfunction 
but not in those with a preserved renal function.[21] Because these investigators used 
anemia at discharge as predictor, and thus made hemodilution less likely as cause 
from anemia, this supports our hypothesis of ‘true anemia’ among patients with renal 
dysfunction. Our data provide new evidence on the very long-term prognosis of patients 
with acute HF since we found that anemia, even after 10 years of follow-up, continued to 
have additive prognostic value among patients with renal dysfunction.
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Strengths and limitations
The unique strength of our study is the duration of the follow-up of 10 years after the initial 
hospitalization. This enabled us to investigate the prognostic impact of renal dysfunction, 
anemia, as well as their interrelationship on short- en (very) long-term. Research covering 
three decades with such a long follow-up time is quite unique in this research field.
Despite these strengths, some limitations should be considered in the interpretation of 
the results of this study. Since our study was done in a tertiary referral hospital, external 
validity could have been affected. However, despite the fact that our hospital was a 
tertiary referral center, a significant part of our patients still were primary and secondary 
referrals. Therefore, our population consisted of patients within the whole, broad range 
of patients admitted with acute HF. Second, analyses were made on a composite outcome 
and therefore caution is needed when interpreting the estimates of the covariates, since 
these are estimates on the composite outcome only and not on the separate outcomes. 
Third, we were not able to identify the cause of anemia in all patients, nor were we always 
able to assess whether patients had chronic or acute renal dysfunction. Furthermore, 
while it has been suggested that changing hemoglobin and creatinine levels during 
admission may influence prognosis,[2, 22] the design of our study did not allow us to 
assess trends in hemoglobin and creatinine levels. Finally, since we had no data on the 
ethnicity of our patients, we could not multiply for black race in the MDRD formula. 
Therefore, the eGFR that we employed might be an underestimation of the real renal 
function. However, such misclassification could have only led to underestimation of the 
effects observed.
Conclusions
We found renal dysfunction to be a strong predictor of both short- and long-term 
composite endpoint of  all-cause mortality, heart transplantation and LVAD implantation 
among patients with acute HF. In addition, we established that the long-term prognosis 
of patients with a preserved renal function significantly improved over the last decades. 
However, in patients with renal dysfunction, the prognosis did not improve over the last 
decades. These findings emphasize the importance of renal dysfunction as comorbidity in 
patients with HF and underscore the need for new therapeutic modalities, especially for 
patients with renal dysfunction. Furthermore, we established anemia as a prognosticator 
of short-term outcome both among acute HF patients with and without renal dysfunction. 
Among patients with renal dysfunction, the presence of anemia was also associated 
with impaired long-term prognosis. Anemia did not influence the long-term prognosis 
of patients with preserved renal function. Further research should be undertaken to 
investigate the pathogenesis of the prognostic impact of anemia and renal dysfunction 
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CHAPTER 6
Heart failure (HF) entails high mortality rates.1 Mortality rates presented in literature are 
usually based on cumulative probabilities, providing statistical estimates for the entire 
duration of the follow-up period. Presented this way, aspects of prognosis in HF are 
missed that may contain important information for the patient or treating physician. 
Additional insights into prognosis may be gained by using relative and conditional survival 
analysis, approaches commonly used and proven highly useful in oncology research.2 We 
explored these measures of survival in a large cohort of patients with acute HF. 
We used a consecutive single-center cohort of acute HF patients with long-term follow-
up.3 Briefly, 1810 patients admitted with acute HF to Erasmus MC, Rotterdam, the 
Netherlands, were included in a prospective registry between 1985-2008 (baseline 
characteristics: Supplemental Table 1). We calculated cumulative survival rates for 10 
years, stratified by age in four equal groups, using the Kaplan-Meier method (Figure, 
Panel A; Supplemental Table 2). As expected, one- and ten-year survival rates were low 
(between 56%-65% at one year and 9%-35% at ten years). Overall, younger patients had 
better survival than older patients. 
The steep decline in survival in the first year attenuated during subsequent follow-up. 
This became even more evident when one-year conditional survival rates were calculated, 
which indicate the probability of surviving one year, given that the patient had already 
survived up to that time, and show how a patient’s estimated survival changes over time 
(Panel B). For example, patients aged 55 or younger had a cumulative survival probability 
of 56% at one year and of 50% at two years of follow-up. However, if those patients 
survived the first year, survival probability of also surviving the second year increased 
to 89%. These much higher one-year survival rates persisted throughout the remainder 
of the follow-up (panel B). A similar pattern was seen in the other age groups. Younger 
patients had higher one-year conditional survival rates than older patients. 
How much of the all-cause mortality in this cohort can be attributed to HF is shown 
by relative or relative conditional survival (RCS). Relative survival directly compares a 
patient’s survival to the survival of a person in the general population with the same age 
and gender, retrieved from Statistics Netherlands.4 RCS demonstrates at which point in 
time the survival of a patient becomes similar to that of the general population (RCS=1).5 
Panel C shows the one-year RCS estimates. For example, if patients aged 75 or older 
survive the first year, their survival is 79%, This corresponds to a prognosis that is 85% of 
the general population. The RCS probability lines never reach the value of one, indicating 
that during the entire 10 year follow-up period, all patients continue to have an increased 
mortality rate compared to the general population. Relative survival rates show more 
overlap for the different patient groups than in the conditional analysis. So, although 
younger patients have better prognosis than older patients, compared to their peers 
survival remains suboptimal and increased HF mortality persists throughout follow-up. 
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We repeated the analyses stratifying on sex, left ventricular ejection fraction (LVEF), 
etiology, diabetes, hypertension and kidney function (results: Supplemental material). 
For patients with a poor LVEF, survival was lower in the first year compared to the other 
patients. Interestingly, this difference disappeared when patients with poor LVEF survived 
the first period, as demonstrated by RCS. Patients with severe kidney dysfunction similarly 
showed lower survival rates. This difference persisted, although less pronounced, 
when calculating (relative) conditional survival. For the other factors and comorbidities 
differences were less evident, but in line with previous literature. For every stratifying 
factor, all patient groups showed excess mortality compared to the general population. A 
multivariable relative regression model was estimated (details in Supplemental material). 
In short, the first follow-up period, age, LVEF, eGFR, diabetes, and hypertension were 
significantly independently associated with relative excess risk, in line with results of the 
stratified analyses.
In conclusion, acute HF entails high mortality. (Relative) conditional survival can be used 
to gain additional insights into the disease course and communicate this more clearly 
to patients. Using these measures, we found that mortality occurs largely in the first 
period, and there is substantial improvement thereafter. Thus the first period after 
hospitalization is crucial. Cardiologists could use conditional survival to update patient 
prognosis during each visit and show higher survival probabilities to patients once they 
survive the first year. The RCS estimates however show that, for these acute HF patients, 
survival never becomes 'normal' again. This also holds for younger patients, patients 
without specific comorbidities, and with ejection fraction≥45%. This notion is particularly 
important for young patients, who will carry the burden of their disease for the rest of 
their lives.
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Supplemental Table 1. Baseline characteristics
Variable n = 1810
Age, mean (sd) 63.5 (14.8)
Gender (Male), n (%) 1153 (64%)
Etiology (Ischemic), n (%) 740 (47%)
Left ventricular function, n (%)
Good (ejection fraction≥45%) 381 (29%)
Moderate (ejection fraction 30%-44%) 312 (24%)
Poor (ejection fraction <30%) 620 (47%)
eGFR, n (%)
>60 (Mildly reduced/normal kidney function) 665 (41%)
30-60 (Moderately reduced kidney function) 653 (40%)
<30 (Severely reduced kidney function) 308 (19%)
Diabetes, n (%) 384 (21%)
Hypertension, n(%) 590 (33%)
eGFR; estimated glomerular filtration rate
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Supplemental figure 1 shows the results for the cumulative survival, one-year conditional 
and one-year relative conditional survival (RCS) analyses, stratified on different factors: 
left ventricular ejection fraction (LVEF), kidney function (assessed by estimated glomerular 
filtration rate (eGFR)), sex, etiology (ischemic or non-ischemic), diabetes and hypertension. 
In general, all stratified analyses illustrate the steep decline in cumulative survival in 
the first year, and low cumulative survival at ten years. The conditional survival curves 
demonstrate improved and stable one-year survival estimates for the patients that 
survive the first period. The RCS panels demonstrate however, that for all patient groups 
survival never reaches the level of the general population (RCS < 1). 
The results of the stratification on LVEF and eGFR are discussed in the main manuscript 
and the cumulative survival findings are in line with previous literature.1, 2 In Supplemental 
Figure 1C, women appear to have slightly higher survival rates coinciding with the survival 
benefit shown in prior heart failure studies.3 This difference in survival is no longer 
present in the patients that survive the first period. Patients with ischemic heart failure 
(Supplemental Figure 1D) have higher mortality rates than patients with non-ischemic 
heart failure. The differences between ischemic and non-ischemic patients are not present 
early during follow-up, but appear after surviving the first year. This difference in survival 
was previously shown by Gajanna et al (2016).4 Similar, although less pronounced, results 
are found for diabetes (Supplemental Figure 1E). Patients with diabetes have lower 
survival rates than patients without diabetes, as expected5, although this difference is not 
present in the first period. Survival seems slightly better for patients with hypertension 
in the first period (Supplemental Figure 1F).  This paradoxical association has been 
identified previously.6 For patients surviving the first year, this difference disappears and 
the conditional survival curves become similar for patients with or without hypertension
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D. Left ventricular ejection fraction
E. Estimated glomerular filtration rate (eGFR)
F. Sex
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The first panel in each graph shows cumulative survival in years (with 95% confidence intervals) for different groups. 
The second panel shows the 1-year survival estimates, conditional on surviving the number of years indicated on 
the x-axis. Panel C shows the 1-year conditional survival relative to the general population. The estimates at year 0 
in Panel B and C correspond to (relative) survival estimate at one year since hospitalization. Additionally in panel C, 
the dashed line indicates a survival equal to that of the general population (relative survival=1).
Relative survival regression model
Due to the relatively limited number of patients in the cohort, simultaneous stratification 
on multiple variables and applying the current method is not feasible. Alternatively, a 
multivariable relative survival regression model can be estimated to account for multiple 
variables. Briefly, this model estimates the number of deaths in each time interval (every year 
of follow-up), assuming a Poisson distribution.7 The model estimates the relative excess risk 
(RER) per variable (i.e., the difference between the observed and expected risk). The results 
can be found in Supplemental Table 3. The model includes the stratification factors as in the 
stratified analyses, age as continuous variable and an indicator for the first year of follow-up. 
The RER of the first year compared to the remainder of follow-up of 4.69 means that the 
excess risk of mortality (compared to the general population) in the first year is almost five 
times higher than in the remainder of the follow-up. This corresponds to the lower relative 
survival at time 0 in the figures. In the relative survival model the first year of follow-up, 
age, LVEF, eGFR, and diabetes are independently significantly related to higher excess risk. 
Hypertension shows a lower excess risk, in line with the findings in the stratified analysis. 
Supplemental Table 3. Results from the Poisson relative survival model
Parameter Relative Excess Risk (estimated) 95 % CI p-value
Follow-up
First year vs remainder
4.69 (3.98 – 5.52) <0.001
Sex
Female vs Male
0.94 (0.79 – 1.11) 0.454
Age (per year) 1.01 (1.001 – 1.02) 0.018
Etiology 
Ischemic vs Non-Ischemic
1.15 (0.96 – 1.37) 0.124
LVEF 
Poor vs Good
1.72 (1.40 – 2.10) <0.001
LVEF 
Moderate vs Good
0.98 (0.76 – 1.26) 0.876
Diabetes
Yes vs No
1.30 (1.08 – 1.57) 0.007
Hypertension
Yes vs No
0.82 (0.69 – 0.98) 0.032
eGFR 
Severe vs Mild-Normal
2.13 (1.71 – 2.65) <0.001
eGFR 
Moderate vs Mild-Normal
1.45 (1.20 – 1.75) <0.001
Parameter estimates are interpreted as relative excess risk estimates. The estimate for follow-up of 4.69 indicates 
that the excess risk of mortality (compared to the general population) in the first year is almost five times higher than 
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Aims: To investigate the left ventricular (LV) remodeling and long-term prognosis of 
patients with new-onset acute heart failure (AHF) with reduced ejection fraction (HFrEF) 
who were pharmacologically managed and survived until hospital discharge. We 
compared patients with ischaemic and non-ischaemic aetiology.
Methods and Results: This cohort study consisted of 111 patients admitted with new-
onset AHF in the period 2008-2016 (62% non-ischaemic aetiology, 48% supported by 
inotropes, vasopressors or short-term mechanical circulatory devices, left ventricular 
ejection fraction [LVEF] at discharge 28% [IQR 22-34]). LV dimensions, LVEF and mitral valve 
regurgitation were used as markers for LV remodeling during up to 3 years of follow-up. 
Both patients with non-ischaemic and ischaemic HF had significant improvement in LVEF 
(p<0.001 and p=0.004, respectively) with significant higher improvement in those with 
non-ischaemic HF (17% vs. 6%, p<0.001). Patients with non-ischaemic HF had reduction in 
LV end-diastolic and end-systolic diameters (6mm and 10mm, both p<0.001) but this was 
not found in those with ischaemic HF (+3mm [p=0.09] and +2mm [p=0.07], respectively).
During a median follow-up of 4.6 years, 98 patients (88%) did not reach the composite 
end-point of left ventricular assist device implantation, heart transplantation or all-cause 
mortality, with no difference between with ischaemic and non-ischaemic HF (HR 0.69 
[95% CI 0.19-2.45]).
Conclusion: Patients with new-onset acute HFrEF discharged on optimal medical 
treatment have a good prognosis. We observed a considerable LV remodeling with 
improvement in LV function and dimensions, starting already at 6 months in patients 
with non-ischaemic HF but not in their ischaemic counterparts.
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Introduction
Hospitalisation for new-onset heart failure (HF) often indicates a severe HF phenotype, 
in which introduction and titration of medication may be difficult and the response to 
treatment is influenced by the severity of EF impairment.(1) Less is known about the 
natural course of patients with new-onset acute HFrEF who can be medically managed, 
but in whom the severity of left ventricle (LV) dysfunction raises the question whether 
advanced treatment is indicated. A too early decision for left ventricular assist device 
(LVAD) or heart transplantation (HT) in patients with first admission for new-onset HF 
with reduced ejection fraction (HFrEF) and who tolerate HF medication may have a heavy 
impact on the morbidity and mortality risks of the individual patients as well as on health 
care resources, as LV function may recover in some of these patients.(2)
In the current study, we aimed to investigate the LV remodeling and long-term prognosis of 
patients with new-onset acute HFrEF who were pharmacologically managed and survived 
to hospital discharge. We designed this study in patients with new-onset acute HF in order 
to evaluate the effect of HF medication in a formerly non-exposed patient with HF. Because 
the remodeling is dependent on the HF aetiology, we compared the LV remodeling between 
patients with ischaemic and non-ischaemic aetiology of acute HFrEF.
Methods
Study population
This retrospective cohort study consisted of patients admitted with acute HF to the 
Erasmus Medical Center in the period January 2008 until December 2016. The inclusion 
criteria were (1) a diagnosis of acute HF at admission, (2) no history of chronic HF or any 
other structural heart disease and (3) an left ventricular ejection fraction (LVEF) <40% 
at admission. Patients were excluded if they received an LVAD, underwent HT or died 
before discharge and in case of limited or no follow-up in our hospital.
Our hospital is a tertiary referral centre and serves as one of the national referral centres 
for patients with advanced HF with need for mechanical circulatory support or HT for 
a significant part of the Netherlands. This study was conducted in accordance to the 
declaration of Helsinki.(3) Our local research ethics committee has given approval for 
this study.
Data collection
We extracted the variables from patients’ records and discharge letters. Data collection 
started at day of admission for new-onset acute HF. Follow-up was considered complete 
after approximately 3 years. Variables were collected during admission (i.e. baseline), at 
6 months, and at 1, 2 and 3 years after admission (all ±3 months). Data collection ended 




In addition to the variables age and sex, we collected body mass index, medical history 
and aetiology of HF. At baseline and during follow-up moments, we gathered systolic and 
diastolic blood pressure, heart rate, rhythm on electrocardiogram, medical and device 
therapy and a selection of laboratory parameters. 
We also collected a number of echo parameters with transthoracic echocardiography. 
These included left ventricular end-diastolic (LVED) diameter, left ventricular end-systolic 
(LVES) diameter and LVEF. The LVEF was determined by using the Simpson method with 
software Image-Com 5.5 (TomTec Imaging Systems GmbH, Unterschleissheim, Germany). 
If available, we measured the following parameters of diastolic function: E/A ratio, 
mitral valve deceleration time and E/e’ ratio. The severity of mitral valve regurgitation 
and tricuspid valve regurgitation were classified into absent, mild, moderate or severe. 
Mitral and tricuspid valve regurgitation was defined by using the qualitative and 
semiquantitative criteria as defined in the ESC guideline about valvular heart disease.(4) 
Grading the severity of mitral and tricuspid valve regurgitation was done according to the 
guidelines of the European Association of echocardiography.(5) Right ventricular function 
was quantified with the TAPSE. Lastly, we measured the inferior caval vein’s diameter.
Definitions
We defined the recovery of the LV as an LVEF of at least of 50% in a patient with previously 
HFrEF as this definition has been used in several other studies.(6, 7) Furthermore, in the 
TRED-HF trial on withdrawal of HF medication after recovery of dilated cardiomyopathy, an 
improvement of LVEF to 50% was required before withdrawal was attempted.(8) Furthermore, 
we used an increase of > 10% of LVEF as a measure of significant LV reverse remodeling.
Endpoint
The primary endpoint of our study was the LV remodeling during up to 3 years of follow-
up. LVED diameter, LVES diameter and LVEF were used as markers for LV remodeling. 
Next to those markers, we analysed the pattern of mitral valve regurgitation.
We also studied the patient’s prognosis (up to 10 years) using the composite of all-cause 
mortality, HT and LVAD implantation. We also analysed the HF rehospitalisation according 
to aetiology. The Municipal Civil Registries were consulted to assess the survival status of 
the included patients.
Statistical analyses
Continuous variables were presented as median with interquartile range (IQR) and 
categorical variables as numbers and percentages. The Mann-Whitney U test and χ2 test 
were used to compare continuous and categorical variables, respectively. 
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We used the Kaplan-Meier method in order to estimate the cumulative event rates. Cox 
proportional hazard models were applied to evaluate the difference in the composite 
endpoint between patients with ischaemic and non-ischaemic HF. The results are 
presented as hazard ratio (HR) with their 95% confidence interval (95% CI).
Linear mixed-effects models were fitted for LVEF, LVED diameter and LVES diameter 
(dependent) to assess remodeling. To compare remodeling between ischemic HF and 
non-ischemic HF patients, we calculated the delta remodeling by subtracting the baseline 
measurement from the measurements taken at least 6 months after inclusion per patient, 
as we expected that most remodeling will have occurred within the first six months after 
admission. Subsequently, these deltas were used as dependent in the adjusted linear 
mixed-effects models. Lastly, Cox proportional hazard regression was used to relate the 
repeated LVEF, LVED and LVES measurements to outcome. To avoid bias, parameters of the 
linear mixed-effects models and Cox regression models were combined in a joint-model.
All tests were two-tailed and p<0.05 were considered as statistically significant. SPSS 
software (SPSS 24.0, IBM Corp., Armonk, NY, USA) was used for the descriptive statistical 
analyses and the survival analyses. R statistical software (version 3.4.3) was used for the 
linear mixed-effects models and joint-models, in particular the packages nlme and JMbayes. 
Results
Baseline characteristics
During the inclusion period, 141 patients admitted with acute HF potentially qualified for 
inclusion. Of these, 17 patients were excluded because they died or received an LVAD 
before discharge and 13 patients were excluded due to limited follow-up in our hospital. 
Consequently, we included 111 patients admitted with new-onset acute HF (Figure 1).
Figure 1. Flow chart of patient selection
HF, heart failure; LVAD, left ventricular assist device
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The included patients had a median age of 50.0 (IQR 38.6-60.3) years, almost half were men 
and 38% of the patients had ischaemic HF (Table 1). Non-ischaemic HF was predominately 
diagnosed as idiopathic dilated cardiomyopathy (n=27), toxic cardiomyopathy (n=13) 
and myocarditis (n=11). During admission, 48% of the patients required inotrope and/
or vasopressor support and 23% needed in addition short-term mechanical circulatory 
support by ECMO and/or IABP. Of the patients with ischaemic HF, 33 had a percutaneous 
coronary intervention and 1 underwent coronary artery bypass grafting during the initial 
hospitalisation. At discharge, NYHA class and HF treatment were comparable between 
patients with ischaemic and non-ischaemic HF.











Age 50.0 (38.6-60.3) 58.9 (50.3-64.9) 43.8 (32.9-54.7) <0.001
Male 62 (56%) 26 (62%) 36 (52%) 0.32
Body mass index 24.9 (22.3-27.3) 24.9 (22.7-27.2) 24.9 (21.8-28.0) 0.91
Aetiology heart failure <0.001
Ischaemic 
STEMI 31 (28%) 31 (74%)
Non STEMI 3 (3%) 3 (7%)
Stable coronary artery disease 8 (7%) 8 (19%)
Idiopathic dilated cardiomyopathy 27 (24%) 27 (39%)
Non-compaction cardiomyopathy 5 (5%) 5 (7%)
Hypertensive cardiomyopathy 5 (5%) 5 (7%)
Immune-mediated cardiomyopathy 2 (2%) 2 (3%)
Toxic cardiomyopathy 13 (12%) 13 (20%)
Peri-partum cardiomyopathy 4 (4%) 4 (6%)
Myocarditis 11 (10%) 11 (16%)
Tako-tsubo cardiomyopathy 2 (2%) 2 (3%)
Medical history
Atrial fibrillation 2 (2%) 1 (2%) 1 (1%) 1.00
Diabetes 8 (7%) 7 (17%) 1 (1%) 0.008
Hypertension 27 (24%) 19 (45%) 8 (12%) <0.001
Hypercholesterolemia 11 (10%) 9 (21%) 2 (3%) 0.007
Smoker 0.82
Current smoker 35 (32%) 16 (38%) 19 (28%)
Former smoker 17 (15%) 7 (17%) 10 (15%)
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Renal dysfunction 3 (3%) 2 (5%) 1 (1%) 0.57
Anaemia 2 (2%) 0 (0%) 2 (3%) 0.51
Chronic obstructive pulmonary disease 2 (2%) 1 (2%) 1 (1%) 1.00
Malignancy 8 (7%) 1 (2%) 7 (10%) 0.13
Depression 5 (5%) 1 (2%) 4 (6%) 0.39
Advanced therapy during admission
IABP treatment 24 (22%) 21 (50%) 3 (4%) <0.001
ECMO treatment 3 (3%) 1 (2%) 2 (3%) 1.00
Inotrope/vasopressor support 53 (48%) 25 (60%) 28 (41%) 0.05
Characteristics at discharge
Systolic blood pressure (mmHg) 103 (90-115) 105 (88-116) 103 (93-115) 0.53
Diastolic blood pressure (mmHg) 63 (55-75) 65 (55-75) 62 (56-75) 0.85
Heart rate (bpm) 74 (65-83) 76 (69-84) 72 (63-82) 0.19
Sinus rhythm 101 (92%) 40 (95%) 61 (90%) 0.48
Bundle branch block 0.67
Left bundle branch block 5 (5%) 1 (2%) 4 (6%)
Right bundle branch block 6 (5%) 2 (5%) 4 (6%)
Therapy at discharge
Beta-blocker 103 (93%) 36 (86%) 67 (97%) 0.05
ACE inhibitor or ARB 106 (96%) 41 (98%) 65 (94%) 0.65
Mineralocorticoid receptor antagonist 67 (60%) 24 (57%) 43 (62%) 0.59
Diuretics 97 (87%) 36 (86%) 61 (88%) 0.68
Digoxin 55 (50%) 16 (38%) 39 (57%) 0.06
Statin 45 (41%) 39 (93%) 6 (9%) <0.001
(Direct) oral anticoagulant 78 (70%) 27 (64%) 51 (74%) 0.28
Thrombocyte aggregation inhibitor 36 (32%) 30 (71%) 6 (9%) <0.001
Pacemaker 1 (1%) 0 (0%) 1 (1%) 1.00
ICD 26 (23%) 7 (17%) 19 (28%) 0.19
CRT 4 (4%) 0 (0%) 4 (6%) 0.16
Laboratory values at discharge
Creatinine (µmol/L) 91 (76-116) 94 (80-129) 89 (72-112) 0.22
eGFR (ml/min) 64 (54-83) 60 (48-80) 67 (56-86) 0.11
Sodium (mmol/L) 139 (137-141) 139 (137-141) 139 (137-141) 0.86












Urea (mmol/L) 9.2 (6.8-12.3) 9.3 (6.7-12.3) 9.2 (7.0-12.3) 0.82
ASAT (U/L) 29 (23-38) 26 (19-33) 31 (25-43) 0.06
ALAT (U/L) 35 (24-60) 26 (19-43) 39 (29-70) 0.02
Haemoglobin (mmol/L) 7.6 (6.7-8.6) 7.0 (6.3-7.8) 8.2 (7.0-9.7) <0.001
Haematocrit (L/L) 0.38 (0.33-0.41) 0.35 (0.31-0.38) 0.39 (0.36-0.43) 0.001
NT-proBNP (pmol/L) 251 (100-577) 577 (392-738) 234 (87-401) 0.02
Results depicted as N (%) or median (interquartile range) 
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ASAT, aspartate aminotransferase; 
ALAT, alanine aminotransferase; CRT, cardiac resynchronization therapy; ECMO, extra-corporeal membrane 
oxygenation; eGFR, estimated glomerular filtration rate; HF, heart failure; IABP, intra-aortic balloon pump; ICD, 
implantable cardioverter defibrillator; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; STEMI, 
ST-elevated myocardial infarction
Left ventricular remodeling
At discharge, both the LVED and LVES diameter were significantly larger in patients with 
non-ischaemic HF than in those with ischaemic HF (Table 2). In addition, patients with 
non-ischaemic HF had lower LVEF than patients with ischaemic HF (26% [IQR 21-33] and 
32% [IQR 25-36], respectively). The prevalence of poor LVEF (i.e. LVEF ≤30%) at discharge 
was higher in patients with non-ischaemic HF than in those with ischaemic HF (67% 
versus 48%, p=0.047). Furthermore, 44% of the patients exhibited moderate to severe 
mitral valve regurgitation and 26% moderate to severe tricuspid valve regurgitation. 
Table 2. Echocardiography parameters at discharge of patients with ischaemic and non-ischaemic HF
  Total 
population
Ischaemic HF Non-ischaemic 
HF
p-value
LVED diameter (mm) 58 (53-66) 54 (52-62) 60 (56-68) 0.001
LVES diameter  (mm) 48 (39-56) 43 (36-49) 52 (46-59) <0.001
LVEF (%) 28 (22-34) 32 (25-36) 26 (21-33) 0.03
Mitral valve regurgitation 0.80
Absent 22 (21%) 10 (25%) 12 (18%)
Mild 37 (35%) 12 (30%) 25 (37%)
Moderate 24 (22%) 9 (23%) 15 (22%)
Severe 24 (22%) 9 (23%) 15 (22%)
E/A ratio 1.6 (1.0-2.3) 1.4 (0.9-2.2) 1.7 (1.1-2.3) 0.29
Deceleration time mitral valve (ms) 158 (123-190) 171 (136-201) 151 (113-181) 0.06
E/E' 14.7 (10.2-19.8) 13.9 (10.1-23.1) 14.7 (10.3-19.4) 0.70
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  Total 
population
Ischaemic HF Non-ischaemic 
HF
p-value
Tricuspid valve regurgitation 0.95
Absent 44 (43%) 16 (41%) 28 (44%)
Mild 32 (31%) 13 (33%) 19 (30%)
Moderate 17 (17%) 7 (18%) 10 (16%)
Severe 9 (9%) 3 (8%) 6 (10%)
Tricuspid insufficiency gradient (mmHg) 27 (21-36) 36 (26-43) 25 (21-29) 0.002
Diameter inferior caval vein (mm) 16 (13-19) 17 (13-18) 16 (13-20) 0.79
TAPSE (mm) 18 (16-22) 19 (16-22) 18 (16-22) 0.59
Results depicted as N (%) or median (interquartile range)
LVED, left ventricular end-diastolic; LVEF, left ventricular ejection fraction; LVES, left ventricular end-systolic
During 3 years of follow-up, LVEF recovered in 10% of the patients with ischaemic HF 
and in 39% of those with non-ischaemic HF (p<0.001). Of the patients with LVEF recovery, 
recovery was already present in half of the patients during the echocardiographic 
assessment at 6 months after discharge. In total 26% of the patients with ischaemic HF 
had a significant (at least 10%) improvement of LVEF, compared to 72% of those with 
non-ischaemic HF (p<0.001). The LVEF recovery and significant improvement of LVEF was 
comparable between patients with an LVEF ≤30% and LVEF >30% (p=0.06). 
 
Figure 2 presents the time-dependent changes in LVED diameter, LVES diameter and 
LVEF after discharge (see Supplemental Table 1 for fitting values). Both patients with non-
ischaemic and ischaemic HF had significant improvement in LVEF (p<0.001 and p=0.004, 
respectively). This improvement was significant higher in those with non-ischaemic 
HF (17% vs. 6%, p<0.001). Furthermore, while patients with non-ischaemic HF had a 
significant reduction in LVED and LVES diameters (6mm and 10mm, both p<0.001), these 
diameters did not change in those with ischaemic HF (+3mm [p=0.09] and +2mm [p=0.07], 
respectively). In addition to the above mentioned parameters of LV remodeling, we also 
found that the severity of mitral valve regurgitation decreased during the first 6 months 
(p=0.02) in patients with non-ischaemic and not in those with ischaemic HF (Figure 3). 
Furthermore, the NT-proBNP levels decreased in both ischaemic and non-ischaemic HF 
patients during follow-up, especially in the first 6 months (Table 3).
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Figure 2. Changes in LVEF (A), 
LVES diameter (B) and LVED 
diameter (C) over time in patients 
with ischaemic and non-ischaemic 
heart failure
LVED, left ventricular end-diastolic; 
LVEF, left ventricular ejection 
fraction; LVES, left ventricular end-
systolic
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Figure 3. Severity of mitral valve 
regurgitation in patients with ischaemic (A) 
and non-ischaemic (B) HF
Table 3. NT-proBNP during follow-up in patient with ischaemic and non-ischaemic HF
  Ischaemic HF Non-ischaemic HF p-value
Baseline 577 (392-738) 234 (87-401) 0.02
6 months 237 (101-514) 48 (22-114) <0.001
1 year 170 (80-285) 38 (18-81) 0.004
2 years 137 (79-294) 22 (12-95) 0.008
3 years 74 (41-151) 16 (6-124) 0.17
Results depicted as median (interquartile range)
HF, heart failure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide
Since there was no consistent policy on the interval between the echocardiograms, we 
had missing values in LVED diameter, LVES diameter, LVEF and mitral valve regurgitation 
during the 3 years of follow-up (Supplemental Table 2). Nevertheless, the median number 




During a median follow-up time of 4.6 years, 13 patients (12%) reached the composite 
end-point of all-cause mortality, HT and LVAD implantation. Prognosis was comparable 
between patients with ischaemic and non-ischaemic HF (HR 0.69 [95% CI 0.19-2.45]; Figure 
4). Eleven patients died during follow-up; 3 patients received an LVAD and 2 underwent 
HT. Thirteen patients (12%) needed rehospitalisation for HF during the follow-up, with 
no difference between patients with and without ischaemic aetiology (HR 2.02 [95% CI 
0.68-6.02]). 
Figure 4. LVAD/HT-free survival curve of patients with ischaemic and non-ischaemic heart failure
HF, heart failure; HT, heart transplantation; LVAD, left ventricular assist device
Furthermore, we found that higher increase in LVEF was associated with better prognosis 
(HR per 5% increase 1.13 [95% CI 1.10-1.43]). In contrast, decreases in LVED diameter and 
LVES diameter were not associated with better outcome (HR per 1 mm decrease in LVED 
diameter 1.002 [95% CI 0.93-1.07] and HR per 1 mm decrease in LVES diameter 1.00 [95% 
CI 0.92-1.06]). Adjustment for HF aetiology did not change these associations.
Among the patients with clinical follow-up until 3 years (n= 58), 28 patients received an 
ICD and 5 patients of them a CRT device. During up to 3 years of clinical follow-up, 8 
patients had 9 shock events. Of these, 4 shocks were inappropriate.
After the initial hospitalisation, 4 patients underwent cardiac surgery (3 coronary artery 
bypass grafting and 1 mitral valve replacement) and 8 patients received catheter based 
therapy (8 percutaneous coronary interventions, 1 mitraclip implantation, 1 transcatheter 
aortic valve implantation).
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Discussion
This study describes the LV remodeling and long-term prognosis in a cohort of patients with 
new-onset severe HFrEF, who required admission and in many cases needed inotropes 
(48% of the patients) and short-term mechanical support (23% of the patients), but who 
were eventually successfully weaned from support and discharged with medication. The 
improvement in LVEF was already present at 6 months in the patients with non-ischemic 
aetiology and increased exponentially up to 2 years of follow-up, which mirrored the 
decrease of LV diameters, both end-diastolic and end-systolic. Furthermore, in these 
patients the severity of mitral regurgitation significantly decreased at 6 months. On the 
contrary, in their ischaemic counterparts, the LVEF modestly increased linearly during 
follow-up, while LV diameters and the severity of mitral regurgitation did not change. 
The prognosis of this subpopulation of patients discharged on medication after the first 
episode of severe acute HFrEF is much better as compared with other studies on large 
cohorts with acute decompensated HF.
Indeed, it is not very unique to study recovery of LVEF and its relation with prognosis.(9-
12) However, our study has some unique strengths. First, we included a less heterogenic 
population than others. Although other studies did not include de novo heart failure 
patient specifically, in our opinion, left ventricular remodeling should be studied in an 
early stage of HF because of recovery of the LVEF takes place early. Further, compared to 
other studies, echocardiography in our study was repeated after a relatively short period. 
This enables us to say something about the trend in remodeling. Last, we included clinical 
variables that are missing from other studies.
Left ventricular remodeling
Improvement of LVEF in a minority of patients with dilated cardiomyopathy within 6 
months and therefore deferral of listing for HT was already reported in 1994, before 
the introduction of beta-blocker therapy.(13) However, after the introduction of beta-
blockers and aldosterone-antagonists in HF treatment a significant improvement 
of LVEF was shown in one-third of patients with recently diagnosed HFrEF, and in 
half of them this improvement already occurred at 6 months.(14) More studies have 
investigated improvement of LVEF and prognosis in outpatients with recent onset dilated 
cardiomyopathy.(15) To the best of our knowledge, our study is the first to investigate the 
LV remodeling in a subpopulation of severe new-onset HFrEF that required admission. 
A large proportions of our patients received digoxin (57% of the patients with non-
ischemic HF). The beneficial properties of digoxin in acute HF syndromes have been 
attributed to the improvement of hemodynamics by attenuating tachycardia without 
negative inotrope effects and to the absence of side effects at lower dosages.(16) The 
inotropy-dependent low-output patients in our cohort could be immediately treated with 
digoxin, while introduction of beta-blocker was postponed until the relief of congestion 
and achievement of euvolemia, according to a previously published protocol  from our 
center.(1) At discharge > 90% of patients were treated by beta-blockers in combination 
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with ACE-inhibitors or angiotensin-receptor blockers. The patients were followed weekly 
thereafter at our outpatient clinic and the medication has been up titrated till maximum 
tolerated dosage according to the ESC heart failure guidelines.(17)
We found a clear difference in LV remodeling between patients with non-ischaemic HF 
and those with ischaemic HF. This difference can primarily be explained by the aetiology 
of HF. To qualify for LV remodeling, there should be limited replacement fibrosis and 
enough viable myocardium.(18) Patients with ischaemic HF are less potential to develop 
LV remodeling because ischaemic myocardium is more extensively and irreversibly 
damaged. In contrast, patients with non-ischaemic HF may have more viable myocytes.(7, 
18) Indeed, it has been observed that some specific non-ischaemic causes like myocarditis 
and peripartum cardiomyopathy have a relatively high chance to recover.(6) However, 
optimal HF treatment may be another explanation for LV remodeling. HF treatment and 
in particular neurohumoral blockers have been associated with LV remodeling.(19, 20) 
Optimal therapy with beta-blockers, ACE-inhibitors, angiotensin receptor blockers and 
MRAs is of great importance.
In literature, several other factors, besides optimal medical treatment, have been found 
to be associated with LVEF improvement.(9-12, 14) In several studies, female sex has 
been associated with improvement of LV function.(9-12) In our study, the distribution of 
sex was not different between the ischaemic and non-ischaemic HF, and we found no 
difference in the outcomes. However, the size of our cohort may be too small to assess 
the effect of sex on top of the medical treatment. The presence of hypertension and 
diabetes have also been correlated with LVEF changes. Furthermore, it has been reported 
that LVEF improvement was more common in patients with HF with non-ischaemic cause 
than in subjects with ischaemic HF. However, so far, the time-dependent evolution of LV 
remodeling including LVEF, LV dimensions and mitral valve regurgitation has never been 
compared in patients with ischaemic and non-ischaemic HF.
Further, we also found a decrease in severity of mitral valve regurgitation. Decrease in 
mitral valve regurgitation has found to be associated with better prognosis and symptom 
relieve.(21, 22) Our study showed that LV remodeling by medical treatment also leads 
to reduction of mitral valve regurgitation, which is consistent with other reports.(21-23)
Prognosis
The prognosis of patients with acute HF has been studied extensively. Mortality rates of 
up to 35% at 1 year(24-28) and up to 75% at 5 years follow-up(25, 27) are reported. These 
cohorts included acute HF patients of the whole broad range: both new-onset acute HF 
and decompensated chronic HF, with and without cardiac history, patients admitted to 
secondary and tertiary hospitals. Notably, our patients had a more favourable prognosis 
with an LVAD/HT-free survival of 88% during a follow-up of up to 10 years. The better 
prognosis in our study can be explained by the specific inclusion of new-onset HF in 
patients without a history of HF or any structural heart disease and exclusion of patients 
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who could not be weaned from advanced support and received a permanent LVAD or 
died in hospital. Furthermore, we included patients in a more recent era than previous 
studies and, hence, our patients were treated with the broad range of guideline based HF 
medication, including a large number of patients using beta-blocker therapy.
Furthermore, we found that improvement in LVEF was associated with a better prognosis. 
This was in accordance with a recent meta-analysis by Jorgensen et al.(29) who showed 
that patients in whom LVEF improved were found to have a better prognosis consisting 
of both improved survival rate and lower risk of appropriate ICD shocks.
Implications for clinical practice
As already mentioned, patients with HFrEF should be treated according to the guidelines 
with optimal dosage of beta-blocker, renin angiotensin aldosterone system inhibition 
and MRAs.(17) Recently, data from the PIONEER-HF trial show that introduction of 
angiotensin-receptor neprilysin inhibitor (ARNI) during hospitalisation for acute heart 
failure significantly improved the clinical outcome as compared to ACE-inhibitors.(30) 
Although not investigated in our study, replacing ACE-inhibitor by ARNI  should be 
considered before discharge or at the outpatient clinic. Optimal medical treatment does 
not only carry prognostic benefit but it may also contribute to the LV remodeling. Since 
we found that remodeling may occur until 2 years after the initial event mainly in non-
ischaemic HF, clinicians should optimize medication and give time to remodel before 
concluding that LVAD or HT is necessary.(2)
Since almost half of our study patients needed inotrope and/or vasopressor support and 
almost a quarter of the patients received mechanical circulatory support, this indicates 
that we included very ill HF patients. Despite this adverse clinical presentation, we found 
remodeling in a significant part of these patients. Since we included patients with severe 
HFrEF with or without cardiogenic shock at presentation, part of them may currently 
qualify for LVAD or HT. Indeed, LVAD therapy also leads to cardiac remodeling. However, 
LVAD therapy has several potential complications like stroke, pump thrombosis, bleeding 
and infection.(31) Therefore, we propose persuasion of the attempts to wean the 
support in patients with the first hospitalisation for new-onset HFrEF during concomitant 
optimization of HF medication. Only under the condition that patients remain inotrope-
dependent, one should proceed to urgent LVAD or HT. 
It still remains uncertain how patients with recovered LVEF should be treated in the long-
term. Indeed, patients with recovered LV function may have abnormal biomarker levels 
and may still have an adverse long-term prognosis.(32) Recently, the TRED-HF trial has 
shown that withdrawal of pharmacological treatment negatively influenced the course of 
dilated cardiomyopathy.(8) In our hospital, patients with completely recovered LVEF and 
without HF symptoms are continued to be treated with beta-blocker and ACE-inhibitor 
or angiotensin receptor blocker. Basuray and Fang(6) also advocated continuation of HF 




Several study limitations should be acknowledged. First and foremost, the retrospective 
nature of this study resulted into a significant number of missing LVED diameters, LVES 
diameters, LVEF, mitral valve regurgitation and NT-proBNP measurements during follow-
up. However, we used the delta remodeling in the linear mixed-effects models in order to 
make optimal use of all the available measurements. Secondly, despite the long inclusion 
period, we had a relatively small number of patients. This is suggesting that there are only 
a limited number of patients with severe new-onset HFrEF without any previous structural 
heart disease requiring hospitalisation. Thirdly, since we are a tertiary referral centre, part 
of our patients initially presented in another hospital. Consequently, there may be a bias 
since a number of patients were not referred to our hospital which may reduce the external 
validity. Next, we excluded patients who died or received an LVAD during the initial hospital 
admission, because we designed this study to investigate the LV remodeling in patients 
treated with medical HF therapy. However, this may have influenced the prognostic end-
point of this study. Furthermore, there were low implantation rates of ICD and CRT. This 
could be explained by the LVEF improvement during follow-up and therefore the lack of 
indication for ICD. Also, the low number of events did not allow a proper multivariable 
analysis, because the event-per-variable ratio would lead to significant overfitting in the 
model and a high risk of statistical error. Lastly, we did not measure LV volumes which 
could give additional information regarding LV remodeling.
We also acknowledge the lack of treatment with ARNIs and SGLT2-inhibitors, which were 
not available at the moment of our study, but nevertheless may present a limitation for 
extrapolation of our results to the modern clinical practice. 
Conclusion
This study investigated LV remodeling and prognosis in patients with new-onset acute 
severe HFrEF. There was no difference in prognosis between patients with ischaemic and 
non-ischaemic HF, although the LV remodeling differed considerably between these two 
patient groups. In contrast to those with ischaemic HF, patients with non-ischaemic HF 
showed significant LV remodeling already at 6 months, which progressed exponentially 
in the first 2 years of medical treatment. Hence, our study emphasizes the importance of 
optimal medical treatment at discharge, as this is a determinant of LV remodeling and a 
good long-term prognosis.   
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Supplemental Table 1. Fitting values belonging to Figure 2
Left ventricular ejection fraction
  Estimates 95% confidence interval P-value
Ischaemic HF 0.988 0.331 1.644 0.004
Non-ischaemic HF 2.864 2.234 3.494 <0.001
Left ventricular end-diastolic diameter
  Estimates 95% confidence interval P-value
Ischaemic HF 0.529 -0.073 1.131 0.09
Non-ischaemic HF -0.958 -1.342 -0.575 <0.001
Left ventricular end-systolic diameter
  Estimates 95% confidence interval P-value
Ischaemic HF 0.576 -0.046 1.195 0.072
Non-ischaemic HF -1.616 -2.161 -1.071 <0.001
Estimates are per 6 months
HF, heart failure
Supplemental Table 2. Number of missing values  
  LVED diameter LVES diameter LVEF MVR NT-proBNP
Baseline 5 5 0 4 84
6 months 35 36 32 33 58
1 year 48 48 45 45 73
2 years 63 64 60 60 82
3 years 79 80 76 76 86
LVED, left ventricular end-diastolic; LVEF, left ventricular ejection fraction; LVES, left ventricular end-systolic; MVR, 
mitral valve regurgitation; NT-proBNP, N-terminal prohormone of brain natriuretic peptide
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Preventive ICD-therapy in Contemporary 
Clinical Practice
More stringent selection criteria long overdue
Deckers JW
Arshi B
van den Berge JC
Constantinescu AA




While the efficacy of the intracardiac defibrillators (ICDs) for primary prevention is 
not disputed, the relevant studies were carried out a long time ago. Most pertinent 
trials,  including MADIT-II, SCD-Heft and DEFINITE, recruited patients more than 20 
years ago. Since then, improved therapeutic modalities including, in addition to 
cardiac-resynchronization therapy, mineralocorticoid-receptor antagonists, angiotensin 
receptor-neprisylin inhibitors and, most recently, inhibitors of sodium-glucose 
cotransporter 2,  have lowered present-day rates of mortality and of sudden cardiac 
death. Thus, nowadays, ICD therapy may be less effective than previously reported, and 
not as beneficial as many people currently believe. However, criteria for ICD-implantation 
remain very inclusive. The patient must (only) be symptomatic and have ejection fraction 
(EF) ≤35%. The choice of EF 35% is notable because the average EF in all large trials was 
much lower, and clinical benefit was mainly limited to EF ≤30%. This EF cut-off value 
defines a substantial portion of potential ICD recipients. It seems therefore reasonable 
to limit ICD eligibility criteria in the EF range 30 to 35% to patients at highest risk only. 
We discuss and present some rational criteria to assist the clinician in improving risk 
stratification for preventive ICD implantation.
133
Preventive ICD-therapy; new selection criteria
Introduction
Each month, over 10,000 cardioverter-defibrillators (ICDs) are being implanted in the 
US alone, while the overall volume of worldwide implantations continues to increase 
as well.(1-3) Most devices are implanted in patients at high risk of sustained ventricular 
tachycardia or fibrillation.(2) While the efficacy of the ICDs for this indication - primary 
prevention – is not disputed, it is fair to say that the relevant studies were carried out 
a long time ago.(4-10) Most trial reports date from early this century, implying that 
their results were obtained in – and in theory thus only applicable to - patients treated 
over twenty years ago. Since then, the principle of electric shock for life-threatening 
arrhythmias has not changed much, while other therapeutic options have progressed 
and rates of sudden cardiac death have decreased.(11) Thus, present-day ICD therapy 
may be less effective than previously reported, and not as beneficial as many people 
currently believe. This assessment is validated by the results of the most recent and large 
study on preventive ICD-implantation, which reported only a minor survival advantage 
of ICD-placement compared to usual clinical care in individuals with a cardiomyopathy 
of non-ischemic origin.(12) Admittedly, patients with ischemic heart disease (IHD) are at 
higher risk of sudden cardiac death, but their recruitment in the applicable trials also 
dates back two decades, and the therapy that they received reflects that. Therefore, time 
has come for an updated qualitative assessment of current indications for preventive 
ICD-therapy, and that is the aim of our paper. 
The trails 
In ischemic heart disease
Preventive ICD-implantation in IHD has been investigated in seven randomized trials.
(4-10)  MADIT I and MUSTT started enrolment in 1990 (see Table 1 for characteristics 
of both studies). Electrophysiological investigation (EP) was needed prior to inclusion in 
both, a requirement that has been abandoned in subsequent trials.(4, 6) In fact, MUSTT 
was a comparison of EP guided versus “conventional” therapy and, among the 351 
randomized to EP guided therapy, 161 (46%) patients initially received defibrillators. Two 
“negative” trials – DINAMIT and IRIS - took place shortly (within 40 days) after myocardial 
infarction (MI), and resulted in the contra-indication of ICD-implantation in early post-MI 
survivors.(8, 10) The CABG Patch trial was done in patients undergoing surgical coronary 
revascularization, but found no benefit of ICD-insertion in that population.(5) Thus, 
MADIT II and SCD-HeFT comprise the most recent trials favouring ICD implantation in 
IHD.(7, 9) Because of their significance, both – so-called landmark – trials are described in 
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Starting in July 1997, MADIT II randomized 1232 post-MI patients with advanced left 
ventricular (LV) dysfunction, defined as LV ejection fraction (EF) ≤30% (Table 1).(7) 
The hazard ratio for mortality was 0.69, but the plausible effect range was wide (95% 
confidence interval (CI) 0.51 – 0.93). 
From September 1997 onwards, SCD-HeFT evaluated prophylactic ICD-therapy versus 
placebo (as well as versus amiodarone) in three groups each of about 840 patients 
with symptomatic congestive heart failure and EF ≤35%.(9) The cardiomyopathy was 
of ischemic origin in approximately 50% of the patients. Compared to placebo, ICD-
implantation was associated with a 23% (95% CI 4% to 38%) reduction in mortality. The 
largest survival benefit was observed in patients with NYHA class II heart failure and with 
LVEF ≤30%, characteristics present in 70 to 80% of patients included. 
In non-ischemic cardiomyopathy
As described above, SCD-Heft was a mixed trial of patients with ischemic as well as non-
ischemic heart disease. Randomized trials of preventive ICD therapy in patients with 
exclusively non-ischemic heart disease include – in chronological order - CAT, AMIOVIRT, 
DEFINITE and the DANISH study.(12-15). Both CAT and AMIOVIRT were quite small, each 
including about 100 patients. Enrolment in CAT began in 1991 and required – amongst 
others - EF ≤ 30%.(13) The number of deaths in patients randomized to ICD (n=13) or 
medical therapy (n=17) was not different, the main predictor of mortality was low EF. 
Recruitment in AMIOVIRT commenced in August 1996 and was completed by September 
2000, with the purpose to compare total mortality during therapy with amiodarone or 
ICD.(14) The inclusion EF was ≤35%, but the mean EF of the included patients was much 
lower, namely 23%. Survival at three years was similar among patients treated with ICD 
(88%) and amiodarone (87%). 
DEFINITE randomized 458 symptomatic patients with LVEF ≤35% and ambient 
arrhythmias.(15) The first patient was randomized in 1998, mean EF was 21%. With 
28 and 40 deaths in the ICD and control group, respectively, the point estimate of the 
difference in mortality was sizeable (hazard ratio 0.65, 95% CI 0.40 to 1.06), although not 
statistically significant. 
The DANISH study is the most recent and largest trial in non-ischemic cardiomyopathy.
(12) This study randomized 556 patients with symptomatic systolic heart failure and EF 
≤35% to ICD, and 560 to usual clinical care. After a median follow-up of almost 6 years, 
120 patients in the ICD and 131 patients in the control groups had died (HR 0.87, 95% 
CI 0.68 to 1.12, p =0.28). Although ICD placement was effective in lowering the rate of 
sudden cardiac death - from 8.2% to 4.3%, the authors concluded that prophylactic ICD 
implantation did not reduce long-term mortality.
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When the data from the various trials are combined, the mortality benefits associated 
with preventive ICD-insertion in non-ischemic disease typically range from 19% to 25%.
(16-19) Details of the two largest trials, DEFINITE and the DANISH study, are presented 
in Table 1. 
Current therapeutic options 
Medical treatment in the two first landmark trials in ischemic heart disease, MADIT-II 
and SCD-Heft, was probably standard for that time period, although usage of beta-
blockers and mineralocorticoid receptor antagonists was relatively modest while, as 
a reflection of previous clinical practice, digoxin was used frequently. But in the next 
twenty years, further therapeutic advancements have become available for patients with 
LV dysfunction, with significant bearing on their outcome. 
One relevant development in the treatment of patients with heart failure includes the 
introduction of cardiac-resynchronization therapy (CRT) and with or without ICD. The 
COMPANION investigators established the worth of this treatment modality in 1520 
patients with advanced (NYHA class III and IV) heart failure, 57% of them with IHD. 
Most patients, with mean EF of 22%, received contemporary medical treatment. One-
year mortality, almost 20%, was very high. The combination of CRT and defibrillator 
was successful in reducing all-cause mortality with 34%.(16) CRT has since become 
recommended standard therapy in patients with symptomatic heart failure in sinus 
rhythm and with EF ≤35%, QRS duration ≥150 msec and left bundle branch block QRS 
morphology.(17)    
The most relevant developments in the medical treatment of patient with symptomatic 
heart failure include the mineralocorticoid-receptor antagonists, the angiotensin receptor-
neprisylin inhibitors and, most recently, inhibitors of sodium-glucose cotransporter 2 
(SGLT2).(18-21) Both eplerenone and spironolactone – not separately reported in DEFINITE, 
infrequently used in MADIT-II and SCD-Heft and employed in about 60% of patients in the 
DANISH trial - were found to lower mortality with 20% in advanced heart failure.(18, 19) 
Neprisylin inhibition with LCZ696 in lieu of ACE-inhibition, and associated with a relative 
and absolute reduction in mortality of 16% and 1.8%, respectively, was not used in any of 
the preventive ICD trials.(20) And neither was the SGLT2 inhibitor, a relatively novel drug 
that lowered mortality with (relative) 17% and (absolute) 2.8% compared to recommended 
therapy in symptomatic patients with heart failure.(21) The main characteristics of the 
largest modern-day heart failure drug trials are also given in Table 1. 
The data in Table 1 illustrate the limited use of currently available optimal medical 
treatment in the early trials, just as the – probably partly ensuing - high event rates of the 
early studies compared to the more recent. In addition, it is obvious that event rates in 
non-ischemic cardiomyopathy are lower than in IHD. The data in Table 1 make it also clear 
that the benefits of each of the new therapeutic modalities clearly fall within the plausible 
effect ranges of the most recent ICD trials (while their combined effects could be larger). 
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Complications and costs 
Immediately after their introduction, controversy about the costs and complications 
associated with ICD-implantation was unleashed.(7, 22) This debate has continued 
ever since. The ICD implantation itself carries approximately 9% peri-procedural risk of 
complication.(23-26) During follow-up, in addition to the regular device interrogations, 
inappropriate shocks and re-hospitalizations are not uncommon, while generator 
replacement every 4 to 7 years carries a risk of minor and major complications.(27) A list 
of short- and long-term ICD complications is summarized in Table 2.
Table 2. Short, medium and long-term complication rates of ICD implantation 







During 3 to 4 years follow-up(25, 26)
Inappropriate ICD shock 12%
Device malfunction or lead failure 6%
Device or lead infection 2%





Hematoma requiring intervention 2%
As it currently stands, 25 ICD’s are required to save one life.(17, 28) In view of their high 
levels of current employment, the financial burden of preventive ICD-implantation 
apparently seems to be acceptable at individual levels in rich countries. However, this 
is much less the case from a societal point of view. Rising numbers of implantations 
and the prospect of even larger numbers of future patients with heart failure in aging 
populations are unwelcome from that perspective. It is thus logical that measures have 
been taken in some countries to minimize the rate of implantations, for instance by 
limiting the number of implanting centres. It is unknown whether this has been effective.
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ICD cost-effectiveness decreases when event rates decline. There can be no doubt that – 
in addition to the observed decrease in overall mortality observed in the pharmacological 
trials depicted in Table 1 – the risk of sudden death has also decreased substantially, 
reportedly by 44%, in the last decades.(11) Importantly, the absolute rate of sudden 
death was found to be lower among patients with a recent diagnosis of heart failure, 
consistent with the cumulative benefit of evidence-based medication on this mode of 
death. These findings can probably be extrapolated to the population at large.(29) In our 
region, we have witnessed a reduction of about 40% in the rate of sudden cardiac death 
in middle aged and elderly men and women, a much larger decrease than the observed 
decline in overall mortality in the same population.(30) 
Ejection fraction and icd selection criteria
Historically, when new and – in their early phase - expensive pharmaceutical agents were 
introduced, for instance with the early clinical introduction of ACE-inhibitors, statins and 
- now - PCSK9-inhibitors, their clinical application has been tailored to men and women 
at highest risk.(31-33) But this has not been the practice for preventive ICD’s. Despite 
many attempts to identify specific patient groups in whom the devices would be more 
(cost) effective, such efforts have not resulted in modification of guidance on their use 
in clinical practice. In fact, with time, the criteria for ICD-implantation have only become 
more inclusive and lenient. Both the European and American guidelines currently state 
that the patient (only) needs to be symptomatic (NYHA class II or III) and have an ejection 
fraction ≤35% (while receiving “optimal” medical treatment).(17, 34) In patients with a 
non-ischemic cardiomyopathy, treatment with “optimal” medical treatment for three 
months is additionally advised, although improvement in LV function (“remodeling”) may 
happen after longer period of times.(35, 36)
The cut-off value of EF 35% is important because this criterion identifies and defines a large 
group of potential ICD recipients. For example, exactly 50% of the patients in PARADIGM-
HF had an ejection fraction between 30 and 35%.(20) Of note, the EF inclusion criterion in 
SCD-Heft was ≤35% and ≤30% in MADIT-II, but the average EF in both trials, 25% and 23% 
respectively, was much lower, just as in the DANISH study and in DEFINITE. The evidence 
of ICD benefit in the low EF range is considerable, but this is much less the case when LV 
function is better preserved. For instance, the positive effects of ICD-implantation in SCD-
Heft were only observed in patients with EF ≤30%, who – importantly - comprised 80% 
of the study population.(9) In MUSTT, with EF ≤40% as LV function inclusion criterion, the 
relation between ejection fraction and event rates was highly significant whether EF was 
treated as continuous or dichotomized variable, and total mortality in patients with EF 
≤30% was more than 50% higher compared to EF between 30 and 40%.(37)
Of course, sudden arrhythmic death will continue to occur, but - given the currently 
available therapeutic options - at a much lower rate than observed in the landmark and 
other trials.(11) The conclusion that this affects ICD-therapy effectiveness is not new, 
and has led to multiple attempts to identify patients at highest risk. But individualized 
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prediction of sudden cardiac death remains notoriously difficult(38-42) and, despite the 
development of innovative clinical risk models, the continuing increase in ICD insertions 
as well as the unchanged guidance in their use indicate that such methods of selection 
have not been successful.(43, 44) 
There can be little doubt that, within the EF range between 30 and 35%, the evidence 
for ICD benefit in primary prevention is limited. This is in particular true in non-ischemic 
cardiomyopathy where event rates are lower than in IHD. Of note, the risk of arrhythmic 
endpoints is reportedly larger in the presence of myocardial fibrosis assessed with late 
gadolinium enhancement.(45, 46) And the finding of such fibrosis, although its relevance 
has not yet been confirmed in randomized comparisons, may tip the balance in favouring 
ICD implantation in non-ischemic cardiomyopathy. In patients with myocarditis, longer 
duration of medical therapy than 3 months may be necessary to establish improvement 
of LV function.(35, 36) Lastly, patients with normal QRS duration have often been reported 
to be at relatively low risk, and ICD implantation may be deferred in such instances.(40) 
Table 3 provides a summary of these recommendations. 
Summary and Conclusions
Findings from the landmark ICD-trials, interpreted in combination with the clinical 
evidence and effective therapeutic options since accumulated, and set against the costs 
and the potential complications of ICD implantation, now demand and allow for better 
and more stringent ICD implant selection criteria in primary prevention. Moreover, while 
it must be acknowledged that the relationship between LVEF and ICD effectiveness is 
not straightforward – benefit is both low in those at extremely high and at very low risk 
– LV function is a major determinant of prognosis in all studies of patients with heart 
failure, regardless of their cause.(17, 47, 48) In the most recent and largest trials, ICD 
benefit was mainly confined to patients with LVEF ≤30%. At this moment, it seems 
reasonable to limit the ICD eligibility criteria in the EF range 30 to 35% to patients at 
highest risk only, and to defer ICD implantation in subjects within this EF range without 
features suggesting high risk. In Table 3, such criteria have been presented. We realize 
that these cover only a limited selection of risk categories, and will only be applicable 
to a limited number of patients and implant decisions. Nevertheless, we hope that the 
rational and considerations presented in this paper will gain following and will encourage 
modifications in clinical practice as well as in future guidance. 
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Table 3. Factors associated with ICD benefit or harm in EF range 30 to 35%
Factors favouring ICD implant
Ischemic heart disease
QRS width ≥150 msec and LBBB*
Presence of fibrosis on MRI
Factors not favouring ICD implant
Limited life-expectancy
Myocarditis < 6 months
QRS width <120 msec 
 EF, ejection fraction; ICD, intracardiac defibrillator; LBBB, left bundle branch block; MRI, magnetic resonance 
imaging
* with cardiac resynchronization therapy
It goes without saying that a proper assessment of the contemporary benefit of preventive 
ICD in patients with relatively mild LV dysfunction, with or without CRT, will require a 
new randomized clinical trial. The study should include symptomatic patients with heart 
failure of any cause with an EF above the range currently debated, thus with LVEF over 
30%, and must employ baseline imaging techniques detailed enough to establish their 
worth in subsequent clinical risk stratification. Given the current ICD implantation rates, 
the recruitment of such patients should be relatively straightforward. 
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Background: The relation between non-cardiac comorbidities and health-related quality 
of life (HRQoL) in patients with heart failure (HF) has been studied to a limited extent. 
Aim: To investigate the HRQoL and their determinants among HF patients with and 
without comorbidities.
Methods: TRIUMPH (TRanslational Initiative on Unique and novel strategies for 
Management of Patients with Heart failure) is a Dutch prospective, multicenter study 
enrolling 496 acute HF patients between 2009 and 2014. We included 334 patients who 
had completed the HRQoL questionnaires at baseline. The HRQoL was measured by the 
Kansas City Cardiomyopathy Questionnaire (KCCQ) en EuroQuality-of-life 5 Dimensions 
(EQ-5D). Comorbidity was defined as having a history of at least one of the following 
comorbidities: chronic kidney disease, diabetes mellitus, chronic obstructive pulmonary 
disease (COPD) and/or cerebrovascular accident (CVA).
Results: Patients with comorbidity (n=205, 61%) had lower scores on the physical 
limitation scale and clinical summary score of the KCCQ (p=0.03 and p=0.01, respectively). 
Female sex, COPD, previous HF, increasing BMI, elevated NT-proBNP, high systolic blood 
pressure and the presence of anxiety and/or depression negatively influenced the HRQoL 
among HF patients with comorbidity. Besides anxiety and depression, we hardly found 
any other determinant of HRQoL in patients without comorbidity. 
Conclusion: HF patients without comorbidity had better HRQoL than patients with 
comorbidity. Sex, previous HF, BMI, COPD, systolic blood pressure, NT-proBNP levels and 
also anxiety and depression were determinants of HRQoL in patients with comorbidity. In 
those without comorbidity, apart from anxiety and depression, no further determinants 
of HRQoL were found.
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Introduction
Heart failure (HF) is a clinical syndrome that is frequently accompanied by non-cardiac 
comorbidities such as renal dysfunction, chronic obstructive pulmonary disease (COPD), 
diabetes, cerebrovascular accident (CVA) and anemia. Some of these comorbidities may be 
a result of HF, whereas other diseases may be associated with the development of HF.1, 2 
It has also been established that among patients with HF, those with one or more 
comorbidities have a worse prognosis when compared with those without comorbidities.2 
Besides a poor prognosis, HF patients also have an impaired health-related quality of 
life (HRQoL).3 The HRQoL among patients with HF has not only been found to be worse 
than that in the general population, but it is even worse than that of patients with other 
chronic conditions.4, 5 Moreover, an impaired HRQoL is a driver of adverse outcome in 
HF.6 Also from a patient’s perspective, HRQoL is very important. Some studies have found 
that patients value quality of life at least as important as longevity.7, 8 Therefore, HRQoL is 
an interesting and important topic from a clinical and research perspective.
The relation between non-cardiac comorbidities and HRQoL in patients with HF has 
been studied to a limited extent. The relative few studies available have shown a relation 
between comorbidities and HRQoL,3, 9-11 but there is inconsistency among the different 
studies.12 However, there have been no studies reporting on differences in determinants 
of HRQoL between patients with and without (multi-)comorbidity. Therefore, we aimed 
to investigate the HRQoL and their determinants among HF patients with and without 
somatic comorbidities based on data from the TRIUMPH study (TRanslational Initiative on 
Unique and novel strategies for Management of Patients with Heart failure [TRIUMPH]: 
NTR1893).
Methods
Study population and procedures
The design of the TRIUMPH study has been described previously.13, 14 In short, this study 
is a prospective, observational study performed in 14 hospitals in the Netherlands. In 
the period of September 2009 until December 2013, patients aged 18 years and older 
hospitalized with acute HF were enrolled. Acute HF was defined as either new onset HF 
or worsening symptoms of chronic HF. We included patients admitted with acute HF 
with evidence of sustained systolic of diastolic dysfunction. Additionally, patients were 
included if their natriuretic peptide level should be at least three times higher than the 
upper limit of normal and they should be treated with intravenous diuretics during the 
hospitalization. We obtained written informed consent from all patients. All participating 
center’s ethical committees have given approval for the study. The investigation conforms 
with the principles outlined in the Declaration of Helsinki.15
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The primary aim of the TRIUMPH study was to investigate the clinical value of repeated 
measurements of several biomarkers in patients with acute HF. One of the secondary 
aims was to study HRQoL in patients with acute HF. 
During hospitalization, patients were visited three times: at admission, at day 2 to 4 
following admission and on the day of discharge. After hospital discharge, four follow-
up moments were planned: at 2 to 4 weeks, 3 months, 6 months and 9 to 12 months. 
At each measurement moment, patients underwent physical examination (including 
blood pressure, heart rate and weight measurement), blood sampling and patients were 
scored according to the New York Heart Association (NYHA) classification. Patients were 
treated in accordance to the European Society of Cardiology Guidelines16 by their treating 
physician. The TRIUMPH study did not intervene in the usual care.
Quality of life measurement
Patients were asked to complete several questionnaires before hospital discharge and 
at the last follow-up visit. HRQoL was measured by the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) en EuroQuality-of-life 5 Dimensions (EQ-5D). Symptoms of anxiety 
and depression were measured by the Hospital Anxiety and Depression Scale (HADS). 
The KCCQ is a disease-specific questionnaire to measure the HRQoL of patients with 
HF. This 23-item questionnaire covers the following six domains: physical limitation 
(KCCQ-PL), symptom stability, total symptom score (combination of symptom frequency 
and symptom burden), self-efficacy score, quality of life score and social limitation. Two 
summary scores can be computed from these domains: the clinical summary score 
(KCCQ-CS) comprising the domains physical limitation and total symptom score, and the 
overall summary score (KCCQ-OS) which captures the domains physical limitation, total 
symptom score, quality of life and social limitation. Each domain and summary score has 
been transformed into a 0 to 100 scale. Higher scores indicate better HRQoL.17
The EQ-5D is a general, non-disease-specific HRQoL questionnaire that consists of 
two components. The first component is the health state description and the second 
component is the health state evaluation. We used the 3-level version of the EQ-5D for 
health state description. The three levels were: (1) no problems, (2) some problems, 
and (3) extreme problems. A total of five dimensions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) were scored according to these three levels. 
For each dimension, patients were asked to choose the statement which best described 
their health status that day. In the second part (i.e. health state evaluation) patients were 
asked to score their health status by using a visual analogue scale within a range of 0 
(worst imaginable health status) to 100 (best imaginable health status).18
The HADS has been shown a valid and reliable instrument to assess symptoms of 
anxiety and depression. Patients were asked to answer fourteen questions. Seven 
items contribute to each of the two subscales (anxiety and depression, respectively) and 
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were answered on a 4-point Likert scale from 0 to 3, which implies a total score range 
per subscale of 0-21.19, 20 A score of ≥8 points on the subscale anxiety as well as on the 
subscale depression was used to determine whether patients had an anxiety disorder 
and/or depression.19
Definitions
To answer our research question, analyses were stratified by comorbidity. Comorbidity 
was defined as having a history of at least one of the following significant, non-cardiac 
comorbidities: chronic kidney disease, diabetes mellitus, COPD and/or CVA. The presence 
of the comorbidities was according to the investigator’s statement of the medical history 
in the case report form. These four comorbidities were chosen because of their high 
prevalence in HF and because there is evidence that they may influence HRQoL and/or 
the presence of anxiety and depression.
HF with reduced ejection fraction was defined as a left ventricular ejection fraction below 
50%. During admission, NYHA classification was determined at three time points. Since 
the NYHA classification at discharge was considered the most stable of these three, this 
measurement was used as the baseline NYHA classification.
Statistical analyses
Categorical variables are presented as numbers and percentages. The χ2 test was 
used to compare categorical variables. Continuous variables are given as median with 
interquartile range (IQR) and were compared with the Mann-Whitney U test.
The determinants of HRQoL (based on the EQ-5D and KCCQ) were analyzed by using linear 
regression models and logistic regression, respectively. First, we performed univariable 
analyses in the total study population with all baseline characteristics. Anxiety and 
depression were included as predictors, using the HADS model to define whether there 
was anxiety and/or depression or not. Then, all determinants with p<0.2 in the univariable 
analyses were included in the multivariable analyses (forward step method) in order to 
search for determinants of HRQoL in the total population. Further, the significant (i.e. 
p<0.05) determinants of HRQoL in the total population plus age and sex were included in 
the multivariable analyses (enter method) to test determinants of HRQoL in patients with 
and without comorbidity. Finally, we tested for interaction between comorbidity and the 
determinants of HRQoL. 
All tests were two-tailed and p-values <0.05 were considered statistically significant. We 





In total, 496 patients were enrolled in the TRIUMPH study. Three patients withdrew their 
informed consent. Another 18 patients were excluded from statistical analyses because of 
inclusion violation since they had no evidence of sustained systolic or diastolic dysfunction. 
Of the 475 remaining patients, we included the 334 patients (70%) who had completed 
the HRQoL questionnaires at baseline into the analyses set. Besides higher occurrence 
of comorbidity and higher levels of NT-proBNP, the baseline characteristics of the 141 
patients (74% with comorbidity) who did not complete the HRQoL questionnaires were 
almost comparable with that of the patients in the analyses set (see Supplemental Table 1).
The included patients consisted of 219 men (66%), the median age was 74 years (IQR 
65-81) and 205 patients (61%) had at least one of the comorbidities diabetes mellitus, 
chronic kidney dysfunction, COPD or prior CVA (Table 1). Almost half of the patients had 
ischemic HF and 85% had HF with reduced ejection fraction.








  n=334 n=205 n=129  
Demographics
Age, years 74 (65-81) 76 (66-81) 73 (60-80) 0.04
Male 219 (66%) 145 (71%) 74 (57%) 0.01
Caucasian 319 (96%) 196 (96%) 123 (95%) 0.59
Medical history
Previous heart failure 215 (65%) 144 (71%) 71 (55%) 0.004
Previous heart failure hospitalization within 
last 6 months
69 (21%) 49 (24%) 20 (16%) 0.06
Ischemic heart failure 158 (47%) 115 (56%) 43 (33%) <0.001
Heart failure with reduced ejection fraction 228 (85%) 134 (82%) 94 (89%) 0.15
Hypertension 166 (50%) 119 (58%) 47 (36%) <0.001
Atrial fibrillation 143 (43%) 94 (46%) 49 (38%) 0.16
Diabetes mellitus 118 (35%) 118 (58%) 0 (0%) <0.001
Chronic obstructive pulmonary disease 65 (20%) 65 (32%) 0 (0%) <0.001
Chronic kidney dysfunction 55 (17%) 55 (27%) 0 (0%) <0.001
Cerebrovascular accident 52 (16%) 52 (25%) 0 (0%) <0.001
Baseline measurements
Body mass index, kg/m2 28 (25-31) 28 (25-32) 26 (24-30) 0.004
Systolic blood pressure, mmHg 125 (110-148) 125 (110-148) 124 (110-145) 0.53
Diastolic blood pressure, mmHg 74 (64-85) 70 (65-82) 78 (64-89) 0.049
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  n=334 n=205 n=129  
Heart rate, bpm 85 (72-100) 84 (70-99) 90 (76-105) 0.02
Kreatinin, umol/L 122 (100-158) 134 (106-181) 111 (95-140) <0.001







Left ventricular ejection fraction, % 30 (21-40) 30 (22-42) 30 (20-39) 0.09
NYHA classification 0.29
I 35 (13%) 20 (12%) 15 (14%)
II 127 (47%) 71 (43%) 56 (52%)
III 98 (36%) 65 (39%) 33 (31%)
IV 12 (4%) 9 (6%) 3 (3%)  
Results depicted as median (interquartile range) or N (%)
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association
Comorbidity defined as presence of one or more of the following: diabetes mellitus, chronic obstructive pulmonary 
disease, chronic kidney disease and/or prior cerebrovascular accident
P-value for comparison between patients with and those without comorbidity
On average, patients with comorbidity were 3 years older, more frequently male, 
and more often had a history of HF and an ischemic cause of HF. Of the patients with 
comorbidity, 135 patients (65%) had only one of the four comorbidities and 14 patients 
(7%) had three or more. The most common comorbidity was diabetes mellitus. Notably, 
indicators of cardiac function like left ventricular ejection fraction, NT-proBNP en NYHA 
class did not differ between patients with and without comorbidity.
Differences in HRQoL according to comorbidity
The NYHA classification at discharge of patients with and without comorbidity was 
comparable (Table 2). Furthermore, the EQ-5D score neither did differ between patients 
with and without comorbidity (p=0.16). In contrast, the HRQoL measured by the disease-
specific questionnaire (i.e. KCCQ) showed that patients with comorbidity had a significant 
lower KCCQ-PL and KCCQ-CS (p=0.03 and p=0.01, respectively). Lastly, patients with 




Table 2. HRQoL, anxiety and depression in patient with and without comorbidity
Baseline 1 year follow-up














I 20 (12%) 15 (14%) 0.29 10 (12%) 23 (37%) 0.002
II 71 (43%) 56 (52%) 55 (65%) 24 (39%)
III 65 (39%) 33 (31%) 19 (22%) 14 (23%)





0.68 (0.34-0.81) 0.69 (0.43-0.86) 0.16 0.81 (0.65-0.89) 0.86 (0.77-1.00) 0.04
EQ-5D VAS 60 (49-70) 60 (50-70) 0.33 70 (55-80) 70 (60-80) 0.19
KC
CQ
KCCQ-PL 33 (13-63) 42 (21-71) 0.03 58 (33-82) 75 (44-96) 0.01
KCCQ-CS 31 (16-54) 35 (25-61) 0.01 69 (41-88) 77 (50-96) 0.05
KCCQ-OS 30 (18-51) 35 (21-56) 0.14 65 (40-85) 77 (49-91) 0.06
H
AD
S Anxiety 63 (32%) 46 (36%) 0.41 17 (19%) 12 (20%) 0.8
Depression 83 (42%) 38 (30%) 0.03   24 (26%) 10 (17%) 0.19
Results depicted as median (interquartile range) or N (%)
CS, clinical summary score; EQ-5D, EuroQuality-of-life 5 Dimensions; HADS, Hospital Anxiety and Depression Scale; 
HRQoL, health-related quality of life; KCCQ, Kansas City Cardiomyopathy Questionnaire; NYHA, New York Heart 
Association; OS, overall summary score; PL, physical limitation; VAS, visual analogue scale
A total of 154 of the 334 included patients (46%) also completed the HRQoL questionnaires 
after 9-12 months of follow-up. This response rate was comparable between patients 
with and without comorbidity (p=0.43). After 1 year follow-up, the NYHA classification was 
worse in patients with comorbidity (Table 2). Both the generic (i.e. EQ-5D) and disease-
specific (i.e. KCCQ) questionnaires measured a worse HRQoL in patients with comorbidity 
after 9-12 months of follow-up.
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Determinants of HRQoL
The studied comorbidities (i.e. COPD, CVA, chronic kidney dysfunction and diabetes 
mellitus) were found to be modest predictors of the HRQoL in the total study population. 
After multivariable adjustment, COPD was the only of these comorbidities that was found 
to be a significant determinant, namely for KCCQ-PL and KCCQ-CS (β -10.439 [95% CI 
-18.721 - -2.157], β -7.815 [95% CI -14.527 - -1.103], respectively; Table 3).
Table 3. Multivariable adjusted determinants of HRQoL in the total population
  β 95% CI lower 
bound
95% CI upper 
bound
EQ-5D score
Age (per 10 years increase) -0.038 -0.061 -0.015
Male 0.109 0.046 0.172
NYHA class III/IV -0.081 -0.143 -0.02
Anxiety -0.150 -0.221 -0.079
Depression -0.244 -0.314 -0.174
EQ-5D VAS
Age (per 10 years increase) -0.093 -2.978 0.471
Male 3.820 -0.868 8.508
Previous HF -5.051 -9.646 -0.456
LVEF (per % increase) 0.252 0.095 0.409
Anxiety -8.342 -13.589 -3.094
Depression -5.803 -10.963 -0.644
KCCQ-PL
Age (per 10 years increase) -0.382 -2.939 2.175
Male 13.607 6.977 20.238
Previous HF -9.090 -15.686 -2.494
Chronic obstructive pulmonary disease -10.439 -18.721 -2.157
BMI (per 1 point increase) -0.845 -1.429 -0.262
NT-proBNP (per 100 points increase) -0.063 -0.107 -0.020
Depression -15.179 -21.841 -8.517
KCCQ-CS
Age (per 10 years increase) -0.526 -2.635 1.583
Male 10.185 4.749 15.621
Previous HF -7.133 -12.643 -1.622
Chronic obstructive pulmonary disease -7.815 -14.527 -1.103
BMI (per 1 point increase) -1.047 -1.527 -0.567
Systolic blood pressure (per 10 points increase) 1.143 0.209 2.077
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  β 95% CI lower 
bound
95% CI upper 
bound
NT-proBNP (per 100 points increase) -0.058 -0.094 -0.022
Depression -13.677 -19.142 -8.212
KCCQ-OS
Age (per 10 years increase) 0.441 -1.511 2.393
Male 7.167 2.183 12.151
Previous HF -5.872 -10.907 -0.836
Ischemic HF -6.009 -10.904 -1.115
BMI (per 1 point increase) -0.718 -1.150 -0.285
Systolic blood pressure (per 10 points increase) 1.034 0.184 1.884
NT-proBNP (per 100 points increase) -0.052 -0.084 -0.019
Anxiety -7.463 -12.945 -1.981
Depression -14.279 -19.695 -8.864
BMI, body mass index; CI, confidence interval; CS, clinical summary score; EQ-5D, EuroQuality-of-life 5 Dimensions; 
HADS, Hospital Anxiety and Depression Scale; HF, heart failure; HRQoL, health-related quality of life; KCCQ, Kansas 
City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide; NYHA, New York Heart Association; OS, overall summary score; PL, physical limitation; VAS, 
visual analogue scale
Besides the studied comorbidities, other factors were associated with HRQoL. Increasing 
age, female sex, increasing BMI and higher NT-proBNP were the major determinants of 
an adverse score on the KCCQ. Furthermore, depression (as measured with the HADS) 
was also associated with lower HRQoL scores, both on the EQ-5D (β -0.244 [95% CI -0.314 
- -0.174]) and on the KCCQ (PL: β -15.179 [95% CI -21.841 - -0.8517]; CS: β -13.677 [95 CI 
-19.142 - -8.212]; OS: -14.279 [95% CI -19.695 - -8.864]). 
The determinants of HRQoL differed considerably between patients with and without 
comorbidity (Figure 1). Sex, previous HF, BMI, NT-proBNP and systolic blood pressure 
at discharge were determinants of HRQoL among HF patients with comorbidity. The 
presence of anxiety and/or depression also negatively influenced the HRQoL of patients 
with and without comorbidity. Besides anxiety and depression, we hardly found any 
other determinant of HRQoL in patients without comorbidity. 
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Figure 1. Multivariable adjusted determinants of 
HRQoL in patients with and without comorbidity. 
Round symbols indicate results for patients with 
comorbidity, square symbols indicate results for 
patients without comorbidity. BMI, body mass index; 
CI, confidence interval; COPD, chronic obstructive 
pulmonary disease; CS, clinical summary score; EQ-
5D, EuroQuality-of-life 5 Dimensions; HADS, Hospital 
Anxiety and Depression Scale; HF, heart failure; 
HRQoL, health-related quality of life; KCCQ, Kansas 
City Cardiomyopathy Questionnaire; LVEF, left 
ventricular ejection fraction; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; NYHA, New York Heart 
Association; OS, overall summary score; PL, physical 





In this prospective, multi-center study, we found that patients with one or more of the 
four investigated comorbidities (i.e. COPD, diabetes mellitus, chronic kidney disease and/
or prior CVA) had a higher prevalence of depression at baseline than patients without 
comorbidity. Of the four comorbidities, only COPD was modestly associated with worse 
HRQoL. Important determinants of HRQoL in our population were sex, history of HF, 
BMI, NT-proBNP at admission, systolic blood pressure at discharge and the presence 
of a depression. Most of these characteristics were also associated with HRQoL in the 
subgroup of patients with comorbidity. In contrast, besides anxiety and depression, we 
hardly found any other determinant of HRQoL in patients without comorbidity. 
Differences in HRQoL
To the best of our knowledge, this study is the first investigating differences in 
HRQoL between HF patients with and without a cluster of four selected non-cardiac 
comorbidities. Despite a comparable severity of HF (indicated by equal NT-proBNP levels 
and comparable NYHA classification) in patients with and without comorbidity, we found 
lower HRQoL and higher prevalence of depression in HF patients with comorbidity. A 
possible explanation of this might be that patients with comorbidity already had a worse 
HRQoL pre-admission. This potential lower HRQoL pre-admission may not only be due 
to the comorbidities for which was stratified in this study (i.e. prior CVA, chronic kidney 
dysfunction, diabetes and COPD), but we also found other factors that may cause lower 
HRQoL in patient with comorbidity, like higher BMI, more frequent a history of HF before 
inclusion and hypertension.9
Question remains why there was a difference in HRQoL measured with the KCCQ 
questionnaire between patients with and without comorbidity and no difference in the 
EQ-5D score despite the fact that there is some overlap in the questions among both 
questionnaires.17, 18 This inconsistency may be due to the fact that two questionnaires 
consist of different questions on different aspects of HRQoL and, hence, may give different 
outcome. Further, the KCCQ questionnaire is disease-specific and the EQ-5D is short and 
very generic. On the other hand, we think that the difference in way of asking the questions 
may also be responsible for this difference. In the EQ-5D questionnaire, patients were 
asked about their functioning  at that day.18 However, the KCCQ questionnaire specifically 
asked to complete the questions about their functioning and to compare it with their 
functioning two weeks ago.17 This explicitly stated two-week time frame may cause that 
patients answer the questions in a different way.
Determinants of HRQoL
A unique aim of this study was to investigate the determinants of HRQoL in patients with 
and without comorbidity. Female sex, previous HF, COPD, increasing BMI and higher NT-
proBNP levels at admission were found to be important determinants of worse HRQoL 
in patients with comorbidity. Those determinants were also associated with HRQoL in 
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studies that did not investigate differences in determinants of HRQoL in patients with and 
without comorbidity.21, 22 Furthermore, female patients, patients with a history of CVA and 
patients with worse NYHA classification at discharge were at higher risk for depression.
A striking finding was that we, apart from depression, hardly found any determinant of 
HRQoL in patients without comorbidity. A possible explanation for this might be that HF 
itself is by far the most important determinant of the reduced HRQoL in patients without 
comorbidity. Another possible explanation might be that there are other determinants 
of HRQoL in patients without comorbidity that we did not measure (e.g. patients’ illness 
knowledge, patients’ coping strategy23 and socioeconomic status24). Indeed, these 
determinants may also influence the HRQoL of patients with comorbidity and not only in 
those without comorbidity.
Besides the above-mentioned demographic and clinical factors, we also found 
psychosocial determinants of HRQoL: presence of anxiety and depression negatively 
influenced HRQoL. This may have important clinical implications for both patients with 
and without comorbidity.
Clinical implication
Our opinion is that HRQoL should get more attention among clinicians. Prognosis should 
not be the only therapeutic goal. Since HF patients value HRQoL at least as important 
as longevity,7, 8 clinicians should strive for better HRQoL instead of focusing on survival 
per se. Indeed, in our study, we only found a limited number of determinants of HRQoL 
that may be influenced by clinicians, although we think that optimal HF treatment in 
accordance with the guidelines is an important intervention for improving HRQoL.25 
Also, optimal treatment of comorbidities like diabetes mellitus, chronic kidney disease 
and COPD, and managing the risk factors BMI and systolic blood pressure may improve 
HRQoL. This is in line to what Lawson et al. recently stated based on data of the Swedish 
Heart Failure Registry, namely that in order to improve HRQoL, HF guideline-driven 
care needs to include optimal management of the most prevalent non-cardiovascular 
comorbidities.9 Furthermore, psychosocial interventions to intervene with depressive 
and anxiety symptoms may also break the vicious circle of anxiety/depression and 
HRQoL. The last, but very important and maybe a ‘bit forgotten’ intervention we would 
like to emphasize, is cardiac rehabilitation. Cardiac rehabilitation should at least consist 
of exercise therapy and patient education.25-27 Besides improving HRQoL, cardiac 
rehabilitation in patients with HF has proven to be favorable for other endpoints like 
rehospitalization and probably (long-term) mortality.28 Despite the proven effectiveness 
and the strong recommendations in the HF guidelines,25 the number of referrals to 




This study is the first reporting HRQoL and their determinants in HF patients with and 
without comorbidity. Moreover, we used a set of different questionnaires to get an 
impression of a patient’s QoL, namely EQ-5D, KCCQ and HADS. However, some limitations 
should be mentioned. First, this study was designed as a sub study of the TRIUMPH study. 
Therefore, results of this sub study may be underpowered. Another limitation is that the 
choice for the comorbidities CVA, chronic kidney disease, COPD and diabetes was relatively 
arbitrary. Indeed, we have chosen common HF non-comorbidities that may influence 
HRQoL9 but others may have chosen other comorbidities. However, as there were no 
previous studies investigating this topic, we should make a selection. Finally, 70% of the 
initial study population completed the baseline questionnaires. Part of the patients who 
could not complete the questionnaires at discharge were those who died during admission. 
The other part of the 30% non-responders were patients who have not completed the 
questionnaires for reasons unknown or who may have not received the questionnaires 
from their caregivers. Anyway, the baseline characteristics of the responders and non-
responders were largely comparable so the missing seems to be at random.
Conclusions
In conclusion, HF patients without comorbidity had better HRQoL and less depression than 
patients with comorbidity. Sex, previous HF, COPD, BMI, NT-proBNP levels and presence 
of anxiety and depression were determinants of HRQoL in patients with comorbidity. 
In contrast, we have found hardly any demographic or clinical determinants of HRQoL 
in those without comorbidity. In clinical practice, in addition to aiming for improved 
survival, physicians may pay greater attention to improving HRQoL of HF patients both 
with and without comorbidity. 
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  n=334 n=141  
Demographics
Age, years 74 (65-81) 72 (64-80) 0.42
Male 219 (66%) 79 (56%) 0.049
Caucasian 319 (96%) 130 (92%) 0.18
Medical history
Previous heart failure 215 (65%) 86 (62%) 0.58
Previous heart failure hospitalization within last 6 
months
69 (21%) 25 (18%) 0.5
Ischemic heart failure 158 (47%) 71 (51%) 0.47
Heart failure with reduced ejection fraction 228 (85%) 80 (78%) 0.11
Hypertension 166 (50%) 76 (55%) 0.32
Atrial fibrillation 143 (43%) 55 (40%) 0.51
Diabetes mellitus 118 (35%) 54 (39%) 0.44
Chronic obstructive pulmonary disease 65 (20%) 27 (20%) 0.98
Chronic kidney dysfunction 55 (17%) 36 (26%) 0.02
Cerebrovascular accident 52 (16%) 29 (21%) 0.16
Comorbidity 205 (61%) 102 (74%) 0.009
Baseline measurements
Body mass index, kg/m2 28 (25-31) 27 (25-32) 0.83
Systolic blood pressure, mmHg 125 (110-148) 130 (110-147) 0.53
Diastolic blood pressure, mmHg 74 (64-85) 75 (66-89) 0.32
Heart rate, bpm 85 (72-100) 82 (70-99) 0.21
Kreatinin, umol/L 122 (100-158) 133 (103-170) 0.18
NT-proBNP, pg/ml 3738 (1928-8601) 5658 (2781-
10085)
0.005
Left ventricular ejection fraction, % 30 (21-40) 35 (25-47) 0.045
NYHA classification 0.92
I 35 (13%) 10 (12%)
II 127 (47%) 42 (51%)
III 98 (36%) 27 (33%)
IV 12 (4%) 4 (5%)  
Results depicted as median (interquartile range) or N (%)
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Implications of the ACC/AHA risk score for 
prediction of heart failure: The Rotterdam 
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Background: Despite the growing burden of heart failure (HF), there have been no 
recommendations for use of any of the primary prevention models in the existing 
guidelines. HF was also not included as an outcome in the American College of Cardiology/
American Heart Association (ACC/AHA) risk score. 
Methods: Among 2743 men and 3646 women ≥55 years free of HF from the population-
based Rotterdam Study cohort, 4 Cox models were fitted using the predictors of the 
ACC/AHA, ARIC, Health-ABC and ACC/AHA+NT-proBNP. Performance of the models for 
10-year HF prediction was evaluated. Afterwards, net reclassification improvement (NRI) 
for adding NT-proBNP to the ACC/AHA model was assessed.
Results: During a median follow-up of 13 years, 429 men and 489 women developed HF. 
The ARIC model had the highest performance [c-statistic (95% confidence interval[CI]): 
0.80 (0.78; 0.83) and 0.80 (0.78;0.83) in men and women, respectively]. The c-statistic for 
the ACC/AHA model was 0.76 (0.74;0.78) in men and 0.77 (0.75; 0.80) in women. Adding 
NT-proBNP to the ACC/AHA model increased the c-statistic to 0.80 (0.78 to 0.83) in men 
and 0.81 (0.79 to 0.84) in women. Sensitivity and specificity of the ACC/AHA model did not 
drastically change after addition of NT-proBNP. NRI(95%CI) was -23.8%(-19.2%;-28.4%) in 
men and -27.6%(-30.7%;-24.5%) in women for events and 57.9% (54.8%; 61.0%) in men 
and 52.8%(50.3%; 55.5%) in women for non-events.
Conclusions:  Acceptable performance of the model based on risk factors included in 
the ACC/AHA model advocates use of this model for prediction of HF risk in primary 
prevention setting. Addition of NT-proBNP modestly improved the model performance 
but did not lead to relevant discrimination improvement in clinical risk reclassification. 
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Background
Heart failure (HF) remains a major public health problem among men and women worldwide.
[1, 2] The growing morbidity and mortality of HF, along with poor quality of life and prognosis, 
high costs, and the challenges of treating clinically overt HF highlight the need for more 
efficient preventive strategies.[3, 4] To identify high risk individuals who would benefit most 
from early prevention, several HF risk prediction models have been developed.[5, 6] However, 
none of these models have been recommended for routine use in clinical practice.[5]
The recent American College of Cardiology (ACC)/American Heart Association (AHA) 
guidelines use the pooled cohort equations (PCE) to predict 10-year risk of atherosclerotic 
cardiovascular disease (ASCVD). Compared to the previous guidelines, the newer 
guidelines have expanded the focus from coronary heart disease (CHD) only to an 
ASCVD outcome that additionally includes stroke.[7] Due to variability between studies in 
ascertainment of HF, incident HF has not been included in this newly expanded outcome. 
The PCE is comprised of the traditional cardiovascular risk factors which were among the 
ten most consistently reported predictors included in HF prediction models in a recent 
meta-analysis.[6] Compared to the more specific HF prediction models, risk factors 
included in the PCE are simple to measure and available in most clinical settings. 
In this study, we assessed the performance of a model fitted based on the risk factors 
used in the PCE (ACC/AHA model) for 10-year HF prediction among men and women 
from the large prospective population-based Rotterdam Study. We also compared the 
performance of this model for HF prediction with the performance of models based on 
risk factors included in the two risk scores that have been specifically developed and 
validated to predict HF in the general population; namely the Atherosclerosis Risk in 
Communities (ARIC) and the Health Aging and Body Composition (Health ABC) HF risk 
scores.[8, 9] Furthermore, we investigated whether addition of NT-proBNP, to the ACC/
AHA risk score improved HF risk prediction. 
Methods
Study sample
This project was carried out within the framework of the Rotterdam Study, a prospective 
population-based study among subjects 45 years and older in Rotterdam, the 
Netherlands. The baseline examination of the Rotterdam Study included 7983 individuals 
and was completed between 1989-1993 (RS-I). The cohort has been extended twice (3011 
individuals, RS-II , recruited in 2000-2001 and 3932 individuals, RS-III, in 2006) to include 
participants who were 45 years or older or had moved to the study area. Rotterdam 
Study participants have been followed-up ever since and the examinations have been 
repeated every 3-4 years. The overall response for all three study cycles at entry was 
72.0% (14,926 of 20,744). The rationale and design of the study have been previously 
described.[10] The Rotterdam Study has been approved by the Medical Ethics Committee 
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of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of 
Health, Welfare, and Sport (Population Screening Act WBO, license number 1071272-
159521-PG). The Rotterdam Study has been entered into the Netherlands National Trial 
Register (NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry 
Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalog number 
NTR6831. All participants provided written informed consent to participate in the study 
and to have their information obtained information from their treating physicians.
The present study used data from the third examination of the original cohort (RS-I-3, 
1997-1999, n = 4755) and the first examination of the extended cohort (RS-II-1, n=3011) 
had blood samples ( RS-I-3, n=4063 and RS-II-1, n=2630) . We excluded participants with 
a history of HF at baseline (n = 258), those with incomplete data at baseline or lost to 
follow-up (n=46). After exclusions, 6389 participants (2743 men, 3646 women) were 
included in the study. (Figure 1)
N= 6693
RS-I-3 with blood samples = 4063
RS-II-1 with blood samples = 2630
Prevalent heart failure at baseline = 258
Lost to follow-up = 3
Incomplete data at baseline = 43





Figure 1. Flowchart of the included study participants
Predictors of HF
Body mass index (BMI) was calculated based on weight in kilograms divided by height in 
meters squared. Blood pressure was measured on the right arm using a random-zero 
sphygmomanometer at sitting position. Two measurements were performed and the average 
of the two was used in the analyses. Antihypertensive treatment for hypertension, use of 
lipid lowering medication, history of diabetes mellitus and history of CHD were based on 
clinical information obtained from general practitioners and letters or discharge reports from 
medical specialists.[11] Information on smoking behavior was acquired from questionnaires. 
For the ACC/AHA model, participants were classified as current smokers versus former 
or never smokers. For the Health ABC and ARIC models, smoking status was classified as 
current, former and never. Fasting serum glucose levels were determined using the glucose 
hexokinase method and serum total and high-density lipoprotein (HDL) cholesterol were 
measured using an automatic enzymatic procedure (Hitachi 911, Roche CHOD PAP). Serum 
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creatinine levels were measured using an enzymatic assay (Roche Diagnostics, Mannheim, 
Germany) which was calibrated by isotope dilution mass spectrometry. Serum NT-proBNP 
was measured using a commercially available electrochemiluminescence immunoassay 
(Elecsys proBNP, F Hoffman-La Roche Ltd) on an Elecsys 2010 analyzer.[12] Left ventricular 
hypertrophy (LVH) was diagnosed based on Sokolov-Lyon criteria by the Modular ECG 
Analysis System program with an algorithm taking into account QRS voltages with an age-
dependent correction and repolarization.[13] Presence of atrial fibrillation (AF) was based on 
the clinical and ECG evidence from medical records.[11]
HF Assessment
Ascertainment of HF for the Rotterdam Study has been previously described.[11] 
Information on prevalent HF cases at entry were obtained from a database containing 
hospital discharge diagnoses from all hospitals in Rotterdam at entry.[11, 14] During 
follow-up, diagnosis of incident HF was also based on clinical information systematically 
collected from the general practitioner medical records and verified hospital discharge 
diagnoses collected from all hospitals in Rotterdam. Based on the criteria of the European 
Society of Cardiology (ESC), the diagnosis of definite HF was based on the presence of 
two signs or symptoms suggestive of HF, established by objective evidence of cardiac 
dysfunction, confirmed by a medical specialist.[15] HF was classified as probable if at 
least two typical symptoms of HF were present and at least one of the following: history 
of CVD (MI, valvular heart disease, hypertension), response to treatment for HF or 
objective evidence of cardiac dysfunction, while symptoms could not be attributed to 
another disease. In accordance with the ESC guidelines, only definite and probable cases 
were used in the Rotterdam study definition. [15]
The incident date for HF was defined as the date of the first occurrence of symptoms 
suggestive of HF from the medical records or the day of receipt of a first prescription for a 
loop diuretic or an angiotensin-converting enzyme inhibitor, whichever one preceded.[11]
Statistical Analysis
Baseline characteristics of men and women were presented as mean [standard deviation 
(SD)] for normally distributed data and as median [interquartile range (IQR)] for skewed 
data and were compared using the Student-t tests for continuous variables and χ2 tests 
for categorical data. Logarithmic transformation was made on NT-proBNP to account for 
its skewed distribution. We used multiple imputation for missing values on covariates 
(All missing <5%).[16] Parameter estimates were obtained by pooling 5 imputed datasets 
using Rubin rules.[16]
Three different Cox proportional hazards models were developed by refitting risk factors 
from the PCE risk score (ACC/AHA model), the ARIC HF risk score (ARIC model) and the 
Health ABC HF risk score (Health ABC model). Although these models were refitted, 
for simplicity we call them ACC/AHA, ARIC, and Health ABC models.10-year HF risk was 
estimated per model. Predictors included in the ACC/AHA model were age, total and HDL 
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cholesterol, systolic blood pressure, antihypertensive treatment, current smoking, and 
history of  diabetes. The ARIC model included age, heart rate, systolic blood pressure, 
antihypertensive treatment, history of diabetes, history of CHD, smoking status (current, 
former, never), BMI and NT-proBNP. The Health ABC model included age, history of CHD, 
LVH, systolic blood pressure, heart rate, smoking status (current, former, never), glucose 
and creatinine. Due to unavailability, albumin measurement was left out of the Health 
ABC model. In addition, a fourth model was built that additionally included NT-proBNP 
in the ACC/AHA model as a predictor (ACC/AHA+NT-proBNP model). All models were 
separately developed for men and women. 
For each model, a full model including interaction terms between age and NT-proBNP and 
between SBP and antihypertensive medication use (if applicable) and natural splines with 
2 knots for age and NT-proBNP (if applicable) was first specified, forcing on the variables of 
the respective risk scores. Schoenfeld’s test of residuals using the Kaplan-Meier estimate 
of the survival function was used to check the proportionality of the regressions. Then, 
backward selection was performed using log likelihood ratio to compare all these nested 
models. A P-value of 0.2 was considered for inclusion of nonlinear and interaction terms 
in multivariable models. 
To compare the models, Akaike information criterion (AIC) was used. Calibration of the 
models was graphically evaluated by creating model-based risk plots and was further 
assessed with the Greenwood-D’Agostino-Nam test.[17] The discriminative performance 
of the fitted models was assessed by calculating the modified c-statistic by using the 
technique of inverse probability of censoring weighting (IPCW) for censored data.[18]
To evaluate the implication of NT-proBNP on risk assessment, performance of the ACC/
AHA and the ACC/AHA+NT-proBNP models for 10-year HF prediction were compared. 
We assessed the performance of the two models by calculating the time-dependent 
sensitivity, specificity, positive and negative predicted values for survival data. To do 
this, risk cut-offs introduced by the ACC/AHA guideline for ASCVD (5%, 7.5% and 20%) 
were used.[19] We also calculated continuous and categorical NRIs. Reclassification 
tables were constructed to investigate the number of individuals with and without the 
HF event, reclassified to a higher or lower category of 10-year risk for HF. Risk categories 
were defined using the same cut-offs [low-risk (<5%), borderline risk (≥5% and <7.5%), 
intermediate risk (≥7.5% and <20%) and high risk (≥20%)].
The original ACC/AHA model was developed for ASCVD risk calculation among 
asymptomatic individuals. Therefore, as a sensitivity analysis, the performance of the ACC/
AHA model was also evaluated after addition of CHD history to the model. Furthermore, 
all analyses were once repeated in a sample with further exclusions for prevalent CHD 
and AF and use of lipid lowering medication based on the ACC/AHA guidelines. 
All analyses were performed using R version 3.6.1 (Packages: mice, rms, survC1, timeROC, 
ggplot2)
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Results
Mean (SD) age was 68.0 (7.78) years in men and 69.2 (8.58) years in women (Table 1). Mean 
BMI (kg/m2) was slightly higher in women [26.5 (3.27) in men versus 27.3 (4.39) in women]. 
Glucose and creatinine levels were higher in men [6.09 (1.70) mmol/l in men and  5.87 
(1.47) mmol/l in women for glucose and 89.0 (18.2) mmol/l in men and 70.8 (13.5) mmol/l 
in women for creatinine]. However, total and HDL cholesterol levels were higher in women. 
33% of men and 35% of women used antihypertensives while 14% and 12% took lipid 
lowering medications, respectively. More men (13.8%) had a history of CHD than women 
(3.3%). Likewise, more men had diabetes (14.7% compared to 11.6% in women). Median 
NT-proBNP levels were higher in women [median (IQR): 8.19 (13.4) in men and 10.8 (13.2) 
in women]. Data on covariates were missing for less than 5% in men and women.
Table 1. Characteristics of the study population
Clinical features Men (N = 2743) Women (N = 3646) P-value*
Age, years 68.0 (7.78) 69.2 (8.58) <0.001
BMI, kg/m2 26.5 (3.27) 27.3 (4.39) <0.001
Systolic blood pressure, mmHg 142 (20.8) 143(21.5) 0.350
Hear rate, bpm 69.4 (11.9) 71.7 (10.9) 0.032
Total cholesterol, mmol/l 5.54 (0.95) 6.01 (0.95) <0.001
HDL, mmol/l 1.24 (0.32) 1.50 (0.40) <0.001
Antihypertensive use, N (%) 856 (32.7) 1220 (35.3) <0.001
Lipid lowering medication, N (%) 364 (13.8) 420 (12.0) <0.001
Creatinine, mmol/l† 89.0 (18.2) 70.8 (13.5) <0.001
Glucose, mmol/l 6.09 (1.70) 5.87 (1.47) <0.001
LVH, N (%) 176 (7.30) 119 (3.80) 0.034
NT-proBNP, pmol/l† 8.19 (13.4) 10.8 (13.2) <0.001
Prevalent CHD, N (%) 370 (13.8) 118 (3.30) <0.001
Prevalent diabetes, N (%) 403 (14.7)     423 (11.6) 0.009
Smoking,  N (%) <0.001
Current 652 (25.3) 614 (17.2) -
Past 1604 (62.2) 1315 (36.8) -
Never 322 (12.5) 1648 (46.1) -
Data are mean (standard deviation (SD))for continuous variables, †median (interquartile range (IQR)) for skewed 
variables, and number (percentage) for categorical variables from the original data.
BMI; body mass index, CHD; coronary heart disease, HDL; high-density lipoprotein, LVH; left ventricular hypertrophy
* P-value for differences in characteristics between men and women.
Proportion of missing: Among men: SBP: 0.18%, heart rate: 0.55%, total cholesterol, BMI and glucose: each 0.9%, 
HDL: 1.7%, creatinine:1.6%, NT-proBNP: 1.6%, antihypertensive use: 2%, smoking: 2.7%, LVH: 2.9%.
Among women: SBP: 0.86%, heart rate: 1.43%, total cholesterol, glucose: 1.6 %, antihypertensive use: 1.8%, 
smoking: 1.9%, BMI:2.1%, creatinine:1.8%, NT-proBNP: 2%, HDL: 2.6%, LVH: 2.6%.
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During a median follow-up of 13 years, 429 and 489 incident cases of HF were identified 
in men and women, respectively (incident rate: 14.5 per 1000 person-years in men and 
11.4 per 1000 person-years in women). Supplemental Table 1 details the multivariable-
adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) for 10-year incident 
HF for the ACC/AHA, the ARIC, the Health ABC and the ACC/AHA+NT-proBNP models in 
men and women.
Comparing the models, the Health ABC model had the lowest AIC in men and women 
(5651.2 and 6656.2, respectively) with 11 degrees of freedom (See Supplemental Table 2). 
The overall fit of the ARIC model was 5953.2 in men 6908.0 in women with 9 degrees of 
freedom. The AIC of the ACC/AHA model was 6213.4 in men and 7503.2 in women. The AIC 
of the ACC/AHA model improved substantially (P for the log-likelihood ratio test <0.001) after 
adding NT-proBNP (5970.9 in men and 7179.4 in women). Calibration plots of observed and 
predicted risks were reasonable (See Supplemental Figure 1). The Greenwood-D ’Agostino-
Nam test also indicated that all models were well-calibrated  (All P >0.20).
Figure 2 shows the discriminative performance of each model in men and women. The 
ARIC model had the highest discriminative ability in men and women [c-statistic (95% CI): 
0.80 (0.78 to 0.83) and 0.80 (0.78 to 0.83), respectively]. The c-statistic for the ACC/AHA 
model was 0.76 (0.74 to 0.78) in men and 0.77 (0.75 to 0.80) in women. By adding NT-
proBNP to the ACC/AHA model, the c-statistic increased to 0.80 (0.78 to 0.83) in men and 
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Figure 2. Discriminative performance of models for 10-year heart failure prediction 
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Using cut-off s introduced by the recent ACC/AHA guidelines, the ACC/AHA model 
categorized 0.04% of men as low risk, 1.5% as borderline, 27.6% as intermediate and 
70.9% as high risk (Figure 3). Among women, the ACC/AHA model allocated 7% as low 
risk, 14.4% as borderline, 38.2% as intermediate and 40.4% as high risk. Continuous 
NRI (95% CI) after adding NT-proBNP to the ACC/AHA model was 0.075 (-0.08 to 0.16) 
in men and 0.12 (0.02 to 0.22) in women. As for categorical NRI, event NRI (95% CI) was 
-23.8% (-28.4% to -19.2%) and non-event NRI (95% CI) was 57.9% (54.8% to 61.0%) for 
men. Among women, event and non-event NRI (95% CI) were -27.6% (-30.7% to -24.5%) 
and 52.8% (50.3% to 55.5%) respectively (See Supplemental Table 3). Reclassifi cation of 
individuals with and without the HF event to higher or lower risk categories is depicted in 
(See Supplemental Figure 2).
Figure 3. Observed risk categories based on the ACC-AHA model in men and women
Risk categories are: low-risk (<5%), borderline risk (≥5% and <7.5%), intermediate risk (≥7.5% and <20%) and high 
risk (≥20%)] 
Overall the sensitivity of the ACC/AHA + NT-proBNP model was higher using diff erent 
cut-off s in men and women. Specifi city and predictive discrimination values were similar 
for both models at the 5.5 and 7.5% risk thresholds (Supplemental Table 4). As expected, 
the sensitivity declined and the specifi city increased for both models when risk threshold 
increased from 5% to 7.5% and to 20%. Using a cut-off  of 20%, the ACC/AHA model 
correctly classifi ed 9% of men and women who developed HF during follow-up at high 
risk (sensitivity). Also, 99% of men and women who remained event free during follow-up 
were correctly classifi ed at low risk (specifi city) by the ACC/AHA model. But, for the ACC/
AHA+NT-proBNP model, the sensitivity and specifi city were 16% and 99% in men, and 
21% and 99% in women. From men and women categorized as >20% risk by the ACC/AHA 
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model 88%  and 57% developed HF during follow-up (positive predicted value), whereas 
from those categorized at low-risk group 89% of men and 92% of women remained event 
free during the follow-up (negative predicted value). For ACC/AHA+NT-proBNP model, 
the positive and negative predicted values were 84% and 90% in men, respectively. In 
women, the ACC/AHA+NT-proBNP model, the positive and negative predicted values 
were 69% and 93%, respectively. Results for the analyses using the thresholds of 5%, 
7.5% and 20% 10-year HF risk are shown in Table 2.
In sensitivity analyses, prevalent CHD was added to the ACC/AHA and the ACC/AHA+NT-
proBNP models. We also repeated the analyses excluding participants with AF and prevalent 
CHD and those using lipid lowering medication according to the ACC/AHA guidelines. The 
performance of the models did not change substantially (data not shown).
Table 2. Comparison of the performance of the ACC/AHA model and ACC/AHA model with  addition of  NT-proBNP
Risk thresholds
Men 5% 7.5% 20%
Sensitivity
         ACC/AHA 80% (78% to 82%) 50% (47% to 53%) 9% (8% to 11%)
         ACC/AHA + NT-proBNP 83% (81% to 85%) 58% (55% to 61%) 16% (14% to 18%)
Specificity
         ACC/AHA 70% (69% to 71%) 90% (89% to 91%) 99% (99% to 100%)
         ACC/AHA + NT-proBNP 72% (71% to 73%) 90% (89% to 91%) 99% (99% to 100)
Positive predicted value (95%CI)
         ACC/AHA 27% (25% to 28%) 40% (37% to 43%) 88% (80% to 96%)
         ACC/AHA + NT-proBNP 29% (27% to 30%) 44% (41% to 46%) 84% (79% to 90)
Negative predicted value (95%CI)
         ACC/AHA 96% (96% to 97%) 93% (92% to 93%) 89% (87% to 89%)
         ACC/AHA + NT-proBNP 97% (96% to 97%) 94% (93% to  95%) 90% (89% to 90%)
Women 5% 7.5% 20%
Sensitivity (95%CI)
         ACC/AHA 81% (79% to 83%) 52% (49% to 55%) 9% (8% to 12%)
         ACC/AHA + NT-proBNP 85% (83% to 87%) 63% (60% to 66%) 21% (18% to 23%)
Specificity (95%CI)
         ACC/AHA 67% (66% to 78%) 89% (88% to 90%) 99% (99% to 100%)
         ACC/AHA + NT-proBNP 69% (68% to 70%) 87% (86% to 88%) 99% (99% to 100%)
Positive predicted value (95%CI)
          ACC/AHA 19% (18% to 20%) 31% (29% to 33%) 57% (48% to 67%)
          ACC/AHA + NT-proBNP 21% (20% to 22%) 33% (31% to 35%) 69% (64% to 74%)
Negative predicted value (95%CI)
         ACC/AHA 97% (97% to 98%) 95% (95% to 96%) 92% (91% to 93%)
         ACC/AHA + NT-proBNP 98% (98% to 99%) 96% (95% to 96%) 93% (92% to 93%)
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Discussion
A simple model based on traditional cardiovascular risk factors included in the ACC/
AHA model showed a reasonable performance in predicting 10-year HF among men and 
women from the population-based Rotterdam Study. The performance of the model 
based on ACC/AHA risk factors for HF prediction was comparable to the models based 
on risk factors included in the ARIC and Health ABC HF models. Adding NT-proBNP to 
the ACC/AHA model modestly improved model performance but did not lead to relevant 
clinical improvement in risk reclassification. 
Compared to CHD and stroke, prediction of incident HF remains a challenge.[5, 6] In 
spite of the large number of risk prediction models developed for incident HF, there have 
been no recommendations for routine clinical use of any of the models in the existing 
guidelines.[5] This is while, preventive interventions significantly reduce the risk of incident 
HF.[3] In addition to generalizability issues and methodological heterogeneity, models 
specifically developed to predict HF are based on various markers which have higher 
technical demands and might not be available in all clinical settings.[5, 8, 9, 20] HF can 
have ischemic or non-ischemic origins. Although CHD and hypertension are the leading 
causes of HF, a high proportion of this syndrome is attributed to other cardio-metabolic 
risk factors.[21] Moreover, biomarkers have shown limited predictive capability for HF risk 
stratification and have not profited clinical decision making.[22] The ACC/AHA model for 
ASCVD risk assessment consists of the traditional cardiovascular risk factors that are also 
associated with HF.[7] In our analysis, the model based on traditional cardiovascular risk 
factors included in the ACC/AHA model had a performance almost similar to the Health 
ABC model and close to the ARIC model for HF risk assessment in general population. In 
a meta-analysis of HF prediction models, among the 53 potential predictors considered 
in 19 studies between 1990 and 2016, age, sex and systolic blood pressure were the 
most common selected predictors.[6] To note, the predictors in the ACC/AHA model 
were among the 10 most used predictors in these dedicated HF prediction models. They 
are also commonly used in predicting HF prognosis and other cardiovascular outcomes.
[23] The acceptable performance of the model based on risk factors from the ACC/AHA 
algorithm for HF prediction in our study advocates implementing this model for primary HF 
prevention. Addition of NT-proBNP to the ACC/AHA model improved model performance 
in both sexes. There was overlap between men and women in the discrimination of both 
the ACC/AHA and the ACC/AHA+NT-proBNP models. Nevertheless, the improvement in 
the c-statistic after addition of NT-proBNP was slightly greater among women. To note, 
levels of NT-proBNP/BNP have not shown to be different between men and women with 
acute or chronic HF.[24] Also, women have slightly lower NT-proBNP/BNP levels in clinical 
setting which has been attributed to higher prevalence of HF with preserved ejection 
fraction among women.[25] Thus, an overlap in the performance of the model by adding 
this biomarkers is not far from expectation. 
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Studies have shown mixed results regarding the contribution of NT-proBNP/BNP to 
improvement of CVD risk predictions in men and women.[26] NT-proBNP has displayed 
no or only modest impact in increasing the discriminative ability or risk classification of the 
CVD risk prediction models in general population.[22, 25, 27-29] On the contrary, in high-
risk individuals with previous history of CVD, higher prognostic ability has been reported.
[25] It should be considered that a wide variety of cardiac and non-cardiac conditions are 
also associated with elevated serum levels of this biomarker.[30] Moreover, high levels of 
NT-proBNP are associated with creatinine levels, sex, age and inversely associated with 
BMI independent of ventricular function.[1, 19, 31] This is probably why its discriminative 
ability for detection of left ventricular systolic dysfunction has been suboptimal, limiting 
its utility in mass screening.[32]
Using different cut-offs, addition of NT-proBNP was accompanied by slight increases 
in the sensitivity and specificity of the models in both sexes. Only at the 20% cut-off, 
the difference in the sensitivity and specificity of the two models was more evident and 
NT-proBNP increased the NPV and PPV of the model more evidently. Also, continuous 
NRI in men was smaller than women. However, using the ACC/AHA risk cut-offs, NT-
proBNP mainly correctly down-classified participants without the event in both sexes 
and did not show large improvement in reclassifying participants with the event. In line 
with our study, Willeit et al. showed a strong association between NT-proBNP and the 
composite outcome of stroke, CHD and HF.[28] But the increase in the c-statistic of the 
model after adding NT-proBNP was modest. Interestingly, they also specified that NT-
proBNP improved risk prediction by appropriately down classifying the clinical risk of 
those without the event. Moreover, they observed similar changes using cut-offs used by 
different guidelines. [28] 
NT-proBNP/BNP is an established diagnostic and prognostic biomarker in HF patients.
[31] For prediction of incident HF alone, NT-proBNP/BNP has shown to improve model 
performance.[8, 33, 34]  However, despite the association of increasing NT-proBNP/BNP 
levels with substantial risk of HF, it is not a cost-effective screening tool to assess for 
preclinical heart failure or LV dysfunction, limiting its utility to highly selected populations.
[30] In this regard, NT-proBNP testing has a clear and valuable role in the diagnosis of 
CHF in the emergency diagnosis of patients with dyspnea.[35] The strength of BNP is in 
its ability to rule out CHF in this setting. Likewise, the favorable clinical utility of adding 
NT-proBNP to the ACC/AHA model in risk reclassification was mainly limited to the non-
events in our study. To add, BNP has shown a high NPV to rule out diastolic dysfunction 
or LVH.[36, 37] The ACC/AHA +NT-proBNP model also showed a high NPV for HF in our 
study using different risk cut-offs but the differences were more evident among those at 
high risk, using a cut-off of 20% which again emphasizes that NT-proBNP might be useful 
in prediction of HF only among high risk populations. Specifically, this utilization might be 
more towards ruling out HF rather than its rule-in ability.[30]
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Strengths of our study are use of a large sample size and detailed long follow-up 
data. Our HF event adjudication was robust and well-defined. Moreover, a large set of 
various and precisely measured variables were available for this study. There are also 
limitations. The Rotterdam Study population is mainly white and 45 years of age and 
older, compared with the ARIC and the PCE study populations. Mean age of the study 
population in the ARIC study [54.1(6.0) years] was younger than our total population [69.7 
(8.27)] while mean age in the health ABC study [73.6 (2.9)] was somewhat closer to our 
study population, but with less variability. As the strongest predictor of HF, differences 
in age could explain to some extent the differences in the performance of the models. 
Hence, we refitted the models based on the variables used in the risk scores. Our study is 
an attempt for internal validation of the ACC/AHA risk score for prediction of incident HF 
which may have led to overestimation of its performance. To assess the transferability of 
predictive models, they need to be externally validated to make it possible for them to be 
used in clinical settings.[5, 6] Also, because of unavailability of albumin, we were not able 
to include it in the Health ABC model. In addition, we did not have data on HF subtypes 
at the time of diagnosis. Inaccessibility of data on subtypes of HF is also a limitation of 
population based cohort studies, like the ARIC and the health ABC studies. Moreover, our 
results might not be generalizable to younger individuals and other ethnicities.
Conclusion
The model based on traditional risk factors included in the ACC/AHA model had an 
acceptable performance, comparable to more sophisticated models, for predicting 
10-year HF among men and women from general population. Our results therefore 
advocate use of this model for HF primary prevention. Addition of NT-proBNP to the 
ACC/AHA model leads to modest improvement in model performance, in particular 
among women. However, the clinical relevance of adding this biomarker for correct risk 
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Supplemental Material
Supplemental Table 1. Hazard ratios for incident HF in the ACC/AHA model, ARIC model, Health ABC model and 
ACC/AHA+NT-proBNP model in men and women
Men Women
ACC/AHA model HR (95%CI) HR (95%CI)
Age 1.10 (1.09 to 1.12) 1.1. (1.09 to 1.11)
Total cholesterol 0.97 (0.88 to 1.08) 0.95 (0.86 to 1.05)
HDL cholesterol 0.56 (0.40 to 0.77) 0.83 (0.66 to 1.05)
Systolic blood pressure 1.01 (1.01 to 1.02) 1.01 (1.00 to 1.01)
Antihypertensive use 2.87 (0.77 to 10.6) 4.78 (1.41 to 16.2)
Smoking(current) 1.44 (1.15 to 1.80) 1.12 (0.85 to 1.46)
Prevalent diabetes 1.31 (1.03 to 1.67) 1.15 (0.89 to 1.49)
Systolic blood pressure: Antihypertensive use 1.00 (0.99 to 1.01) 0.99 (0.99 to 1.00)
ARIC model HR (95%CI) HR (95%CI)
Age 1.07 (1.05 to 1.09) 1.07 (1.06 to 1.09)
Log (NT-proBNP) 1.72 (1.57 to 1.90) 2.03 (1.83 to 2.26)
Heart rate 1.01 (1.00 to 1.01) 2.33 (0.70 to 7.70)
BMI 1.09 (1.05 to 1.12) 1.00 (1.00 to 1.01)
Systolic blood pressure 1.01 (1.00 to 1.01) 1.06 (1.03 to 1.08)
Antihypertensive use 1.27 (0.35 to 4.67) 1.00 (1.00 to 1.01)
Smoking(current) 2.1 (1.39 to 3.15) 1.24 (0.94 to 1.65)
Smoking(past) 1.47 (1.01 to 2.15) 1.22 (1.00 to 1.48)
Prevalent diabetes 1.21 (0.95 to 1.54) 1.25 (0.96 to 1.62)
Prevalent CHD 1.33 (1.05 to 1.68) 1.51 (1.06 to 2.15)
Systolic blood pressure: Antihypertensive use 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.00)
Health ABC model HR (95%CI) HR (95%CI)
Age 1.10 (1.08 to 1.11) 1.11 (1.09 to 1.12)
Systolic blood pressure 1.01 (1.01 to 1.01) 1.01 (1.00 to 1.01)
Smoking(current) 2.14 (1.42 to 3.22) 1.33 (1.00 to 1.76)
Smoking(past) 1.64 (1.13 to 2.39) 1.38 (1.14 to 1.67)
Prevalent CHD 2.09 (1.68 to 2.60) 2.45 (1.73 to 3.47)
Heart rate 1.00 (1.00 to 1.01) 1.00 (0.99 to 1.01)
LVH 2.10 (1.58 to 2.78) 2.21 (1.58 to 3.10)
Creatinine 1.00 (1.00 to 1.01) 1.00 (1.00 to 1.01)




ACC/AHA+NT-proBNP model HR (95%CI) HR (95%CI)
Age 1.07 (1.05 to 1.08) 1.07 (1.06 to 1.08)
Log (NT-proBNP) 1.73 (1.58 to 1.90) 2.02 (1.82 to 2.25)
Total cholesterol 1.03 (0.93 to 1.14) 1.01 (0.92 to 1.11)
HDL cholesterol 0.52 (0.37 to 0.71) 0.78 (0.62 to 0.98)
Systolic blood pressure 1.01 (1.00 to 1.01) 1.00 (1.00 to 1.01)
Antihypertensive use 1.97 (0.56 to 6.98) 3.20 (0.98 to 10.5)
Smoking(current) 1.34 (1.07 to 1.67) 1.07 (0.82 to 1.39)
Prevalent diabetes 1.35 (1.06 to 1.72) 1.35 (1.04 to 1.75)
Systolic blood pressure: Antihypertensive use 1.07 (1.05 to 1.08) 0.99 (0.99 to 1.00)
BMI; body mass index, CHD; coronary heart disease, Diabetes; diabetes mellitus, HDL; high-density lipoprotein, 
LVH; left ventricular hypertrophy, HR; hazard ratio, CI; confidence interval
Supplemental Table 2. Overall goodness-of-fit for the ACC/AHA model, ARIC model, Health ABC model and 
ACC+NT-proBNP model in men and women
Men Women
Models AIC degrees of 
freedom
ACC/AHA 6213.38 7503.19 8
ARIC 5953.16 6908.03 11
Health ABC 5651.17 6656.15 9
ACC/AHA + NT-proBNP 5970.96 7179.38 9
AIC: Akaike information criterion










Up Down Up Down
Men 1.40 25.18 -23.8 (-19.2 to -28.4) 0.22 57.08 57.9 (54.8 to 61.0)
Women 5.52 33.13 -27.6 (-30.7 to -24.5) 2.25 55.08 52.8 (50.3 to 55.5)
† NRI (95% CI) for reclassification of events and non-events after adding NT-proBNP to the ACC/AHA model. Event 
NRI was calculates as: (number of events reclassified up minus number of events reclassified down) / total number 
of events . Non-event NRI was calculates as: (number of non-events reclassified up minus number of non-events 
reclassified down) / total number of non-events
* Percentages of persons with or without an event who moved to a higher (up) or lower risk (down) category after 
extension of the ACC/AHA model with NT-proBNP. 
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Supplemental Table 4. Fine and Gray's subdistribution hazard ratios for incident HF and mortality in the ACC/AHA 
model, ARIC model, Health ABC model and ACC/AHA+NT-proBNP model in men and women
Heart failure Mortality
Men Women Men Women
ACC/AHA model HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
Age 1.06 (1.04 to 1.07) 1.05 (1.04 to 1.06) 1.09 (1.08 to 1.10) 1.10 (1.10 to 1.11)
Total cholesterol 0.99 (0.89 to 1.10) 0.99 (0.89 to 1.08) 0.95 (0.69 to 1.02) 1.00 (0.93 to 1.07)
HDL cholesterol 0.59 (0.44 to 0.80) 0.91 (0.72 to 1.13) 0.97 (0.80 to 1.19) 0.83 (0.71 to 0.97)
Systolic blood 
pressure
1.01 (1.00 to 1.03) 1.02 (1.00 to 1.03) 1.01 (1.00 to 1.02) 1.00 (0.99 to 1.01)
Antihypertensive use 2.34 (0.64 to 8.59) 4.54 (1.36 to 15.2) 1.89 (0.75 to 4.80) 1.10 (0.44 to 2.71)
Smoking(current) 1.14 (1.10 to 1.42) 0.95 (0.73 to 1.25) 1.56 (1.36 to 1.79) 1.79 (1.55 to 2.07)




1.00 (0.99 to 1.01) 0.99 (0.99 to 1.00) 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.01)
ARIC model HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
Age 1.03 (1.02 to 1.05) 1.03 (1.02 to 1.05) 1.08 (1.07 to 1.09) 1.09 (1.08 to 1.10)
Log (NT-proBNP) 1.49 (1.34 to 1.66) 1.63 (1.45 to 1.83) 1.09 (1.02 to 1.17) 1.10 (1.02 to 1.18)
Heart rate 1.00 (1.00 to  1.01) 1.00 (0.99 to 1.01) 1.01 (1.00 to 1.01) 1.01 (1.00 to 1.01)
BMI 1.09 (1.06 to 1.13) 1.06 (1.04 to 1.08) 0.97 (0.95 to 0.99) 0.98 (0.96 to 0.99)
Systolic blood 
pressure
1.01 (0.99 to 1.02) 1.01 (1.00 to 1.02) 1.01 (1.00 to 1.02) 1.00 (1.00 to 1.01)
Antihypertensive use 1.08 (0.29 to 4.10) 2.51 (0.75 to 8.38) 1.89 (1.74 to 4.82) 1.34 (0.57 to 3.14)
Smoking(current) 1.74 (1.17 to 2.58) 1.07 (0.79 to 1.43) 1.58 (1.25 to 1.99) 1.77 (1.51 to 2.07)
Smoking(past) 1.55 (1.08 to 2.22) 1.26 (1.03 to 1.54) 1.07 (0.86 to 1.32) 1.00 (0.88 to 1.14)
Prevalent diabetes 1.07 (0.83 to 1.38) 1.00 (0.76 to 1.32) 1.20 (1.01 to 1.43) 1.34 (0.12 to  
1.60)




1.00 (0.99 to 1.01) 1.00 (0.99 to 1.00) 1.00 (0.99 to 1.00) 1.00 (0.99 to 1.00)
Health ABC model HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
Age 1.05 (1.04 to 1.06) 1.10 (1.51 to 1.07) 1.09 (1.08 to 1.10) 1.10 (1.10 to 1.11)
Systolic blood 
pressure
1.01 (1.01 to 1.02) 1.01 (1.00 to 1.01) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00)
Smoking(current) 1.73 (1.17 to 2.57) 1.12 (0.84 to 1.49) 1.66 (0.32 to 2.09) 1.82 (1.55 to 2.13)
Smoking(past) 1.65 (1.43 to 2.38) 1.38 (1.14 to 1.68) 1.07 (0.86 to 1.32) 1.01 (0.88 to 1.15)
Prevalent CHD 1.99 (1.59 to 2.51) 2.18 (1.49 to 3.18) 1.00 (0.84 to 1.20) 0.91 (0.61 to 1.35)
Heart rate 1.00 (0.99 to 1.01) 1.00 (0.99 to 1.00) 1.01 (1.00 to 1.01) 1.01 (1.00 to 1.01)
LVH 2.08 (1.53 to 2.82) 1.88 (1.31 to 2.71) 0.80 (0.61 to 1.04) 0.87 (0.63 to 1.20)




Men Women Men Women
Glucose 1.06 (1.01 to 1.11) 1.07 (1.02 to 1.13) 1.04 (1.00 to 1.08) 1.02 (0.98 to 1.06)
ACC/AHA+NT-
proBNP model
HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
Age 1.03 (1.01 to 1.04) 1.03 (1.02 to 1.04) 1.10 (1.08 to 1.10) 1.10 (1.08 to 1.11)
Log (NT-proBNP) 1.49 (1.35 to 1.65) 1.63 (1.45 to 1.82) 1.09 (1.02 to 1.17) 1.10 (1.02 to 1.18)
Total cholesterol 1.04 (0.94 to 1.15) 1.04 (0.95 to 1.14) 0.96 (0.90 to 0.03) 1.01 (0.94 to 1.08)
HDL cholesterol 0.57 (0.42 to 0.77) 0.86 (0.69 to 1.08) 0.97 (0.79 to 1.18) 0.82 (0.71 to 0.96)
Systolic blood 
pressure
1.01 (1.00 to 1.02) 1.01 (1.00 to 1.03) 1.01 (1.00 to 1.01) 1.00 (0.99 to 1.01)
Antihypertensive use 1.90 (0.52 to 6.93) 3.45 (1.10 to 11.2) 1.72 (0.68 to 4.37) 1.08 (0.44 to 2.65)
Smoking(current) 1.04 (1.83 to 1.31) 0.89 (0.68 to 1.17) 1.53 (1.33 to 1.76) 1.78 (1.54 to 2.06)




1.00 (0.99 to 1.01) 0.99 (0.99 to 1.00) 1.00 (0.99 to 1.00) 1.00 (0.99 to 1.01)
BMI; body mass index, CHD; coronary heart disease, Diabetes; diabetes mellitus, HDL; high-density lipoprotein, 
LVH; left ventricular hypertrophy, HR; hazard ratio, CI; confidence interval
215
ACC/AHA risk score for HF prediction
Supplemental Figure 1. Calibration plots for the observed and predicted risk based on 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Risk factors for longitudinal changes in left 

















Objective To evaluate changes in left ventricular diastolic function (LVDF) parameters 
and their associated risk factors over a period of 11 years among community-dwelling 
women and men. 
Methods Echocardiography was performed three times among  870 women and 630 
men (age 67±3 years) from the prospective population-based Rotterdam Study during a 
period of 11 years follow-up. Changes in six continuous LVDF parameters were correlated 
with cardiovascular risk factors using a linear-mixed effect model (LMM).
Results In women, smoking was associated with deleterious longitudinal changes 
in DT (7.73; 2.56, 12.9) and high-density lipoprotein cholesterol was associated with 
improvement of septal e’ (0.37; 0.13, 0.62) and E/e’ ratio (-0.46; -0.84,-0.08) trajectories. 
Among men, diabetes was associated with deleterious longitudinal changes in A wave 
(3.83; 0.06,7.60), septal e’ (-0.40; -0.70,-0.09) and E/e’ ratio (0.60; 0.14,1.06) and body mass 
index was associated with deleterious longitudinal changes in A wave (1.25; 0.84,1.66), 
E/A ratio (-0.007; -0.01,-0.003), DT (0.86; 0.017, 1.71),  and E/e’ ratio (0.12; 0.06, 0.19).
Conclusions Smoking among women and metabolic factors (DM and BMI) among men 
showed larger deleterious associations with longitudinal changes in LVDF parameters. 
The favorable association of HDL was mainly observed among women. This study, for the 
first time, evaluates risk factors associated with changes over time in continuous LVDF 





Left ventricular diastolic dysfunction is highly prevalent and worsen with advancing age(1-
3). Persistence or progression of diastolic dysfunction is a risk factor for heart failure(HF) 
among the elderly(2). Recent data suggest that diastolic dysfunction is present in the 
majority, around 70%, of patients with heart failure with preserved ejection fraction 
(HFpEF)(4). Although plenty of evidence-based treatments for heart failure with reduced 
ejection fraction (HFrEF) exist, there is no treatment with proven benefits for HFpEF(5).  
Impairment of left ventricular diastolic function(LVDF) occurs gradually and has been 
shown to be, at least partly, reversible(1,6), Therefore, early detection of subclinical 
impairment in LVDF and identification and treatment of its associated risk factors to 
prevent or slow the progression to overt HF is important. To date, several risk factors 
associated with LVDF have been identified(7,8). However, longitudinal studies evaluating 
changes in continuous LVDF parameters over time in general population of subjects 
without clinically diagnosed HF are scant and have been mostly performed among 
middle-aged individuals. As occurrence of various HF phenotypes differs between 
women and men(5), it has been suggested that gender differences in susceptibility to 
risk factors might partly explain these dissimilarities(6). However, recent studies have 
failed to address gender differences in the setting of changes in LVDF and its associated 
risk factors(4-7). Notably, while women tend to have a better LVDF until 60 years of age, 
gender disparities are reversed after the menopause(5). To further clarify sex differences 
in the pathophysiology of diastolic dysfunction, studying changes in continuous LVDF 
parameters among women and men and their correlates, especially at older ages, is 
warranted.
We, therefore, aimed to evaluate longitudinal changes in continuous LVDF parameters 
during 11 years of follow-up among women and men from a large prospective population-
based cohort (9). Participants were all free from clinically diagnosed HF at the time of 
echocardiographic examinations and during follow-up. In addition, we investigated the 
risk factors associated with the changes in LVDF parameters among women and men.
Methods
Study Population
The Rotterdam Study(RS) is a prospective population-based cohort that included 
participants aged 55 years and older in the district of Ommoord, Rotterdam, The 
Netherlands(9). The study started in 1990 with 7,983 participants (RS-I) and was extended 
twice; in 2000 (RS-II, n=3,014) and in 2006 (RS-III, n=3,932). The follow-up examinations 
take place every 3-4 years. The RS was approved by the Medical Ethics Committee 




The present study used data for six LVDF echocardiographic parameters from the fourth, 
fifth, and sixth examinations of the first cohort (RS-I) and the second, third, and fourth 
examinations of the second cohort (RS-II). Out of the six LVDF parameters under study, 
three repeated echocardiographic measurements were available for four indexes among 
1,869 participants. We excluded 369 individuals due to poor echocardiographic images, atrial 
fibrillation, artificial pacemaker, moderate-severe valve compromise, and clinically diagnosed 
HF at the time of echocardiographic examinations and during the follow-up. Therefore, we 
included a total of 1,500 participants (630 men and 870 women) (Figure 1). For two LVDF 
parameters, two repeated measurements were available in a total of 1,528 (646 men and 882 
women) subjects from the fifth and sixth examinations of the first cohort (RS-I) and the third 
and fourth examinations of the second cohort (RS-II) (Supplemental Figure 1). 
Figure 1. Flowchart for the participants included in the analysis of longitudinal changes in LVDF parameters 
measured 3 times over 11 years of follow-up. AF, atrial fibrillation; LVDF, left ventricular diastolic function.
Left ventricular diastolic function parameters
We studied six continuous LVDF parameters. The apical 4-chamber view was used to 
measure the early trans-mitral ventricular diastolic filling velocity(E wave) and late 
diastolic filling velocity(A wave) during three cardiac cycles. Tissue Doppler imaging (TDI) 
was used to measure the early diastolic longitudinal filling velocity of the septal mitral 
annulus (septal e’) during three cardiac cycles. The means of the E wave, A wave and 
septal e’ over the three cardiac cycles were used to calculate E/A and E/e’ ratios. Mitral 
valve deceleration time (DT) was measured as the time between the peak E-top wave and 
the upper deceleration slope extrapolated to the zero baseline using a Continuous Wave 
Doppler(10,11). Additional information on echocardiographic measurements, is provided 
in the online-supplemental material.
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Assessment of cardiovascular risk factors
Detailed information regarding the evaluation of cardiovascular risk factors is given in 
the online-supplemental material.
Statistical Analysis
In the descriptive analysis, continuous variables with normal distribution were reported 
as mean (standard deviations) and categorical variables as numbers (percentages). 
We compared the mean and percentage values for women and men using t-test and 
z-proportion tests respectively. Longitudinal changes in LVDF parameters over time 
were plotted, treating age as a time-varying covariate.  For each of the six parameters, 
a longitudinal data analysis using a linear mixed effect model was performed. The 
outcome of interest in each model was the two or three repeated measurements for 
each index as a continuous variable. Systolic and diastolic blood pressure(SBP, DBP), 
heart rate (HR), total and high-density lipoprotein (HDL) cholesterol, blood pressure 
and lipid lowering medications (LLM), diabetes mellitus (DM), current smoking, previous 
coronary heart disease (CHD), left ventricular mass indexed by body surface area (LVM), 
left ventricular ejection fraction (LVEF), physical activity, left atrial diameter (LAD) and 
cohort were included in all models. Age was used as a time-varying covariate. All analyses 
were performed in total population and in women and men separately. We checked 
for possible interaction between sex and different covariates in the total population. 
We additionally checked for the interaction terms between age, as a time-varying, and 
all covariates. We also compared the characteristics of the included participants with 
those who did not return for the follow-up echocardiography examinations. For more 
details regarding the analyses consult the online supplemental material. The analyses 
were performed with R v.3.2.5 (R Foundation for Statistical Computing, Vienna, Austria), 
and STATA (version 14.0, Stata Corp, College Station, TX). A 2-sided P value of <0.05 was 
considered statistically significant. Additionally, we considered a more conservative 
Bonferroni corrected p value of <0.0083 (= 0.05/6, considering six LVDF parameters). 
Results
Table 1 details the baseline characteristics of 870 women and 630 men for the analyses 
of E wave, A wave, E/A ratio, and DT, in whom 3 repeated measurements were available 
during 11.1 years of follow-up. Women had higher HR, total and HDL cholesterol, left 
atrial diameter (LAD) and ejection fraction. Men had larger DBP, LVM, left ventricular 
end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD) and 
CHD prevalence. For septal e’ and E/e’ ratio, two repeated measurements were available 
among 882 women and 646 men during 4.2 years of follow-up (Supplemental Table 1). 
224
CHAPTER 12
Table 1. Baseline clinical and echocardiographic characteristics of the participants.
Women (n=870) Men (n=630) p-value*
Clinical Features
Age, years 67.30 (4.95) 67.29 (4.91) 0.980
BMI, kg/m² 27.42 (4.07) 27.08 (2.94) 0.069
SBP, mmHg 144.40 (18.32) 143.92 (19.20) 0.626
DBP, mmHg 79.84 (10.11) 82.01 (9.90) <0.001
Blood Pressure Lowering Medication, n (%) 261 (30.0) 208 (33.0) 0.2130
Hypertension, n (%) 609 (70.0) 446 (70.8) 0.7378
Heart Rate, beats/min 69.36 (9.70) 65.79 (10.55) <0.001
Total Cholesterol, mmol/L 5.96 (0.94) 5.45 (0.93) <0.001
HDL-cholesterol, mmol/L 1.60 (0.40) 1.31 (0.31) <0.001
Lipid Lowering Medication, n (%) 174 (20.0) 130 (20.63) 0.765
Current Smoker, n (%) 106 (12.2) 58 ( 9.2) 0.069
Prevalent CHD, n (%) 16 (1.84) 61 (9.68) <0.001
Prevalent DM, n (%) 84 ( 9.66) 62 (9.84) 0.908
Echocardiography Features
LVM index, g/m² 70.66 (15.47) 78.17  (18.19) <0.001
Left Atrium Diameter/BSA, mm/m² 21.41 (2.69) 20.76 (2.45) <0.001
LVEDD, mm 49.39 (4.96) 53.36 (4.86) <0.001
LVESD, mm 30.12 (7.87) 33.66 (8.01) <0.001
Relative Wall Thickness, cm 0.29 (0.06) 0.29 (0.05) 1
Ejection Fraction, % 65.87 (6.75) 63.69 (7.92) <0.001
E wave cm/sec 67.38 (13.02) 64.48 (12.97) <0.001
A wave cm/sec 83.33 (17.82) 76.61 (17.68) <0.001
E/A ratio 0.83 (0.18) 0.86 (0.20) <0.001
Deceleration time 204.4 (35.54) 209.19 (39.78) <0.001
e`septal 6.87 (1.79) 7.29 (1.78) <0.001
E/e`septal ratio 10.43 (2.62) 9.54 (2.51) <0.001
* p-value for comparison of different characteristics between women and men. Values are mean (± standard 
deviation) or numbers (percentages). BMI: Body mass index, BSA: Body surface area, CHD: coronary heart disease, 
DBP: diastolic blood pressure, DM: Type 2 diabetes mellitus, LVEDD: Left ventricle end diastolic dimension, LVESD: 
Left ventricle end systolic dimension, LVM: Left ventricular mass, SBP: systolic blood pressure,
Longitudinal changes in LVDF among women and men 
Based on the plots for each statistical model, the shapes of the longitudinal changes in 
all six LVDF parameters over time were similar in women and men (Figure 2). There was 
not interaction between age (as a time-varying covariate) and sex. The plots revealed a 
progressive deleterious mono-directional change in the longitudinal trajectories of all six 
LVDF parameters over time; i.e. a gradual rise in E wave, A wave, DT and E/e´ ratio values 
and a gradual decline in E/A ratio and septal e’. Despite similar trends in LVDF changes in 
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both sexes, there were statistically significant differences in the mean values, with overall 
poorer indexes in women. Supplemental Table 2 presents detailed information on cross-






Figure 2. Plots for changes in LVDF parameters over time among women and men (left charts: women, right 
charts: men). LVDF, left ventricular diastolic function.
Risk factors associated with longitudinal changes in LVDF 
Since E wave, A wave, DT and E/e´ ratio values progressively, and deleteriously, raised 
over time, a positive Beta coefficient for a risk factor means that the risk factor was 
associated with increment in the trajectory of these LVDF parameters over time. On 
the contrary, a negative Beta coefficient means that the risk factor was associated with 
decrement in the trajectory of these LVDF parameters over time. Therefore, a positive 
risk factor coefficient is associated with an unfavorable progression and a negative risk 
factor coefficient into a favorable progression on LVDF parameters over time. E/A ratio 
and septal e’ values progressively, and deleteriously, diminish over time. Therefore, a 
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negative Beta coefficient for a risk factor means that the risk factors was associated 
with decrement and a positive coefficient means that the risk factor was associated with 
increment in the trajectory of these LVDF parameters over time.   Therefore, a positive 
coefficient translates into a favorable progression and a negative coefficient into an 
unfavorable progression on LVDF parameters over time.
Table 2 and table 3 show all beta coefficients and confidence intervals of different risk 
factors with longitudinal changes in LVDF indexes over time among women and men. 
Supplemental Tables 3 and 4 show the summary of the risk factors significantly associated 
with longitudinal changes in LVDF parameters among women and men. Figure 3 shows 
the core findings of our study, summarizing the main differences among women and 
men in risk factors associated with changes in LVDF trajectories. 
Table 2. Association of risk factors with longitudinal changes in left ventricular diastolic function parameters 
among women.



































































































































































































































*Age in this analysis is used as a time-varying covariate.
†P< 0.01; ‡P<0.05.   BMI: Body mass index, BP: blood pressure, CHD: Coronary heart disease, DBP: Diastolic blood 
pressure, DM: Diabetes Mellitus, HDL: High density lipoprotein, SBP: Systolic blood pressure.
Values are betas (95% confidence intervals).
Table 3. Association of risk factors with longitudinal changes in left ventricular diastolic function parameters 
among men.






































































































































































































































*Age in this analysis is used as a time-varying covariate.
†P< 0.01; ‡P<0.05.   BMI: Body mass index, BP: blood pressure, CHD: Coronary heart disease, DBP: Diastolic blood 
pressure, DM: Diabetes Mellitus, HDL: High density lipoprotein, SBP: Systolic blood pressure.
Values are betas (95% confidence intervals).
E wave: Among both women and men, age and SBP were associated with rise in E wave 
while DBP and LVM were associated with decline in E wave over time. Although BMI 
was associated with rise in E wave in both sexes, this association was only significant in 
women(Tables 2-3 & Supplemental Tables 3-4). 
A wave: Age, SBP, BMI and HR were associated with rise in A wave over time in both 
genders, and DM only in men (Tables 2-3 & Supplemental Tables 3-4). 
E/A ratio: Risk factors associated with decline in E/A ratio were age, DBP and HR in both 
genders. Only in men, BMI was significantly associated with decline in E/A ratio and LVEF 
and LAD with rise in E/A ratio(Tables 2-3 & Supplemental Tables 3-4). 
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Deceleration Time: Among women, current smoking was the strongest risk factor 
significantly associated with rise in DT over time. Age was associated with rise in DT in both 
genders. SBP in women and HR in men were significantly associated with decline in DT. BMI 
was associated with rise in DT only in men (Tables 2-3 & Supplemental Tables 3-4).
Septal e’: LVM was associated with decline in septal e’ in both genders. Additionally, LLM 
and prevalent of CHD among women and DM among men were associated with decline 
in septal e’. Among women, age and HDL Cholesterol were also associated with rise in 
septal e’ (Tables 2-3 & Supplemental Tables 3-4). 
E/e’ Ratio: LVM was associated with rise in E/e’ ratio in both genders. Additionally, LLM 
was associated with rise and HDL cholesterol with decline in E/e’ ratio among women. 
Among men, prevalent CHD, BMI and DM were associated with rise in E/e’ ratio(Tables 
2-3 & Supplemental Tables 3-4). P values for sex interaction in the associations of BMI 
and DM with E/e’ ratio were significant.
 
Figure 3. The core findings of our study, showing the main risk factors associated with longitudinal changes in 




In the large prospective population-based Rotterdam Study, women had poorer diastolic 
function than men. However, the tendency of age-related changes in LVDF parameters 
over time was similar in both genders. Current smoking among women and metabolic 
factors such as BMI and DM among men were found to be associated with deleterious 
progression of longitudinal changes in LVDF parameters over time. HDL cholesterol 
showed a favorable association with LVDF trajectories mainly in women.
Although few studies have shown the intrinsic effect of age and several cardiovascular risk 
factors on worsening of LVDF parameters(3,7), a comprehensive longitudinal assessment 
of continuous LVDF parameters by gender over time is scant(6). Patterns of longitudinal 
changes in the LVDF indexes over time in our study indicated a progressive impaired 
relaxation as well as increasing filling pressures with advancing age in both genders. In 
line with our findings, Kuznetsova et al(7) also found an rise in the E/e’ ratio and decline in 
septal e’ and E/A ratio over time. The LVDF parameters we reported are also comparable 
to those reported by Caballero et al(12) in populations older than 60 years, implying a 
worsening of diastolic function with ageing.
We found that the post-menopausal women in our study had a worse diastolic function 
compared to men, providing more evidence regarding the larger burden of diastolic 
dysfunction among women after menopause(5,12). In younger men, a larger decline 
in most of the LVDF indexes over time was observed. Women have a better diastolic 
function until 60 years of age after which they experience a steeper decline and worse 
diastolic function compared to men(5). Ageing per se seems to produce more eccentric 
remodeling and 3-fold larger apoptosis in men compared with women that might explain 
a steeper decline in diastolic reserve and the higher prevalence of diastolic dysfunction 
and HFpEF in women compared to men(13,14).
Longitudinal analyses of risk factors associated with changes in continuous LVDF 
parameters over time from a gender-specific perspective are scarce. Kuznetsova et 
al(7), based on the risk factors identified in cross-sectional studies, evaluated the 
longitudinal determinants of LVDF parameters and showed advancing age, higher insulin 
levels, DBP, and HR to worsen LVDF indexes over time. A recent longitudinal analyses 
of Framingham(15), based on categorical LVDF parameters during 5.6 years follow-up, 
showed that age, female sex, changes in SBP and DBP, BMI, serum triglycerides and 
DM were associated with worsening diastolic function in total population. Our current 
study expands these findings by examining the risk factors associated with changes in 
various continuous LVDF parameters over 11 years of follow-up from a gender-specific 
perspective. The main advantage of analyzing the continuous LVDF parameters is a 
greater power to detect associations and a lower misclassification bias than analysis 
based on categorical classification(16).
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Association of Risk Factors on Longitudinal Changes in LVDF parameters 
among Women and Men
Blood Pressure: SBP and DBP showed significant associations with longitudinal changes 
in E wave, A wave, and E/A ratio among women and men. The opposite direction of the 
effect for SBP and DBP suggested the effect of pulse pressure(PP). Accordingly, when we 
substituted SBP and DBP with PP in our analyses, PP was significantly associated with 
changes in these parameters among women and men. In several epidemiological studies, 
PP has shown a superior predictive value compared to SBP or DBP alone (17,18). Higher 
PP is associated with elevated stress of the left ventricle which can result in ventricular 
hypertrophy and failure, critical determinants of left ventricular diastolic dysfunction(18).
Metabolic Factors: Previous cross-sectional studies have independently associated 
diastolic dysfunction with BMI and DM(19). In our study, DM  was found to be strongly 
associated with worsening of LVDF parameters in men. Expanded myocardial fibrosis 
as well as accelerated apoptosis are among the pathophysiologic features of diabetic 
cardiomyopathy(20). While several previous studies have shown larger deterioration 
of LVDF among diabetics(8), data regarding sex differences in the association of DM on 
LVDF are scarce and conflicting. Diabetes was found to be an independent contributor 
to LVM among women in the Framingham Heart Study(21) but among both women and 
men from the Cardiovascular Health Study(22) and the Strong Heart Study(23). 
In our study, a larger association of BMI with worsening of LVDF over time was found 
among men than in women. The only prior, cross-sectional, study that evaluated sex 
differences of obesity on LVDF, reported no association between BMI and LVDF indexes 
in women >65 years but did describe an association between septal e’ and abdominal 
adiposity among younger women  Among men, BMI and abdominal obesity were 
associated with a higher likelihood of diastolic dysfunction(24). The obesity-related 
mechanisms might be different for women and men. While for younger women the effect 
of obesity might act through its influence on SBP, the effect seems to be predominantly 
direct for men >65 years(24).
Smoking and Lipid Profile: Current smoking was only associated with rise in DT among 
women in our study. Smoking commonly precedes the development of HFpEF(25). While 
smoking confers a greater CHD risk in women compared to men(26), sex differences in 
the setting of HF have not been reported(27). Smoking has been suggested to significantly 
affect LVDF independently of its role as a risk factor for coronary atherosclerosis and 
through other independent pathways(28). 
We found a favorable association of HDL-cholesterol with diastolic function over time 
among women. Moreover, use of lipid lowering medication, as a proxy for chronic 
dyslipidemia, was associated with worse LVDF over time. Previous cross-sectional 
studies have associated hyperlipidemia with coronary endothelial dysfunction and with 
myocardial damage independent of ischemia, leading to diastolic dysfunction(29). Low 
levels of HDL cholesterol and elevated levels of total cholesterol are known risk factors 
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for CHD and increasing LVM, both important factors leading to diastolic dysfunction. 
While increasing HDL levels have a more favorable effect in women compared to men, 
such gender differences in the association of HDL with LVDF require further study.
Study Strengths and Limitations
Our study was based on a large group of women and men from a population-based 
cohort with repeated echocardiographic examinations over 11 years of follow-up. The 
longitudinal design allowed the use of linear mixed effect models to analyze progressive 
long-term alterations in continuous LVDF parameters. Availability of the well-defined 
set of covariates and detailed characterization of the cohort allowed to examine LVDF 
parameters and their correlates from a gender-specific perspective. Nevertheless, 
limitations of our study also merit consideration. The gold standard for diastolic function 
measurement is the pressure-volume relationship which is an invasive approach. 
However, Doppler measurements of mitral inflow and TDI allows for a valid non-invasive 
measurement of diastolic function(10,30). Echocardiography has proven to be a useful 
tool for assessing diastolic function, in order to minimize  inherent limitations operator-
dependent,  a standardized protocol was used by 4 trained echocardiographers with 
good inter and intra-reader agreement(11). Our population included individuals of 
European ancestry. Therefore, the generalizability of our findings to other ethnicities 
should be performed with caution. As inherited to all longitudinal cohort studies, survival 
bias cannot be entirely ruled out.
Conclusions
In our large population-based study, women were found to have poorer diastolic 
function than men. However, age-related changes in continuous LVDF parameters were 
comparable in both genders. Our findings highlight the correlates of asymptomatic 
diastolic dysfunction among women and men.  The differential association of risk factors 
with LVDF among women and men could provide further hypothesis regarding transition 
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For each participant, one echocardiogram was obtained at each examination. In the first 
examination, the first 40% of the echocardiograms were performed with a commercially 
available ultrasonography system (AU3 Partner, Esaote Biomedica, with a 3.5/2.5 MHz 
transducer) and the followings with Acuson Cypress, with a 3V2c transducer. For the 
subsequent second and third examinations, a standardized protocol was used which 
also included two-dimensional resting transthoracic echocardiography performed 
by experienced echocardiographers with an identical standardized protocol for all 
participants and a commercially available ultrasonography system (Vivid I, GE Healthcare, 
Little Chalfont, UK), with a 2.5 MHz transducer. All examinations were performed by the 
same echocardiographers using the same protocol. As described previously, inter-reader 
and intra-reader agreements were good(1). All images were digitally stored and assessed 
offline by the echocardiographers.
The protocol included 2-dimensional scanning in the parasternal long and short axis views, 
the apical and subcostal views. In addition, 2-dimension guided M-mode measurements 
of left ventricle were obtained by scanning in the parasternal long axis view.
Left atrial diameter (LAD), left ventricular end diastolic diameter (LVEDD), left ventricular 
end systolic diameter (LVESD), interventricular septum thickness (IVST),  left ventricular 
posterior wall thickness (LVPWT) and left ventricular ejection fraction were the left-sided 
measurements. Relative wall thickness was calculated according to the formula (2 * LVPWT)/
(LVEDD) (2). Left ventricular mass (LVmass) in grams was calculated according to the formula 
by Devereux and colleagues as 0.8 * (1.04 * ((LVEDD + IVST + LVPWT)3 - LVEDD3)) + 0.6(3), 
and was indexed with Body Surface Area (BSA) (2). Left ventricular fractional shortening (FS) 
was calculated using the formula: FS = (LVEDD-LVESD)/LVEDD * 100%(4).
Assessment of Cardiovascular Risk Factors:
Medical history, current health status, smoking and use of medications were assessed 
by a trained interviewer at the home visit using a computerized questionnaire. Body 
mass index (BMI) was calculated as weight in kilograms divided by height in squared 
meters. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 
twice in sitting position at the right upper arm. We used the average of two consecutive 
measurements. Hypertension was defined as SBP >140 mm Hg, DBP >90 mm Hg, or use of 
blood pressure-lowering medication with an indication for hypertension. Heart rate (HR) 
was measured with an oximeter in the second finger of the right hand and the average 
of two consecutive measurements was used. Total and high density lipoprotein (HDL) 
cholesterol and glucose levels were measured with the use of standardized laboratory 
techniques. Diabetes mellitus (DM) was defined as fasting glucose >6.9 mmol/L, nonfasting 
glucose >11.0 mmol/L, use of blood glucose-lowering medication, or a previous diagnosis 
of DM. A history of coronary heart disease (CHD) was defined as a myocardial infarction 
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or coronary revascularization procedure (5, 6). Physical activity was evaluated using LASA 
questionnaire (LAPAQ) and accelerometer (Actiwatch) (7).
Statistical Analysis:
For the analysis of the diastolic dysfunction indices, using each of the parameters as 
continuous variables, distribution of the outcome variable was graphically assessed for 
normality (histograms, box plots, and QQ plots). To select the correct function for the 
variable age (as a time-varying covariate), several different initial models including linear 
and non-linear functions together with interaction terms for age with other covariates were 
built. Outlier values were removed. The following covariates were included in the fixed part 
of the linear mixed models: Age (as time-varying covariate), systolic and diastolic blood 
pressure (SBP, DBP), heart rate (HR), total and high-density lipoprotein (HDL) cholesterol, 
blood pressure and lipid lowering medications, diabetes mellitus (DM), current smoking, 
previous coronary heart disease (CHD), left ventricular mass indexed by body surface area 
(LVM), left ventricular ejection fraction (LVEF), physical activity, left atrial diameter (LAD) 
and cohort. In the random part of the linear mixed model, age was the only variable (as 
a time-varying covariate) included. First, we evaluated a full model, including interactions 
terms, comparing model with random intercept vs model with both intercept and slope 
random. Second, we evaluated the linear and non-linear terms in the random part of the 
model and selected the model with lower AIC. Third, we evaluated the fixed part of the 
model, comparing full model with interactions terms vs model without interactions terms 
and selected the model with lower AIC. Finally, we evaluated the linear and non-linear 
terms in the fixed part of the model and selected the model with lower AIC. Non-linear 
terms evaluated were polynomials, and natural splines quadratic and cubic. Convergence 
problems of some models were solved increasing the mathematical iterations, using 
optimizer (bobyqua optimizer) and centralized continuous variables if it was needed. 
A residual analysis was made to all final models. Several covariates were missing in <5% 
of the participants and were imputed using fully conditional specification (Markov chain 
Monte Carlo method) with a maximum iteration number of five. 
Supplemental Results
Non-returning participants: 
From the 3,420 participants who were present at examination 1 but not at the follow-
up examinations, 1,867 had died before the next follow-up visit. Of the 3,422 surviving 
participants, 1,553 did not return for the follow-up examinations. Survivors who did not 
return were older; more often women, hypertensive, current smoker, and diabetic; and 
had higher mean values for BMI, SBP, and HR. Among the echocardiographic parameters, 
the non-returning participants had larger LVM and left atrial (LA) diameter, larger chamber 
dimensions, higher relative wall thickness (RWT), smaller FS, higher A wave and DT, and 
lower E/A ratio. (Supplemental Table 5)
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Supplemental Table 1. Baseline clinical and echocardiographic characteristics of the participants for the analysis 
of two left ventricular diastolic function parameters.




Age, years 73.63 (4.98) 73.64 (4.95) 0.990
BMI, kg/m² 27.27 (4.22) 27.02 (3.06) 0.201
SBP, mmHg 150.82 (20.86) 152.35 (20.13) 0.151
DBP, mmHg 85.50 (11.00) 85.81(10.98) 0.594
Blood pressure Lowering Medication, n (%) 414 (46.94) 338 (52.32) 0.038
Hypertension, n (%) 764 (86.6) 583 (90.3) 0.027
Heart Rate, beats/min 68.15 (9.46) 65.21 (10.64) <0.001
Total Cholesterol, mmol/L 5.73 (1.04) 5.06 (1.04) <0.001
HDL-cholesterol, mmol/L 1.64 (0.42) 1.34 (0.34) <0.001
Lipid Lowering Medication, n (%) 232 (26.3) 236 (36.5) <0.001
Current Smoker, n (%) 83 ( 9.4) 43 ( 6.7) 0.048
Prevalent CHD, n (%) 35 ( 3.97) 99 (15.3) <0.001
Prevalent DM, n (%) 137 (15.5) 108 (16.7) 0.531
Echocardiography Features
LVM index, g/m² 66.96 (14.80) 74.47(19.38) <0.001
Left Atrium Diameter/BSA†, mm/m² 22.79 (2.93) 22.18 (2.83) <0.001
LVEDD, mm 49.36 (4.29) 53.23 (5.07) <0.001
LVESD, mm 28.31 (3.50) 31.35 (4.97) <0.001
Relative Wall Thickness, cm 0.27 (0.05) 0.27 (0.05) 1.0
Fractional Shortening, % 43.14 (5.99) 41.92 (7.80) <0.001
* p-value for comparison of different characteristics between men and women.
Values are mean (± standard deviation) or numbers (percentages). 
 BMI: Body mass index, BSA: Body surface area, CHD: coronary heart disease, DM: Type 2 diabetes mellitus, 
DBP: Diastolic blood pressure, LVEDD: Left ventricle end diastolic dimension, LVESD: Left ventricle end systolic 
dimension, LVM: Left ventricular mass, SBP: Systolic blood pressure.
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Supplemental Table 2.  Left ventricular diastolic function parameters stratified by age and gender.
55 – 64 years old 65 – 74 years old >= 75 years old
Women Men p-value* Women Men p-value* Women Men p-value*








































































































Values are mean (± standard deviation). 
* p-value for comparison of different values of left ventricular diastolic function parameters for women and men 
in each age group.
† N/A indicates that e’ and E/e’ ratio were not available at the indicated examination.
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Supplemental Table 3. Association of risk factors with longitudinal changes in left ventricular diastolic function 
parameters among women.
WOMEN E wave A wave E/A DT e`septal E/e`
  MIXED MIXED MIXED MIXED MIXED MIXED
Agetime † † † † ‡  
BMI ‡ †        
SBP † †   ‡    
DBP † †      
BP lowering medication            
Heart rate   † †      
Total Cholesterol            
HDL Cholesterol         † ‡
Lipid low medication         ‡ †
Current SMK       †    
LVM ‡       † †
Prevalent CHD         ‡ ‡
Prevalent DM            
Ejection fraction            
Physical activity            
LAD            
*Age in this analysis is used as a time-varying covariate. †P< 0.0083 (significant at Bonferroni corrected P value); 
‡P<0.05.  
BMI: Body mass index, BP: blood pressure, CHD: Coronary heart disease, DBP: Diastolic blood pressure, 
DM: Diabetes Mellitus, HDL: High density lipoprotein, SBP: Systolic blood pressure.
Values are betas (95% confidence intervals). All presented betas (95% confidence intervals) are based on fully 
adjusted models 
Sex-specific differences are highlighted in gray in the table.
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Supplemental Table 4. Association of risk factors with longitudinal changes in left ventricular diastolic function 
parameters among men.
MEN E wave A wave E/A DT e`septal E/e`
  MIXED MIXED MIXED MIXED MIXED MIXED
Agetime † † † †    
BMI   † † ‡   †
SBP † †       †
DBP †   ‡      
BP lowering medication            
Heart rate ‡ † † ‡    
Total Cholesterol            
HDL Cholesterol            
Lipid low medication            
Current SMK            
LVM †       † †
Prevalent CHD           †
Prevalent DM   ‡     ‡ ‡
Ejection fraction     ‡      
Physical activity            
LAD     ‡      
*Age in this analysis is used as a time-varying covariate. †P< 0.0083 (significant at Bonferroni corrected P value); 
‡P<0.05.  
BMI: Body mass index, BP: blood pressure, CHD: Coronary heart disease, DBP: Diastolic blood pressure, 
DM: Diabetes Mellitus, HDL: High density lipoprotein, SBP: Systolic blood pressure.
Values are betas (95% confidence intervals). All presented betas (95% confidence intervals) are based on fully 
adjusted models 
Sex-specific differences are highlighted in gray in the table.
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Supplemental Table 5. Clinical and echocardiographic characteristics at the first examination for the individuals 







Age, years  67.45 (5.03)  71.47 (6.33) <0.001
Female Sex, n (%)    931 (57.5)   1016 (65.4) <0.001
BMI, kg/m²  27.37 (3.72)  27.88 (4.17) <0.001
SBP, mmHg 144.70 (18.90) 150.16 (20.54) <0.001
DBP, mmHg  80.85 (10.08)  80.18 (10.32)  0.065
Blood Pressure Lowering 
Medication, n (%)
   531 (33.1)    708 (46.2) <0.001
Hypertension, n (%)   1055 (65.9)   1140 (74.7) <0.001
Heart Rate, beats/min  67.85 (10.27)  69.34 (10.93) <0.001
Total Cholesterol, mmol/L   5.73 (0.98)   5.71 (0.96)  0.562
HDL-cholesterol, mmol/L   1.47 (0.39)   1.49 (0.40)  0.154
Lipid Lowering Medication, n (%)    343 (21.4)    355 (23.2)  0.568
Current Smoker, n (%)    166 (10.5)    207 (13.6)  0.363
Prevalent CHD, n (%)     91 ( 5.6)    106 ( 6.8)  0.728
Prevalent DM, n (%)    160 ( 9.9)    201 (12.9)  0.376
Echocardiography Features†
LVM index, g/m²  72.29 (17.33)  74.35 (18.19)  0.013
Left Atrium Diameter/BSA‡, mm/m²  21.13 (2.61)  21.56 (2.99) <0.001
LVEDD, mm  51.08 (5.03)  50.91 (5.28)  0.353
LVESD, mm  30.71 (4.76)  31.11 (5.30)  0.025
Relative Wall Thickness, cm   0.29 (0.05)   0.30 (0.06)  <0.001
Fractional Shortening, %  38.52 (14.54)  36.50 (16.26) <0.001
E wave, cm/s  65.53 (14.56)  64.97 (15.74)  0.305
A wave, cm/s  73.26 (15.58)  77.32 (16.73) <0.001
Deceleration Time, msec 207.86 (40.43) 214.15 (46.86) <0.001
E/A ratio   0.93 (0.23)   0.88 (0.36) <0.001
*p-value for comparison of different characteristics between participants and non-returning individuals.
† In the first evaluation measurements of Echo TDI were not available.
Values are mean (± standard deviation) or numbers (percentages). 
 BMI: Body mass index, BSA: Body surface area, CHD: coronary heart disease, DM: Type 2 diabetes mellitus, 
DBP: Diastolic blood pressure, LVEDD: Left ventricle end diastolic dimension, LVESD: Left ventricle end systolic 
dimension, LVM: Left ventricular mass, SBP: Systolic blood pressure.
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Supplemental Figure 1. Flow chart for the participants included in the analysis of two left ventricular diastolic 
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This thesis describes different outcome measures in patients with heart failure (HF), 
including short- and long-term prognosis, mortality over time, left ventricular remodeling 
and patient-reported outcomes. We studied the impact of changes in HF therapy on 
prognosis and left ventricular remodeling, and investigated determinants of health-
related quality of life (HRQoL) in different types of patients with acute HF, and studied 
incident HF prediction models and sex-related differences in developing diastolic 
dysfunction. This thesis has been divided in three parts:
I. Impact of improved heart failure therapy on left ventricular remodeling and 
prognosis
II. Patient-reported outcomes in acute heart failure
III. Heart failure at a population level
This chapter summarizes our findings, translates these findings into clinical practice and 
offers suggestions for further research.
Part I: Impact of improved heart failure therapy on left ventricular 
remodeling and prognosis
Because HF therapy was developed since the 1980s, one may – with time - expect improved 
survival of patients admitted with acute HF. We investigated this hypothesis with the use 
of a database including 1810 patients admitted with acute HF at the (Intensive) Coronary 
Care Unit of the Erasmus Medical Center. Patients were prospectively included in the 
period from 1985 through 2008. The primary endpoint was the composite of all-cause 
mortality, heart transplantation or implantation of a left ventricular assist device (LVAD).
As shown in Chapter 2, the included patients with acute HF have a poor prognosis with 
35% and 76% of the them reaching the primary endpoint after 1 and 10 years follow-
up, respectively. Patients with ischemic origin of HF had the worst prognosis. Also, male 
sex, diabetes mellitus, older age and poor left ventricular ejection fraction (LVEF) were 
associated with worse prognosis. However, in the period, from 1985 until 1999, there was 
no significant improvement of the prognosis of the patients admitted. We found that the 
prognosis improved modestly in the period 2000-2008, as compared with the earliest time 
period. However, this improvement was only observed in patients with a reduced LVEF 
and not in patients with a preserved ejection fraction. Moreover, the improved prognosis 
only concerned the long-term prognosis (i.e. 10 years) and not the short-term prognosis. 
The reason why the short-term prognosis did not improve is most likely due the a lack of 
improvement in the therapy of acute HF. In contrast, improved therapy for chronic HF (such 
as angiotensin-converting enzyme [ACE] inhibitor, beta-blocker, mineralocorticoid receptor 
antagonist [MRA] and intracardiac defibrillator [ICD]) was most likely the main determinant 
of the improved long-term outcome. This conclusion is supported by the fact that (1) 
prognostic improvement was only found after long-term follow-up; (2) the development of 
new therapeutic options is in line with the prognostic improvement; (3) the new HF therapy 
was found to be effective in patient with reduced ejection fraction which is exactly the 
subset of patients with HF in whom the improved prognosis was observed. 
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The next chapters discuss the prognosis and prognostic improvement in subcategories of 
patients with acute HF. Chapter 3 describes the difference in prognosis between women 
and men with acute HF. Over half of the included patients were men (64%). Women 
were found to have a better prognosis than men, both after 1 year of follow-up (primary 
outcome 30% vs. 38%) and after 10 years of follow-up (72% vs. 79%). This difference 
was most pronounced in patients with poor LVEF. Furthermore, we demonstrated an 
improvement in prognosis of patients admitted in the period 2000-2008, as compared 
to those admitted from 1985 through 1999. This improvement was comparable among 
women and men. This led to our conclusion that women and men have benefited equally 
from the improvement in HF therapies over time.
Differences in prognosis of acute HF patients with and without diabetes mellitus were 
studied in Chapter 4. The distribution of patients with and without diabetes was 21% 
vs. 79%, respectively. We found that patients with diabetes had better 30-day (9% vs. 
16%), comparable 1-year (32% vs. 36%) and worse 10-year (87% vs. 76%) outcome than 
men and women without diabetes. Worse 30-day outcome in patients with diabetes has 
been previously reported1, 2 but no clear explanation has been reported for this finding. 
One possible explanation may be that our patients without diabetes more frequently 
had cardiogenic shock, a condition associated with worse prognosis3. The prognostic 
disadvantage of HF patients with diabetes in the long term could possibly not only 
be explained by HF-related factors but also with long-term complications of diabetes. 
Importantly, the improvement of long-term prognosis over time was found to be 
comparable between patients with and without diabetes. It is likely that the prognostic 
improvement of patients with diabetes may be related to both the improvement of HF 
therapy as well as the ameliorated diabetes treatment.
Chapter 5 examines the relation between renal function, anemia and prognosis in 
patients with acute HF. In this study, 61% of the patients had an impaired renal function, 
including 18% with a severely impaired renal function (eGFR <30 ml/min). Impaired 
renal function was found to be a strong predictor of both poor short- and long-term 
outcome. Prognosis became worse when the renal function was more severely impaired. 
In contrast to patients with preserved renal function, the long-term prognosis of patients 
with impaired renal function did not improve over time. This may be explained by the fact 
that patients with renal dysfunction were less frequently treated with the new developed 
medication (like ACE inhibitors and MRAs) since these therapeutic modalities interact with 
renal function, and cannot be employed beneficially in this population. Another possible 
explanation is the poor prognosis of the renal insufficiency itself. Furthermore, anemia 
was associated with worse short-term prognosis in both patients with and without renal 
dysfunction. For long-term prognosis, anemia was only a prognosticator in patients with 
impaired renal function and not in those with preserved renal function. The mechanism 
of this difference is unclear.
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A relatively new concept in cardiovascular research to measure prognosis, namely 
relative conditional survival, was discussed in Chapter 6. Relative survival compares 
the survival of the patient at issue to the survival of the sex- and age-matched general 
population. Using conditional survival enables to determine the prognosis after surviving 
a certain period. We found that the relative conditional survival of patients with acute 
HF was significantly worse than that of the general population. This remained the case 
after stratifying for several factors. This finding is especially important for young patients 
with HF since their prognosis will be severely diminished. A striking finding in this study 
was the fact that the prognosis improved when patients survived the first year after the 
hospitalization. Clinicians may use relative conditional survival to inform patients more 
clearly about their prognosis.
Chapter 7 describes a retrospective study that included 111 patients admitted with de 
novo, acute HF with reduced LVEF in the period from 2008 until 2016. In total, 62% had 
HF based on non-ischemic causes. This study investigated left ventricular remodeling 
and subsequent prognosis. Left ventricular remodeling was assessed by left ventricular 
end-diastolic and end-systolic diameter and the presence and degree of mitral valve 
regurgitation. Significantly higher rates of LVEF recovery were found in patients with non-
ischemic origin of HF (almost 40%) compared to those with HF of ischemic origin (10%). 
Left ventricular remodeling (for the vast majority occurring in patients with non-ischemic 
HF) was already present after 6 months in a significant number of patients. Importantly, 
LV function improved further during the next 2 years of follow-up, and improvement of 
LVEF was found to be associated with an improved prognosis. Thus, both the etiology of 
HF (i.e. non-ischemic origin) and the achievement of optimal HF therapy with medication 
are the major determinants of improvement of left ventricular function.
Chapter 8 is a qualitative review discussing a cut-off value of 35% for the LVEF as 
qualifying ejection fraction for implantation of an ICD for primary prevention. Based on 
so-called landmark trials in both patients with HF with ischemic and non-ischemic origin, 
we advocate that an LVEF <30% (and symptomatic HF) should be the new criterion for ICD-
implantation for primary prevention. Several arguments support this position of which 
the most important are: (1) most patients included in the trials had an LVEF <30%; (2) the 
original trials are relatively old, and since then HF therapy has significantly improved with 
better prognosis and lower rates of sudden cardiac death as result; (3) cost-effectiveness 
of ICD therapy decreases due to better HF therapy; (4) while the current preventive effect 
of the ICDs in this era is attenuated, the short- and long-term risk associated with ICD 
remains a concern. 
Part II: Patient-reported outcomes in acute heart failure
Studies on patient-reported outcomes included in this thesis are based on data of the 
TRIUMPH study. TRIUMPH was a prospective, observational, multicenter trial including 
496 patients admitted with acute HF in the period September 2009 until December 2013.4 
TRIUMPH examined the clinical value of repeated measurements of several biomarkers. 
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A secondary aim was to investigate the HRQoL in patients admitted with acute HF. HRQoL 
was measured with two questionnaires: the Kansas City Cardiomyopathy Questionnaire 
(KCCQ) and the EuroQuality-of-life 5 Dimensions (EQ-5D). The Hospital Anxiety and 
Depression Scale (HADS) was used to examine symptoms of anxiety and depression. 
Lastly, a questionnaire on symptom occurrence and symptom burden regarding HF-
related symptoms was used. Patients were asked to complete these questionnaires 
at discharge and after 9-12 months of follow-up. In total, 70% of the included patients 
completed the questionnaires at baseline. After 1 year of follow-up, about 60% of the 
patients who were alive at that time completed the questionnaires.
Four non-cardiac comorbidities that frequently accompany HF including chronic 
kidney disease, diabetes mellitus, chronic obstructive pulmonary disease (COPD) 
and cerebrovascular accident (CVA) were studied in relation to the patient-reported 
outcomes. Chapter 9 investigated whether the determinants of HRQoL were different 
between HF patients with and without those comorbidities (61% vs. 39%). At hospital 
discharge, patients with comorbidities had worse HRQoL (as measured with the KCCQ) 
and more depressive symptoms than those without comorbidities. Also, after 1 year of 
follow-up, the HRQoL was worse in patients with comorbidities. Female sex, previous 
HF, increasing body mass index, higher NT-proBNP, higher systolic blood pressure and 
presence of anxiety and depression were negatively associated with HRQoL in HF patients 
with these comorbidities. Among patients without comorbidities, we did not found other 
determinants of HRQoL besides anxiety and depression. In such  patients, HF itself may 
be the major determinant of impaired HRQoL.
Chapter 10 showed that HF patients with depression (37% of the included patients; 
depression according to the HADS) had higher symptom occurrence and higher symptom 
burden than patients without depression. Patients with depression had a significant 
lower HRQoL. These findings were not only present at baseline but also after 1 year of 
follow-up. Results of this study emphasize that depression is often present in patients 
with HF and indicate the need for recognition and adequate treatment of depression in 
patients with HF. 
Part III: Heart failure at a population level
The third part of this thesis included studies based on data of the Rotterdam Study. 
The Rotterdam Study is a prospective, population-based, cohort study among men and 
women living in Rotterdam (district Ommoord). The study started in 1990 and includes 
people of 40 years of age and older. The Rotterdam Study investigates the major 
determinants of most chronic diseases including HF and other cardiovascular disorders.5
In Chapter 11, we evaluated different models to predict 10-year incident HF. The included 
population consists of 2743 men and 3646 women aged 55 years and older of which 429 
(16%) men and 489 (13%) women developed HF during a median follow-up time of 13 
years. The ACC/AHA model was found to be a reasonable prediction model in both men 
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and women. The performance of this model was comparable with two other prediction 
models (ARIC model6 and Health ABC model7). The advantage of the ACC/AHA model is 
its simplicity as it considers determinants that are easily available (age, total cholesterol, 
HDL cholesterol, systolic blood pressure, antihypertensive use, smoking status and 
diabetes). The addition of NT-proBNP to the ACC/AHA model resulted in only a modest 
improvement of the model performance but not in a significant shift in risk classification. 
Therefore, the outcome of the ACC/AHA model could be used for primary prevention 
purposes of HF in both men and women.
Longitudinal changes in left ventricular diastolic function and their risk factors among 
men and women included in the Rotterdam Study are studied in Chapter 12. During 
11 years of follow-up, echocardiographic measurements were made in 630 men and 
870 women without know HF. At baseline, women were found to have more severe left 
ventricular diastolic dysfunction than men. During a follow-up period of 11 years, the 
age-related change in parameters of diastolic dysfunction were comparable in both 
sexes. However, risk factors for changes in diastolic dysfunction differed between men 
and women. Whereas smoking and lower HDL cholesterol levels were the main risk 
factors for worse left ventricular diastolic function over time among women, deleterious 
change in diastolic function was predominantly determined by the presence of diabetes 
and higher body mass index in men. Since impaired left ventricular diastolic function has 
been associated with development of HF,8 recognition and treatment of such risk factors 
are important in order to prevent development of HF.
Clinical implications
Based on this thesis, several lessons for clinical practice may be learned. First, since acute 
HF has such a poor prognosis, it is paramount to prevent it. To prevent de novo HF, 
risk factors for development of HF should be recognized at an early stage and should 
be adequately treated in the general population. In our thesis, for example diabetes, 
hypertension, hypercholesterolemia and smoking were found to be crucial  risk factors 
for HF amenable to proper treatment. New developments in prevention and therapy of 
these risk factors, for example sodium-glucose cotransporter-2 inhibitors for diabetes, 
should be helpful in this regard.9 The other category of acute HF is decompensated 
(or acute on) chronic HF that might be prevented by adequate monitoring and optimal 
treatment of chronic HF. The initial therapy of patients with this syndrome should 
comprise medical treatment with ACE-inhibitors, beta-blockers, MRAs and diuretics and, 
if this is insufficient, with more advanced therapy like angiotensin receptor neprilysin 
inhibitor (ARNI), cardiac resynchronization therapy and ivabradine.10 It may also be 
considered to give ARNIs in an earlier stage in order to replace ACE-inhibitors.11 These 
therapeutic modalities may not only prevent HF deterioration but they may even induce 
left ventricular remodeling. Moreover, close monitoring (e.g. with telemonitoring) of HF 
patients may be a promising tool in the prevention of decompensation of chronic HF 
when this would result in earlier and successful interventions. Furthermore, non-drug 
therapy, as discussed below, is important to prevent acute HF.
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Secondly, since we showed that left ventricular remodeling occurred in a significant part of 
patients with de novo HF under optimal medical therapy, decisions for interventions such 
as heart transplantation or LVAD implantation and ICD implantation should not be made 
too early and quickly. Both interventions have their own important and potentially lethal 
complications.12, 13 Moreover, especially for countries in which heart transplantation of 
LVAD implantation is not or hardly feasible, the possibility of left ventricular remodeling 
with medical treatment has relevant implications.
Third, it should be considered to implant ICDs for primary prevention only if the LVEF 
<30%. Nowadays, LVEF<35% is the cut-off level for implantation of an ICD but, as 
mentioned before, this recommendation is based on relatively old studies and, even 
more important, these studies included predominantly patients with LVEF <30%. As HF 
treatment has been substantially improved since then, ICD shocks have become less 
common. However, the risk for ICD-related complications like inappropriate shocks and 
device infection is still there.  Therefore, the indication for ICD for primary prevention 
should be considered carefully. Another issue that is increasingly raised is that patients 
become older and develop other serious conditions while an ICD is in situ. This confronts 
you with the difficult question of when to turn off the ICD.
Fourth, cardiologists may consider to consult their HF patients about conditional survival 
instead of short- and long-term survival rates. Conventionally, cardiovascular research 
reports prognosis as cumulative survival rates. However, this is difficult to translate to 
patients’ personal situation in an understandable way. It could be more understandable 
for individual patients to understand their prognosis when using conditional survival 
instead. Relative survival provides additional prognostic information about their 
prognosis compared to the general population with the same sex and age. This could 
also be informative for patients with HF.
Five, not only prognosis, but also HRQoL deserves more attention in patients with HF. 
To this end, optimal HF treatment should be pursued to improve not only prognosis but 
also quality of life. However, more action may be needed in order to improve HRQoL. 
Adequate treatment of comorbidities in HF patients is important. Furthermore, it is 
essential to recognize depression and to install proper treatment. Indeed, there is overlap 
between HF symptoms and depressive symptoms. Therefore, a depression screening 
tool should be employed more frequently. Lastly, it is important to refer patients for 
cardiac rehabilitation. In addition to improvement of HRQoL, cardiac rehabilitation has 
been shown to be effective in preventing more symptoms and clinical events.14 Indeed, 
cardiac rehabilitation already has a strong recommendation in HF guidelines,10 but clinical 
practice shows that the number of referrals could be increased.15
Sixth, clinicians should pay more attention to symptom management. There are different 
ways to achieve this. Education of patients, training of patients in symptom recognition 
and psychoeducational intervention may all be appropriate . Furthermore, following on 
the ESC position paper about palliative care in HF,16 incorporation of palliative care in 
patients with HF should receive more attention. 
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Lastly, it remains important to realize the difference between men and women, both in 
research and in clinical practice. For example, this thesis shows relevant sex differences in 
prognosis, etiology of HF, risk factors in developing diastolic dysfunction and distribution 
in preserved versus reduced ejection fraction.
Future challenges
No improvement of short-term prognosis was observed in patients with acute HF. 
Therefore, new therapies to improve treatment and prognosis of acute HF at clinical 
presentation are clearly and urgently needed.  Unfortunately, results of several studies 
in this respect have been disappointing.17 One of the reasons might be the heterogeneity 
of acute HF. Indeed, it is sound clinical practice and specifically recommended to 
manage triggers for acute decompensation like acute coronary syndromes, arrhythmias 
and hypertensive emergencies as soon as possible to prevent further deterioration.10 
However, there is no suitable therapy to amend  the syndrome acute HF itself. Further 
studies on personalized acute HF therapy are strongly needed.
So far, it is also not clear what the optimal therapy should be in patients in whom 
LVEF has recovered following treatment with HF therapy. There is evidence suggesting 
negative influence of stopping HF medication.18 In general, patients with recovered LVEF 
should continue to use ACE-inhibitors and beta-blockers. Other HF medication may be 
discontinued. However, scientific evidence for such action is currently lacking.
Despite the fact that HF is a heterogeneous syndrome, current guidelines provide 
recommendations for patients over the entire spectrum of HF and not further specified 
to different HF phenotypes. Especially the pathogenesis of dilated cardiomyopathy is 
very heterogeneous. Therefore, addition therapy specifically-targeted to the underlying 
etiology or pathological mechanism to the current HF treatment may be of added value 
to improve patients’ prognosis. Different studies investigating this topic have been 
performed or are currently under investigation,19 but only a few targeted therapeutics 
are incorporated in the guidelines until now. 
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Dit proefschrift behandelt verschillende uitkomstmaten bij patiënten met hartfalen 
(HF), waaronder korte- en lange-termijn mortaliteit, trends in mortaliteit, linker ventrikel 
remodeling en patiënt-gerapporteerde uitkomsten (bijv. kwaliteit van leven, symptomen). 
Het proefschrift had als doel om (1) te onderzoeken wat de invloed is van veranderingen 
in de HF-behandeling op prognose en linker ventrikel remodeling, (2) te bestuderen wat 
de determinanten zijn van gezondheidsgerelateerde kwaliteit van leven in verschillende 
groepen van patiënten met HF, en (3) predictiemodellen voor het ontwikkelen van HF 
te onderzoeken alsook het bestuderen van geslacht-gerelateerde verschillen in het 
ontwikkelen van diastolische dysfunctie. Dit proefschrift is opgedeeld in drie onderdelen:
I. De invloed van verbetering in hartfalen behandeling op linker ventrikel remodeling 
en prognose
II. Patiënt-gerapporteerde uitkomsten in acuut hartfalen
III. Hartfalen op populatieniveau 
Deel I: De invloed van verbetering in hartfalen behandeling op linker 
ventrikel remodeling en prognose
Aangezien er sinds de jaren ’80 nieuwe HF-therapie is ontwikkeld, werd onderzocht of 
dit zich vertaalde naar een betere prognose in patiënten met acuut HF. Hiervoor is een 
gegevensbestand gebruikt van 1810 patiënten opgenomen vanwege acuut HF op de 
(Intensive) Coronary Care Unit van het Erasmus Medisch Centrum. De patiënten werden 
prospectief geïncludeerd in de periode 1985 tot en met 2008.
De gegevens gepresenteerd in Hoofdstuk 2 laten zien dat patiënten met acuut HF een 
slechte prognose hebben waarbij 35% van de patiënten de combinatie van mortaliteit, 
harttransplantatie en implantatie van een linker ventrikel assist device (LVAD) bereikte na 
1 jaar follow-up en 76% na 10 jaar follow-up. Patiënten met een ischemische oorzaak van 
het HF hadden de slechtste prognose. Verder waren mannelijk geslacht, diabetes mellitus, 
oudere leeftijd en slechte linker ventrikel ejectiefractie (LVEF) geassocieerd met een slechte 
uitkomst. Er werd geen significante verbetering in prognose gezien gedurende 1985 tot 
en met 1999. Ten opzichte van deze periode verbeterde de prognose wel in de periode 
2000 tot en met 2008. Deze prognostische verbetering werd alleen gezien bij patiënten 
met een slechte LVEF en niet bij patiënten met een behouden LVEF. Bovendien werd de 
prognostische verbetering alleen gezien op de lange-termijn en niet op de korte-termijn. 
Het ontbreken van verbetering in de behandeling van acuut HF is waarschijnlijk de oorzaak 
dat de prognose op korte termijn niet verbeterde. Anderzijds is de belangrijkste oorzaak 
van de verbetering in prognose op lange termijn de verbetering in de behandeling van 
chronisch HF (met onder andere angiotensin-converting enzym [ACE] remmer, bètablokker, 
mineralocorticoïde receptor antagonist [MRA] en intracardiale defibrillator [ICD]). Deze 
veronderstelling wordt ondersteund door het feit dat (1) de verbeterde prognose alleen 
op de lange termijn werd gezien; (2) de ontwikkeling van nieuwe therapeutische opties 
synchroon liep met de prognostische verbetering; (3) de nieuw ontwikkelde therapie alleen 
bewezen effectief was bij patiënten met verminderde LVEF. 
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De hoofdstukken hierna behandelen de prognose en de verbetering hiervan in 
subgroepen van patiënten met acuut HF. Hoofdstuk 3 beschrijft de verschillen in 
prognose tussen mannen en vrouwen met acuut HF. Van de geïncludeerde patiënten was 
de grote meerderheid man (64%). In deze studie hadden vrouwen een betere prognose 
dan mannen, zowel na 1 jaar follow-up (30% vs. 38%) als na 10 jaar follow-up (72% vs. 
79%). Dit verschil was het meest uitgesproken bij patiënten met een slechte LVEF. Verder 
werd ook hier een verbetering gezien in klinische uitkomst bij patiënten opgenomen 
in de periode 2000-2008 vergeleken met patiënten opgenomen tussen 1985 en 1999. 
Deze betere uitkomst was vergelijkbaar tussen mannen en vrouwen. De conclusie is 
dan ook dat mannen en vrouwen evenveel baat hebben gehad van de verbetering in de 
behandeling van HF.
De verschillen in prognose van acuut HF-patiënten met of zonder diabetes mellitus zijn 
onderzocht in hoofdstuk 4. De verhouding tussen patiënten met en zonder diabetes was 
respectievelijk 21% vs. 79%. Wij zagen dat patiënten met diabetes een betere 30-dagen (9% 
vs. 16%), vergelijkbare 1-jaars (32% vs. 36%) en slechtere 10-jaars (87% vs. 76%) uitkomst 
hadden dan patiënten zonder diabetes. Een slechtere 30-dagen prognose is al eerder 
beschreven in de literatuur. De auteurs van dit artikel hadden hiervoor geen duidelijke 
verklaring en wij hebben die ook niet kunnen vaststellen. Een van de verklaringen zou 
kunnen zijn dat in onze studie de patiënten zonder diabetes vaker een cardiogene shock 
hadden hetgeen geassocieerd is met een slechtere prognose. Het prognostisch nadeel 
van patiënten met diabetes zal naast HF-gerelateerde factoren ook te verklaren zijn door 
lange-termijn complicaties door diabetes mellitus. De verbetering van de lange-termijn 
prognose was vergelijkbaar tussen de patiënten met en zonder diabetes. De prognostische 
verbetering van patiënten met diabetes is mogelijk niet alleen te verklaren door verbetering 
in de HF-behandeling, maar ook door een betere behandeling van de diabetes zelf. 
In Hoofdstuk 5 werd de relatie tussen nierfunctie, anemie en prognose in patiënten met 
acuut HF onderzocht. In de onderzochte populatie had 61% een verminderde nierfunctie, 
18% had een ernstig gestoorde nierfunctie (eGFR <30). Daarnaast had ongeveer de helft 
van de patiënten een anemie. Een verminderde nierfunctie bleek een sterke voorspeller 
van slechte korte- en lange-termijn prognose. Hoe slechter de nierfunctie, hoe slechter de 
prognose. De lange-termijn prognose verbeterde niet over de tijd in patiënten met een 
verminderde nierfunctie, dit in tegenstelling tot patiënten met een behouden nierfunctie. 
Een verklaring hiervoor kan zijn dat patiënten met een verminderde nierfunctie minder 
vaak werden behandeld met de nieuw ontwikkelde medicijnen (zoals ACE-remmers en 
MRAs) aangezien die een negatieve invloed hebben op de nierfunctie. Om deze reden 
hadden deze patiënten niet het prognostische voordeel van deze medicijnen. Een andere 
mogelijke verklaring is de slechte prognose van de nierinsufficiëntie zelf. Daarnaast werd 
aangetoond dat ook de anemie zelf geassocieerd was met een slechtere korte-termijn 
prognose, onafhankelijk van de nierfunctie. Echter, voor de lange-termijn prognose was 
anemie alleen een voorspeller van slechte prognose bij patiënten met nierfalen en niet bij 
patiënten met een behouden nierfunctie. Het is onduidelijk wat dit verschil kan verklaren.
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Een relatief nieuw concept in de cardiovasculaire wereld om prognose te bepalen, de 
zogenaamde relative conditional survival, werd behandeld in Hoofdstuk 6. Relative survival 
vergelijkt de overleving van de geïncludeerde patiënt met de prognose van een persoon 
uit de algemene bevolking met hetzelfde geslacht en dezelfde leeftijd. Bij het gebruik 
van conditional survival kan de prognose bepaald worden wat vanaf het moment dat de 
patiënt een bepaalde periode heeft overleefd. In deze studie bleek de relative conditional 
survival van patiënten met acuut HF slechter dan die van de algemene bevolking. Dit 
was ook zo na stratificatie op verschillende factoren. Deze bevinding is in de praktijk 
vooral van belang voor jonge patiënten. Een belangrijke bevinding was dat de prognose 
sterk verbeterde na overleving van het eerste jaar na de ziekenhuisopname. Clinici 
zouden relative conditional survival kunnen gebruiken om op een eenvoudiger manier de 
prognose met hun patiënt te bespreken.
Het onderzoek in Hoofdstuk 7 is gebaseerd op een retrospectieve studie van 111 
patiënten die in de periode van 2008 tot en met 2016 opgenomen waren vanwege 
de novo, acuut HF met een slechte LVEF. In totaal had 62% van deze patiënten niet-
ischemisch hartfalen. We onderzochten specifiek de ontwikkeling van de linker ventrikel 
remodeling. Linker ventrikel remodeling werd vastgesteld door middel van linker ventrikel 
eind-diastolische en eind-systolische diameter en de ernst van mitralisklep insufficiëntie. 
Wij zagen dat herstel van LVEF veel vaker voorkwam (ongeveer 40%) bij patiënten met 
niet-ischemisch HF dan bij patiënten met ischemisch HF (10%). Linker ventrikel remodeling 
(voor de meerderheid in patiënten met niet-ischemisch HF) was in een belangrijk deel 
van de patiënten al aanwezig na 6 maanden follow-up en zette verder door gedurende 
de volgende 2 jaar follow-up. Er werd een belangrijke relatie gevonden tussen linker 
ventrikel remodeling en een betere prognose. Naast de etiologie van HF is optimale 
HF-behandeling met medicatie en devices van invloed op het optreden van de linker 
ventrikel remodeling.
Hoofdstuk 8 is gebaseerd op een review waarbij LVEF <35% als criterium voor een ICD-
implantatie ter primaire preventie ter discussie wordt gesteld. Gebaseerd op de landmark 
trials bij patiënten met ischemisch en niet-ischemisch HF wordt daarin bepleit dat LVEF 
<30% (en symptomatisch HF) het (nieuwe) criterium zou moeten zijn voor een ICD-
implantatie ter primaire preventie. Hiervoor zijn diverse valide redenen: (1) de meeste 
patiënten geïncludeerd in de studies hadden een LVEF <30%; (2) de oorspronkelijke 
studies zijn gedateerd, en sindsdien is de HF behandeling sterk verbeterd met een betere 
prognose en kleine kans op plotse hartdood als resultaat; (3) de kosteneffectiviteit van 
een ICD-implantatie neemt af door betere HF behandeling; (4) daarnaast  blijft het risico 
op complicaties van de ICD bestaan.
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Deel II: Patiënt-gerapporteerde uitkomsten in acuut hartfalen
De studies in dit proefschrift over patiënt-gerapporteerde uitkomsten zijn tot 
stand gekomen met data van de zogenaamde TRIUMPH studie. TRIUMPH was een 
prospectieve, observationele, multicenter studie van 496 patiënten opgenomen met 
acuut HF in de periode tussen september 2009 en december 2013. TRIUMPH onderzocht 
de klinische waarde van het herhaald meten van verschillende biomarkers. Onderzoek 
van de gezondheidsgerelateerde kwaliteit van leven was een tweede doel van deze 
studie. De gezondheidsgerelateerde kwaliteit van leven werd gemeten middels twee 
vragenlijsten: de Kansas City Cardiomyopathy Questionnaire (KCCQ) en EuroQuality-
of-life 5 Dimensions (EQ-5D). Symptomen van angst en depressie werden gescoord 
met behulp van de Hospital Anxiety and Depression Scale (HADS). Tot slot was er een 
vragenlijst over het voorkomen van HF gerelateerde symptomen en de hierdoor ervaren 
symptoombelasting. Patiënten werden gevraagd om deze vragenlijst in te vullen bij het 
ontslag uit het ziekenhuis en na 9-12 maanden follow-up. In totaal vulden 70% van de 
geïncludeerde patiënten de vragenlijst in bij ontslag. Na 1 jaar follow-up vulde 60% van 
de toen nog levende patiënten de vragenlijst in.
Chronische nierinsufficiëntie, diabetes mellitus, chronische obstructieve longziekte 
(COPD) en cerebrovasculair accident (CVA) zijn vier niet-cardiale comorbiditeiten die 
vaak voorkomen in patiënten met HF. Het onderzoek beschreven in Hoofdstuk 9 ging 
na wat de determinanten van gezondheidsgerelateerde kwaliteit van leven verschillend 
waren bij HF-patiënten met of zonder een van deze comorbiditeiten. De uitkomst van 
het onderzoek was dat HF-patiënten met comorbiditeit (61% van de geïncludeerde 
patiënten) bij ziekenhuisontslag slechtere gezondheidsgerelateerde kwaliteit van leven 
(gemeten met de KCCQ) en meer symptomen van depressie hadden dan patiënten 
zonder comorbiditeit. Ook na 1 jaar follow-up was de gezondheidsgerelateerde kwaliteit 
van leven slechter bij patiënten met comorbiditeit. Vrouwelijk geslacht, HF in de 
voorgeschiedenis, verhoogde BMI, hogere NT-proBNP concentratie, hogere systolische 
bloeddruk en de aanwezigheid van angst en depressie hadden een negatieve invloed 
op de gezondheidsgerelateerde kwaliteit van leven in HF-patiënten met comorbiditeit. 
Bij patiënten zonder comorbiditeit werden, behoudens angst en depressie, geen 
andere determinanten gevonden voor slechtere gezondheidsgerelateerde kwaliteit van 
leven. Bij hen is het HF zelf vermoedelijk de belangrijkste determinant van slechtere 
gezondheidsgerelateerde kwaliteit van leven.
De resultaten van het onderzoek beschreven in Hoofdstuk 10 toonden aan dat HF-
patiënten met depressie (37% van de geïncludeerde patiënten; depressie gedefinieerd 
volgens de HADS) meer symptomen en een hogere symptoomlast hadden dan patiënten 
zonder depressie. Daarnaast bleek dat patiënten met depressie een significant lagere 
gezondheidsgerelateerde kwaliteit van leven hadden dan patiënten zonder depressieve 
klachten. Deze bevindingen waren niet alleen aanwezig op baseline, maar ook na 1 jaar 
follow-up. De resultaten van deze studie benadrukken de noodzaak om depressie in HF-
patiënten te herkennen en een adequaat behandelingsplan hiervoor op te stellen.
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Deel III: Hartfalen op populatieniveau 
In het derde deel van dit proefschrift werd gebruik gemaakt van gegevens van de 
zogenaamde Rotterdam Study. De Rotterdam Study is een prospectief cohortonderzoek 
bij een populatie in de Rotterdamse wijk Ommoord, die een redelijke afspiegeling 
vormt van de gemiddelde Nederlandse bevolking van oudere leeftijd. De studie startte 
in 1990 en betreft personen van 40 jaar en ouder. De Rotterdam Study onderzoekt de 
determinanten van verschillende ziekten, inclusief HF en andere cardiovasculaire ziekten.
In Hoofdstuk 11 werd onderzocht wat de validiteit is van verschillende bestaande 
predictiemodellen om het ontwikkelen van HF in de komende 10 jaar te voorspellen. 
De onderzochte populatie bestond uit 2743 mannen en 3646 vrouwen van 55 jaar en 
ouder waarvan 429 (16%) mannen en 489 (13%) vrouwen HF ontwikkelden gedurende 
een mediane follow-up van 13 jaar. Het bleek dat het ACC/AHA model als een 
redelijk voorspelmodel kon worden aangemerkt bij zowel mannen als vrouwen. De 
nauwkeurigheid was vergelijkbaar met twee andere voorspelmodellen (ARIC model 
en Health ABC model), maar het voordeel van het ACC/AHA model is de eenvoud. Het 
bestaat uit relatief makkelijk te verkrijgen en te bepalen parameters en determinanten, 
zoals leeftijd, totaal cholesterol, HDL cholesterol, systolische bloeddruk, gebruik van 
antihypertensiva, rookverleden en diabetes. De toevoeging van de biomarker NT-proBNP 
aan het ACC/AHA model leidde tot een beperkte verbetering in de nauwkeurigheid van 
het model maar niet in een wijziging in de risicoclassificatie. Het gebruik van het ACC/AHA 
model, in combinatie met de toepassing van de geijkte leefstijlaanpassingen en andere 
therapeutische modaliteiten (medicatie), zonder twijfel kan een rol spelen bij de primaire 
preventie van HF bij zowel mannen als vrouwen.
Longitudinale veranderingen in de diastolische functie van de linker ventrikel met 
hun risicofactoren in zowel mannen en vrouwen zijn beschreven in Hoofdstuk 
12. Echocardiografische metingen werden gedurende een periode van 11 jaar drie 
keer verricht in een populatie die bestond uit 630 mannen en 870 vrouwen zonder 
bekend HF. Vrouwen bleken ernstiger diastolische dysfunctie te hebben dan mannen. 
Niettemin was de leeftijdsgerelateerde verandering in parameters van de diastolische 
dysfunctie vergelijkbaar bij mannen en vrouwen gedurende een follow-up van 11 jaar. 
De risicofactoren hiervoor waren wel verschillend tussen beide geslachten. Terwijl bij 
vrouwen roken en een lager HDL cholesterol als de belangrijkste risicofactoren voor 
slechtere linker ventrikel diastolische functie over de tijd naar voren kwamen, werd 
achteruitgang van de diastolische functie onder mannen met name bepaald door de 
aanwezigheid van diabetes en een hoger BMI. Aangezien afname van diastolische functie 
geassocieerd is met de toekomstige ontwikkeling van HF, is de herkenning en behandeling 




Gebaseerd op dit proefschrift kunnen verschillende lessen voor de klinische praktijk 
getrokken worden. Ten eerste, vanwege de slechte prognose van acuut HF, is het van 
groot belang dit ziektebeeld te voorkomen. Om de novo HF te voorkomen moeten de 
risicofactoren voor het ontwikkelen van HF vroeg herkend en adequaat behandeld worden. 
Uit dit proefschrift blijkt dat bijvoorbeeld diabetes, hypertensie en hypercholesterolemie 
belangrijke behandelbare risicofactoren voor HF zijn. Ook ten aanzien van de behandeling 
van deze risicofactoren zijn er nieuwe ontwikkelingen, zoals bijvoorbeeld SGLT2-remmers 
voor mensen met diabetes. De andere groep patiënten met acuut HF zijn patiënten met 
acute-on-chronic HF. Deze complicatie kan voorkomen worden door goede behandeling 
van chronisch HF. De eerste stap in de medicamenteuze behandeling bestaat uit ACE-
remmers, bètablokkers, MRAs en diuretica. Als dit onvoldoende is moet gestart worden 
met meer geavanceerde therapie zoals angiotensin receptor neprilysin inhibitors(ARNI), 
cardiale resynchronisatie therapie en ivabradine. Nieuwe richtlijn suggereren dat ARNIs 
in een eerder stadium gegeven kunnen worden, namelijk in plaats van een ACE-remmer. 
Deze therapie kan niet alleen de achteruitgang van HF voorkomen, maar het kan zelfs linker 
ventrikel remodeling induceren. Dit is vooral bij patiënten met niet-ischemische oorzaak 
voor het HF van toepassing. Verder is nauwkeurige monitoring (bijv. met telemonitoring) 
van HF-patiënten veelbelovend bij het voorkomen van acute-on-chronic HF mits dit ook 
tot vroege en succesvolle interventie leidt. Tot slot zijn leefstijlaanpassingen (zoals vocht- 
en zoutbeperking) en niet-medicamenteuze interventies, welke verderop zullen worden 
besproken, zeker ook van belang in het voorkomen van acuut HF.
Ten tweede, aangezien remodeling van de linker ventrikel optreedt bij een aanzienlijk deel 
van de patiënten met de novo HF ingesteld op optimale therapie, ligt het gevaar op de loer 
om te vroeg te beslissen om over te gaan tot ICD-implantatie, harttransplantatie of LVAD-
implantatie. Beide interventies kennen hun eigen, soms zelfs dodelijke, complicaties. 
Verder is, zeker in landen waar harttransplantatie of LVAD-implantatie niet of nauwelijks 
een optie is, het feit dat linker ventrikel remodeling mogelijk is met medicamenteuze 
therapie een belangrijke boodschap.
Ten derde moet overwogen worden om ICDs ter primaire preventie alleen te implanteren 
als de LVEF <30% is. Tot op heden is het implantatie criterium een LVEF <35%, maar deze 
aanbeveling is, zoals eerder besproken, gebaseerd op oude studies die vooral patiënten 
met LVEF <30% includeerden. ICD-shocks komen minder vaak voor sinds de behandeling 
van HF is verbeterd. Het risico op ICD-gerelateerde complicaties zoals onterechte shocks 
en device infectie blijft  vanzelfsprekend echter aanwezig. Hierom dient de indicatie voor 
ICD-implantatie ter primaire preventie zorgvuldig overwogen te worden.
Ten vierde moeten cardiologen overwegen om conditional survival te gebruiken als ze 
het hebben over de prognose van de individuele patiënt. Traditioneel wordt prognose 
gerapporteerd in de vorm van cumulatieve survival. Het is echter lastig om dit op een 
begrijpelijke wijze aan de individuele patiënt uit te leggen. Bij het gebruik van conditional 
survival is de patiënt beter in staat te begrijpen wat zijn of haar verwachte prognose is. 
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Relative survival geeft patiënten extra informatie over hun prognose aangezien dit wordt 
afgezet tegen de prognose van de algemene bevolking van hetzelfde geslacht en met 
dezelfde leeftijd.
Ten vijfde moet er niet alleen aandacht zijn voor de prognose bij HF-patiënten, maar 
ook gezondheidsgerelateerde kwaliteit van leven. Hiervoor is het belangrijk om 
optimale HF-behandeling na te streven. Goede behandeling van comorbiditeit is een 
belangrijke factor in het verbeteren van gezondheidsgerelateerde kwaliteit van leven. 
Verder is het belangrijk om depressie te herkennen en dit ziektebeeld vervolgens ook 
adequaat te behandelen. Het is juist dat er overlap is in HF-symptomen en depressieve 
klachten. Daarom kan overwogen worden om een depressie screeningsinstrument te 
gebruiken bij patiënten met HF. Tot slot is het van belang om patiënten te verwijzen 
naar hartrevalidatie. Dit is, naast het verbeteren van gezondheidsgerelateerde kwaliteit 
van leven, ook effectief voor andere uitkomstent. Hartrevalidatie heeft al een sterke 
aanbeveling heeft in de richtlijnen, maar de klinische praktijk wijst uit dat het aantal 
verwijzingen verder zou moeten toenemen.
Ten zesde zouden clinici en patiënten meer aandacht moeten hebben voor het omgaan 
met symptomen, zeker ten aanzien van de verergering van klachten die duiden op een 
dreigend acuut HF.  Dit kan op verschillende manieren. Educatie van patiënten, trainen 
van symptoomherkenning bij patiënten en psycho-educatie zijn aan de orde. Verder zou, 
in navolging van het ESC position paper over palliatieve zorg in HF, palliatieve zorg vaker 
moeten worden toegepast in patiënten met HF.
Tot slot blijft het belangrijk om te realiseren dat er verschillen zijn tussen mannen en 
vrouwen, zowel gevonden in het beschreven onderzoek als in de klinische praktijk. Wij 
vonden bijvoorbeeld verschillen in prognose, etiologie van HF, risicofactoren in het 
ontwikkelen van diastolische dysfunctie en verdeling in van goede versus slechte LVEF. 
Dergelijke verschillen hebben praktische betekenis. 
Toekomstige uitdagingen
De korte-termijn prognose van patiënten met acuut HF is niet of nauwelijks verbeterd in 
de afgelopen jaren. Om deze reden is het belangrijk om nieuwe behandelingen voor het 
acuut HF te ontwikkelen. Tot op heden zijn de resultaten van de verschillende studies 
echter teleurstellend. Een van de redenen hiervoor kan zijn dat acuut HF een heterogeen 
ziektebeeld is. Het is juist dat in de richtlijnen wordt aanbevolen om triggers voor acute 
decompensatie zoals acuut coronair syndroom, ritmestoornissen en hypertensieve 
emergency zo snel mogelijk te behandelen om verder verslechtering te voorkomen. 
Maar niettemin er is nog geen behandeling voor het HF zelf op het acute moment. Verder 
onderzoek naar gepersonaliseerde behandeling van acuut HF is nodig.
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Tot op heden is het onduidelijk wat de beste behandeling is van patiënten met een 
herstelde LVEF. Onderzoek  suggereert dat het stoppen van HF-medicatie negatieve 
gevolgen heeft. Over het algemeen gebruiken patiënten met een herstelde LVEF levenslang 
ACE-remmers en bètablokkers, overige HF medicatie wordt meestal beëindigd. Duidelijk 
wetenschappelijk bewijs voor deze handelwijze ontbreekt echter.
Ondanks dat HF een heterogeen ziektebeeld is, geven richtlijnen aanbevelingen die gelden 
voor het hele spectrum van HF patiënten en niet verder zijn toegespitst op de verschillende 
fenotypes. Gedilateerde cardiomyopathie is met name een erg heterogeen ziektebeeld. 
De prognose zou mogelijk kunnen verbeteren als, naast de huidige HF behandeling, 
doelgerichte therapie gericht op de etiologie of pathofysiologisch mechanisme gegeven 
zou worden. Verschillende studies naar doelgerichte therapie zijn al gedaan of worden 
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